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Metabolomics is metabolites profiling in biological matrices and is a key tool for biomarker 
discovery. Over the last decade, metabolomics studies have identified several relevant 
biomarkers involved in complex clinical phenotypes using diverse biological systems. Most 
diseases result in signature metabolic profiles that reflect the sum of external and internal 
cellular activities. Metabolomics signature profiles are useful in clinical care, biomarker 
discovery for several common and rare human diseases, and in understanding disease 
mechanisms and response to therapy.  
Hyper immunoglobulin E (IgE) syndrome [HIES] is characterized by significantly elevated 
serum IgE levels (>2000UL) and recurrent bacterial infections from infancy involving the 
skin and the lungs, chronic eczema and eosinophilia. Bi-allelic mutations in dedicator of 
cytokinesis 8 (DOCK8) are responsible for a form of autosomal recessive type of HIES, 
characterized by increased IgE levels, atopic dermatitis, food allergies, recurrent severe 
cutaneous viral infections, autoimmunity and malignancy. Severe atopic dermatitis (AD) and 
DOCK8 deficiency share some clinical symptoms including eczema, food allergies, increased 
serum IgE levels and eosinophilia. Increased serum IgE levels are characteristic but not 
specific for allergic diseases. DOCK8 exhibits an unusual constellation of clinical features, 
and diagnosis can be confusing and difficult especially during early childhood.The clinical 
management of patients with moderate-severe AD and DOCK8 deficiency can be challenging 
and quite complex as they share many clinical features. Deficiency of DOCK8 protein is 
potentially, life threatening and only curable with bone marrow transplantation. Hence, the 
diagnosis of DOCK8 deficiency is critical and should be sought at an early stage to initiate 
definitive therapy. 
A detailed review on the analytical methods in metabolomics used for biomarker discovery 
and workflow for data analysis is provided in Chapter 1. Metabolomics studies have 
identified several relevant biomarkers involved in complex clinical phenotypes using diverse 
biological systems. In this review, metabolomics strategies were compared and evaluated, to 
focus on the discovery of biomarkers that have diagnostic, prognostic, and therapeutic value, 
validated for monitoring disease progression and responses to various management regimens. 




The work presented in this PhD thesis provides the development of a comprehensive 
metabolomics panel for biomarker discovery. Apart from cytokine biomarkers, metabolomics 
biomarkers differentiating DOCK8-deficient and AD patients were investigated. 
Furthermore, since these patients have food allergies in common, sensitization patterns were 
also evaluated. 
In Chapter 2, a comprehensive cytokine profile revealed distinctive biomarkers that 
differentiate between the DOCK8‐deficient and AD patients. The unique expression profile 
of various inflammatory cytokines in patients with DOCK8 deficiency vs AD likely reflects 
disease‐specific perturbations in multiple cellular processes and pathways leading to 
predisposition to infections and allergies seen in these patients. Significant differential 
expression of the cytokines, CXCL10, CSF3, CCL22, CX3CL1, and TNF‐A were identified 
in DOCK8 deficiency, which possibly contributes to increased susceptibility to infection and 
cancer. CXCL10 and TNF-A were up-regulated in DOCK8-deficient patients when compared 
to AD, possibly contributing towards increased susceptibility to infections and cancer. In 
contrast, epidermal growth factor (EGF) was significantly down regulated in a subgroup of 
DOCK8 deficient and AD when compared to the controls. The cytokine IL‐31, is known to 
be elevated in patients with pruritus and IL-31 expression was found to be elevated in both 
our cohorts thus contributing toward pruritus common to both groups. The unique expression 
profile of various inflammatory cytokines in patients with DOCK8 deficiency vs. atopic 
dermatitis likely reflects upon the disease-specific perturbations in multiple cellular processes 
and pathways leading to a predisposition to infections and allergies seen in these patients. 
This data agrees with the role for EGF replacement therapy in EGF deficient individuals with 
AD as well as DOCK8 deficiency through a potential shared pathway.Hence, CXCL10, TNF‐
A and EGF were found to be signature cytokine biomarkers, leading to early effective 
diagnosis and distinction of DOCK8 deficiency from AD. 
Chapter 3 describes the development and validation of a comprehensive targeted 
metabolomics method for a panel of 225 clinically relevant metabolites on Liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), a powerful analytical technique 
that combines the separating power of liquid chromatography with highly sensitive and 
selective mass spectrometry. The potential clinical usefulness of this method was evaluated 
on different biological matrices such as whole blood, serum, dried blood spots (DBS) and 
murine tissues. The sensitivity, selectivity, stability and linearity of this method was also 




studied under defined preparation and analysis conditions. The method was tested and 
validated on eight different groups of patients with a known diagnosis of Inborn errors of 
metabolism (IEMs), which are rare genetic or inherited metabolic diseases resulting from an 
enzyme defect in biochemical and metabolic pathways, presenting with neurologic signs in 
newborns. The applicability of the method was also tested on various rat tissues to understand 
the metabolic tissue distribution pattern. The advantages of the developed method are small 
volume requirement, clinical relevance and cost effectiveness. 
In Chapter 4, metabolomics based biomarkers were investigated using chemical isotope 
labeling liquid chromatography-mass spectrometry (CIL LC-MS) that is capable of 
distinguishing DOCK8-deficient from AD patients. The metabolomics profiles revealed 
seven positively identified metabolites through binary comparisons between DOCK8-
deficient and AD patients. Aspartic and 3-hydroxyanthranillic acids were up-regulated in 
DOCK8 deficiency, whereas hypotaurine, guanosine and the dipeptides leucyl-phenylalanine 
and glycyl-phenylalanine were down-regulated. Hypotaurine, 3-hydroxyanthranillic acid and 
glycyl-phenyalanine were identified as potential biomarkers specific for DOCK8 deficiency. 
In Chapter 5, In chapter 5 a comparative analysis of food and inhalant allergens, 
metabolomics and cytokines profiles was conducted in allergic patients with DOCK8-
deficiency and AD. Serum samples from DOCK8-deficient and AD patients showed different 
and overlapping sensitization patterns; inparticular, the cat allergen (rFel d1) was 
significantly up-regulated in AD patients when compared to DOCK8-deficient patients. LC-
MS, followed by multivariate analysis revealed distinct signature profiles of dysregulated 
metabolites in the DOCK8-deficient and AD patient groups. Both cohorts commonly showed 
altered amino acid metabolism and taurine & hypotaurine metabolism pathways. DOCK8-
deficient patients demonstrated perturbed tryptophan metabolism pathways whereas in AD 
patient’s caffeine metabolism pathways was altered. Food and inhalant sensitization in 
DOCK8 deficiency and atopic dermatitis induce distinct metabolomic and cytokine profiles 
suggesting both shared as well as unique mechanisms mediating these disorders 
In summary, the newly developed metabolomics method shows a great potential to discover 
novel biomarkers for various diseases. Chemokines, CXCL10, TNF-A and EGF were 
identified to be signature cytokine biomarkers differentiating DOCK8 deficient and atopic 
dermatitis patients.DOCK8 deficiencies appear to have a distinctive metabolomics profile 
characterized by significant differential over expression of 3-hydroxyanthranillic acid, 




aspartic acid and hyptotaurine. The work presented in this thesis provides an important 
contribution towards the development of biomarkers that have diagnostic, prognostic and 
therapeutic values for monitoring disease progression and responses to various management 
regimes. The complex nature of these diseases suggests that no single biomarker will be 
sufficient to meet the clinical needs of such patients. Future work involving the evaluation 
and validation of these biomarkers in larger cohorts involving other Omics will be essential 
before their clinical application is accepted. 
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Hyper immunoglobulin E (IgE) syndrome [HIES] are a group of primary immunodeficiency 
disorders with highly elevated IgE levels, recurrent staphylococcal skin abscesses, eczema 
and pulmonary infections. In 1966, Davis et al, described two girls suffering from 
staphylococcal abscesses, eczema and chronic pulmonary disease, naming this entity as 
‘Job’s Syndrome’. HIES is inherited in both autosomal dominant (AD) and recessive (AR) 
patterns. Most of the AD HIES phenotypes are found to be linked to mutations in the (signal 
transducer and activator of Transcription 3) STAT3, whereas autosomal recessive hyper-IgE 
syndrome (AR-HIES) is a serious inborn error of primary immunity caused by mutations in 
DOCK8 and less frequently PGM3. Mutations on the Dedicator of Cytokinesis 8 (DOCK8) 
were found to account for the patients with AR-HIES. Homozygous and heterozygous 
mutations are reported with frequent large deletions. These patients have an absent or loss of 
function of the DOCK8 protein.(1) (2) DOCK family consists of 11 members and are 
classified in four subfamilies (DOCK-A,B,C and D) based on their sequence homology and 
substrate specificity.(3) DOCK8 is a member of the DOCK180 superfamily of guanine 
nucleotide exchange factor, which interacts with Rho GTPases, DOCK8 has a typical guanine 
nucleotide exchange factor (GEF) for small G proteins of Rho family such as Rac and Cdc42 
DOCK8 proteins regulate actin cytoskeleton, cell adhesion and migration. (4) DOCK8 
mainly has two related conserved protein domains DHR1 and DHR2, wherein the DHR1 
domain binds to phosphatidylinositol-3,4,5-triphosphate (PtdIns 3,4,5)P3 and mediates the 
recruitment of DOCK proteins to the plasma membrane, whereas the DHR2 domain 
functions as a GEF for CDC42.(5) 
Atopic dermatitis is one of the common pediatric chronic inflammatory skin disease and 
certain food-allergens and nutrients are closely related to the development and severity of the 
disease. It is a common chronic or relapsing eczematous dermatitis characterized by intense 
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pruritus and occurs primarily in infants and children. Atopic dermatitis over laps with HIES 
in terms of eczema, eosinophila, food allergies and characteristically increased serum IgE 
levels.  
Combining high throughput experimental “OMIC based” techniques such as genomics, proteomics, 
and metabolomics with computational techniques such as bioinformatics and computer simulations 
enable us to understand specific targets in biological systems. Metabolomics relates to small 
molecule identification and quantification, and the resulting network interactions, which represent 
the individual's functional genome. The entire qualitative collection of metabolites in a biological 
sample is called the “metabolome” which is very dynamic: small molecules are continuously 
absorbed, synthesised, degraded and interact with other molecules, both within and between 
biological systems, and with the environment. Significant environmental and clinical disturbances 
can be monitored at the metabolic level, in an array of different pathways that are crucial for 
cellular homeostasis.(6) The study of metabolites started more than 100 years back; metabolites 
were first measured in the pioneering work of the early biochemist, Sir Hans Krebs, who 
discovered the citric acid cycle and the urea cycle. The term metabolomics was first used in 1998 
by Steve Oliver and colleagues.(7) Metabolomics is the comprehensive and simultaneous profiling 
of metabolites, which evaluates their effective changes resulting from different conditions such as 
diet, lifestyle, genetic, or environmental factors. Metabonomics as a subset of metabolomics is 
defined as “the quantitative measurement of the dynamic ‘especially inter-population’ multi 
parametric metabolic responses of  the living systems to pathophysiological stimuli or genetic 
modification with a particular focus on environmental (including nutritional) stress.(8) 
Developments in instrumentation technologies such as Nuclear magnetic resonance (NMR), 
Mass spectrometers, (MS) and Ultra performance liquid chromatography (UPLC) in 
combination with bioinformatics, have paved the way to an improved understanding of the 
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metabolome.(9, 10) Over the past decade the application of metabolomics platforms in 
clinical research, especially MS based metabolomics, has increased as illustrated in Error! R
eference source not found..  
  





Figure 0.1: Bibliographic searches in PubMed containing the keyword metabolomics (as of 
November 2019). A total of 15230 articles were identified, where the dataset was mined using the 
search parameter mass spectrometry or NMR, and normalized to total number of published 
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Since metabolites represent the end products of cellular biochemical and physiological 
processes, studying the metabolome in combination with transcriptomics and proteomics will 
make more sense to understand disease pathogenesis and mechanism of intervention. Many 
human diseases are heterogeneous in their clinical presentation and etiology and have a 
complex molecular pathogenesis. Thus, genetic and high-throughput molecular profiling can 
be a decisive factor in developing a more comprehensive and informative classification of 
diseases.(11) In systems biology, patient phenotypes and pathological status have opened 
doors to the application of metabolomics in drug discovery processes and personalized 
medicine.(12) For example, Lindon et.al (2005) reported The Consortium on Metabonomic 
Toxicology (COMET) project, launched to assess the use of NMR-based metabolomics for 
determining the early toxicity of drug candidates at preclinical developmental stages and for 
establishing systems predicting target organ toxicity. (13). The panel of metabolites included 
in the metabolome represents a distinct metabolic fingerprint or signature, indicative of its 
current state. Such a profile might also include any molecule that humans ingest, 
catabolize/metabolize, or come in contact with  such as peptides, lipids, amino acids, 
carbohydrates, organic acids, nucleic acids, hormones, vitamins, minerals, and many other 
molecules with molecular weight <1500 Da. (14) The epigenome and the metabolome can be 
quite diverse regarding chemical, biological, environmental and physiological complexity. 
Personalized health is an ancient approach that existed in Chinese medicine and Ayurveda, in 
which the mode of treatment involved a personalized approach to the patient. Hence 
diagnosis and treatment can be improved by blending biology with medicine through the 
integration of Western and Eastern knowledge.(15) In the United States, among the top 10 
highest selling drugs, only up to 25% of the people who use these drugs get the benefit. 
(imprecision medicine). Statins (3-hydroxy-3-methyl- glutaryl coenzyme A (HMG-CoA) 
reductase inhibitors) are used to lower cholesterol, in patients treated for high cholesterol, but 
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only a very low margin of 2% of those patients get the benefit of the drug. Some classical 
drugs that had been developed through clinical trials involving participants from a western 
population can be even harmful to certain ethnic groups.(16) Several leading countries in the 
developed world, such as the USA, have established a precision medicine initiative. 
The NIH funded “All of US Research Program;( https://allofus.nih.gov)” is a historic effort 
that aims to gather clinical and molecular data from one million or more Americans to 
accelerate research and improve health, taking into account individual differences in lifestyle, 
environment, and biology. In Saudi Arabia, as an initiative towards precision medicine, the 
government is taking advantage of the next generation sequencing (NGS) technology and has 
initiated the Saudi Human Genome Project (SHGP) (http://shgp. kacst.edu.sa) that targets 
sequencing the whole genome of 100,000 Saudis within 5 years. Unlike classical clinical 
trials, precision medicine requires several ways of monitoring interventions, which 
encourages researchers to characterize the genetic and environmental factors that impact on a 
person's reaction to a particular intervention. These individual factors need a high throughput, 
comprehensive, and quantitative platform to personalize the diagnosis, which will 
subsequently reflect on the personalized utilized interventions. 
Finding metabolomic signature profiles may be useful in clinical care and biomarker 
discovery for diseases like combined immunodeficiencies and primary immunodeficiencies. 
Currently, a few targeted metabolic profiles such as acylcarnitines, amino acids, very long 
chain fatty acids, and organic acids are routinely performed in newborn screening and 
biochemical genetics laboratories worldwide.(17-20) Few laboratories in the world have 
adopted a comprehensive clinical metabolomics based approach in the evaluation of patients 
suspected of having a metabolic or multifactorial disease. Nutritionists and dietitians are re 
exploring metabolomics to identify novel ways to treat and prevent nutrition related diseases 
such as obesity, diabetes, and some inborn errors of metabolism. (IEM).(21, 22) Therefore, 
Introduction to Metabolomics 
8 
 
there is a strong need for a comprehensive metabolomic database that encompasses many 
physiological health and disease states identified in a large cohort of well-phenotyped 
individuals.(23, 24)  
A combined untargeted metabolomics analysis linked with DNA variants identified by 
“Whole Exome Sequencing” (WES) in healthy volunteers, revealed a range of 
complementary molecular and metabolic abnormalities.(25) In particular, metabolomic 
analysis helped clarify the clinical significance of DNA variants thought to be pathogenic. It 
also identified metabolic abnormality related DNA variants that were not flagged on WES. 
These combined approaches including personalized medicine have contributed toward 
disease risk analysis, disease monitoring, and drug management, which have the potential to 
transform clinical practice and treatment efficacy.(26) In humans, the largest list of 
metabolites available is the Human Metabolome Database, developed by David Wishart and 
his group in Canada defining more than 40,000 metabolites.(27) 
In this review, we provide an overview of the metabolomics based workflow of personalized 
medicine studies: sample preparations, pros, and cons of different methodologies and 
separation techniques involved and discuss its contribution toward the field of precision 
medicine and biomarker discovery. Precision metabolomics may provide a snapshot of the 
current state of health and actionable information to advance clinical decision-making. 
1.2. Clinical sample collection and preparation methods 
High quality results are achieved in metabolomics when a reliable bio specimen is collected, 
processed appropriately, and a typical instrumental analysis method is set up to identify the 
metabolic biomarkers in a cost effective manner. Metabolism operates in constant flux, where 
metabolite concentrations change rapidly compared to other cellular biomolecules, hence 
following standardized procedures for sample collection and storage are vital for sample 
quality and the success of metabolomics experiments. The choice of the sample is dependent 
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on many factors including the biological question posed and the availability of an appropriate 
specimen. Several metabolites may be affected by different factors such as medication, 
environment, fed versus fasting state, time and way of sample collection, storage and the 
processing time. For example, repeated freeze/thawing of cerebrospinal fluid (CSF) has been 
reported to result in changes in transthyretin peptide levels.(28) Failure to adhere to these 
standardized procedures could lead to false positive or false negative results. The less 
invasive sample types, such as urine and blood, are the most ideal and available samples for 
routine clinical analyses. A significant advantage of metabolomics is the capability of 
measuring a broad spectrum of metabolites in urine, serum, plasma, feces, sweat, saliva, 
blood, ascetic fluid, bronchial washes, prostatic secretions, soft tissues, dried blood spots 
(DBS), and CSF. In some applications, exhaled breath condensates are being used as a bio 
specimen for metabolic studies in asthma and airway inflammation,(29) as shown in Error! R
eference source not found.. The sample extraction method should be capable of targeting the 
maximum amount and classes of metabolites present in the target sample by pre-
concentrating the extracts and removing the interfering compounds. Sample preparation 
depends on the range of instrumentation used in metabolomics, where LC-MS/MS and NMR 
are the most commonly used techniques, requiring a clean sample with a compatible solvent 
before the analysis. Sample preparation for MS is accomplished in two stages; quenching 
metabolism and extracting metabolites.  
Quenching is the process of arresting or stopping the cellular metabolic activity with limited 
cell membrane damage. If quenching is not performed, the sample analyzed will not be 
representative of the metabolome at the point of sampling. Snap freezing in liquid nitrogen 
followed by sample storage at −80°C is an ideal and frequently used quenching methods. 
Other techniques like freeze-clamping, acid treatment, or using salt containing aqueous 
methanol at low temperatures have also been used for metabolism quenching.(30) Extraction 
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is the process of isolating the metabolites from the sample using organic solvents like 
methanol, chloroform, and acetonitrile depending on the matrix (serum, plasma, urine). The 
extraction of metabolites from tissues can be achieved by grinding them manually or by using 
an electric tissue homogenizer. Solvent extraction is the most commonly used mode of 
extraction for tissues due to higher extraction efficiency and minimum ionization suppression 
in LC-MS analysis.(31, 32)   The success of an analytical procedure depends on the quality of 
sample preparation, extraction procedure, cell type, chemical properties, and the reactivity of 
the cellular enzymes. The targeted groups of polar and/or non-polar metabolites are extracted 
by choosing solvents that are watersoluble or lipid soluble. NMR-based analysis requires a 
much simpler sample preparation without chemical derivatization. Thus, it is specifically 
useful for metabolic profiling of intact bio fluids and semisolids like intact cells or tissues. 
Hence, experimental procedures should be standardized and optimized to quench, extract and 
store the sample in an identical manner, because small differences in sample processing can 
have a significant effect on the sample quality and validity of the data acquired. 
1.3. Analytical methods in metabolomics 
A striking advantage of metabolomics is the easy transition from a profiling technology to 
specific clinical assays accessible for small molecules. The ultimate goal in metabolomics is 
to generate a reliable profile, for the maximum number of metabolites in a biological sample. 
However, the targeted metabolites have different chemo physical properties, such as 
hydrophobicity, acidity, charge, pKa, and size. Hence, simultaneous separation of all the 
metabolites in a single assay is quite challenging. An extensive metabolomics analysis can 
yield beneficial structural and sensitive quantitative data for complex biological samples. 
NMR and LC-MS/MS are the most commonly used spectroscopic techniques in 
metabolomics. LC- MS/MS is the universal technique, because of its combinability with 
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other chromatographic techniques that allow the separation of the vast majority of molecules 
with very few limitations  
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Blood LC-MS and NMR (47) 
Diabetesmel
litus Taurine,piperidine Saliva CE-ToF-MS (48) 
Oral cancer √  
Suberic acid, 
docosadienoic acid, tri 
hexose and tetra hexose 















Maltose, palmitic acid, 
glycerol, ethanolamine, 
glutamic acid, lactic acid, 
lysine and histidine 




Proline, C14:1,Phe/try and 
Gly/Ala ratios 













































aminopimelic acid CSF GC-MS (58) 
Glioma  √  
Creatinine,creatine,glucose 
















sease √  
Lysine metabolism in 
plasma and Kreb cycle in 
CSF 
Plasma 
and CSF TOF-MS (60) 
Mild 
Cognitive 
Impairment   
√ Cholesterol and sphingolipids transport  
Plasma 
and CSF TOF-MS (60) 





Metabolomics platform Biomarkers/Major 
findings Matrix Platform 
Refer-
ence Targeted Untargeted 
Alzheimerdi
sease  √ 
CSF lactate, serum 
Glucose  and valine in 
serum, urinary Taurine 
CSF/seru
m/urine NMR (61) 
Multiple 









arginine and dimethyl 
glycine 






























disease √  
Taurine, methanol, 
fumarate and tryptophan 
Fecal 







Butyrate, propionate, and 









Decrease in butyrate 
fermentation and enhanced 
excretion of non-esterified 
fatty acids and bile acids 








Increased levels of lactate, 






concentrations were low. 
Decrease in BCAA/AAA 
ratio  





Upregulation of alanine, 
choline, creatinine and 
phosphorylcholine 






Reduced levels of succinic 
acid and 
phosphatidylcholine at 
birth, reduced levels of 
Serum GCxGC ToF (71) 





Metabolomics platform Biomarkers/Major 
findings Matrix Platform 
Refer-








keto leucine and elevated 
glutamic levels 
Dysregulati








Exhaled Nitric oxide and 
FEV1(Forced Expiratory 
Volume in the first second) 
Breath 
condensate NMR (29) 
Childhood 
Asthma √  
Propionyl-carnitine and 






 √     
 
(Abbreviations: GC-MS: Gas Chromatography-Mass Spectrometry, LC-MS/MS: Liquid 
Chromatography-tandem Mass Spectrometry, LC-QToF-MS: Liquid Chromatography Quadrupole 
Time-of-Flight Mass Spectrometry, CE-QToF-MS: Capillary Electrophoresis Quadrupole Time-of-
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1.3.1. Nuclear magnetic resonance (NMR) 
NMR characterizes molecules based on the principle that certain molecular atoms can absorb 
and resonate radiation at specific frequencies when placed in a magnetic field. NMR is 
nondestructive and independent of any analytical separation techniques because samples are 
relatively fast and easy to run at a low running cost. It is also possible to improve on the 
absolute quantitation by spiking samples with a known concentration of the standard internal 
compound. However, in NMR, the sensitivity and difficulty of annotating the metabolites 
signals to useful biological information is a major limitation, in addition to the lack of 
connectivity to separation techniques such as High performance liquid chromatography 
(HPLC), which separates and quantifies compounds using operational pressures, or. Gas 
chromatography (GC), which separates and analyzing compounds that can be vaporized 
without decomposition or Capillary electrophoresis (CE) which employs electrolyte solution 
under the influence of an electric field, for separation.(73, 74) The slow convergence for 
computing the likelihood estimators was made faster through the introduction of an algorithm 
called Fast Maximum Likelihood Reconstruction (FMLR), where computation takes less than 
one minute for a single data set with far higher accuracy than previously possible.(75) A 
recent development, Magic Angle Spinning (MAS) NMR, has also been utilized for 
detection, and spatial mapping of metabolites in intact tissues and cells. This technique is 
often used to perform experiments in solid-state NMR spectroscopy and, more recently, 
liquid Proton nuclear magnetic resonance. The samples are spinning at the magic angle with 
respect to the direction of the magnetic field; the normally broad lines become narrower, 
which increases the resolution for better identification and analysis of the spectrum. 
Andronesi et al presented a brain tumor biopsy based study, where they detected 16 
metabolites within a short time of 45 min through molecular tissue characterization and 
fingerprinting.(76) Since, Breathomics is the metabolomics study of breath condesates or 
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exhaled air, an NMR-based study, done by coupling metabolomics and breathomics revealed 
a marked difference between healthy and asthmatic children.(29)This technology has also 
been used successfully for the determination of biomarkers for clinical conditions such as 
phenylketonuria and multiple sclerosis. Error! Reference source not found. (51, 55) 
1.3.2.  Gas chromatography-mass spectrometry (GC-MS)  
GC-MS is one of the most frequently used techniques in metabolomics for comprehensive 
analysis of primarily volatile and low molecular weight metabolites because of its low 
running cost, performance stability, result reproducibility and high peak capacity. Combining 
mass spectrometry with a separation technique such as GC amplifies the instrument’s 
specificity, sensitivity, and reproducibility. GC-MS is a fundamental technique because 
compound identification is greatly facilitated by extensive, easily searchable databases of 
molecular fragmentation. The analysis of volatile compounds that are not easily detectable by 
LC-MS/MS is possible with high separation efficiency and reproducible retention times. GC-
MS can be used only for volatile and thermally stable compounds, most of them requiring 
chemical derivatization, which prolongs the processing and analysis time. The similarity of 
molecular fragmentation patterns for structural isomers may make compound identification 
difficult in GC-MS.(77-79) Time-of-Flight (TOF) is a mass Analyser, wherein the ions are 
extracted (or produced) in short bursts or packets within the ion source and subjected to an 
accelerating voltage. These ions then ‘drift’ or ‘fly’ down an evacuated tube of specific 
length.The flight times are correlated against at least two known masses from an infused tune 
compound allowing a simple conversion to obtain a typical abundance versus mass to charge 
(m/z) spectrum. GC/MS system coupled with TOF analyzer provides rapid accumulation of 
spectra leading to excellent reproducibility and better signal-to-noise characteristics in a 
small volume of sample. For example, Miyamoto et.al (50) used GC- TOF-MS to examine 
the prognosis for lung cancer through biomarker discovery, as shown in Error! Reference s
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ource not found.Error! Reference source not found.(45) The GC-MS method has undergone a 
few modifications over the past decade, with respect to the mass analyzers used such as TOF 
and the triple quadruple (QqQ). The latest advancement is two-dimensional chromatographic 
separation system (GCxGC-MS), which has been used recently for biomarker selection of 
candidates from untargeted metabolomics analyses.(80).TOF analyzers are preferred because 
of their higher scan speed, sensitivity, compatibility with GC and high resolution as a new 
analyzer, resulting in better characterization of unknown metabolites by using accurate 
masses. This technique has also proved to be useful in studying inborn errors of metabolism 
and identifying early biomarkers for a variety of other human disorders such as polycystic 
ovary syndrome, gestational diabetes mellitus, pediatric chronic kidney diseases, mild 
cognitive impairment, Alzheimer, and breast, thyroid and lungs cancer as shown in Error! R
eference source not found.. (52, 53) 
1.3.3.  Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
LC-MS/MS is not only a powerful analytical technique that combines the separating power of 
liquid chromatography with the highly sensitive and mass spectrometry, but also an important 
analytical tool in metabolomics, where these two universal techniques accommodate the 
chemical diversity of metabolites. (Hydrophobicity, charge, pKa, size, stability). Analysis of 
a wide range of metabolites, ranging from high to low molecular weight and from hydrophilic 
to hydrophobic can be performed by selecting the appropriate stationary phase and mobile 
phase, such as using ion-pairing reagent with phosphor sugars, ATP, AMP.(81, 82) 
Electrospray ionization (ESI) is the source of choice for metabolomics in LC-MS/MS 
because it can ionize a wider spectrum of molecules softly. However, ESI lacks quantitative 
capabilities due to the matrix or ion suppression effects.LC-MS/MS based metabolomics 
analysis of polar and high molecular weight metabolites does not require derivatization. Ultra 
pressure liquid chromatography (UPLC) is a separation technique applicable for particle less 
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than 2μm in diameter to acquire better resolution, speed, and sensitivity compared with high-
performance liquid chromatography (HPLC). The introduction of UPLC (Waters 
Corporation) in 2004, added advantages like shorter run time, improvement in sensitivity, and 
high peak capacity to LC-MS based metabolomics. LC-MS/MS is now widely used in 
clinical metabolomics for precision medicine and disease biomarker discovery applications 
such as cancer and diabetes mellitus as shown in Table 1.1. (47, 53-55) These discovered 
biomarkers will not only contribute to the development of precision diagnosis and treatment 
but also to personalized susceptibility disease assessment, health monitoring, and 
preventative medicine. Fourier transform ion cyclotron resonance (FT-ICR) remains as the 
MS method with the greatest mass resolving power of 1,000,000 FWHM (Full Width at Half 
Maximum), using m/z measurement based on cyclotron frequencies of the ions in a fixed 
magnetic field. The Orbitrap MS combines premium dual- pressure linear ion trap with a 
novel high field Orbitrap™ mass analyzer to create an analytical instrument, which is easier 
to use and maintain and can easily be coupled to LC by ESI source. Orbitrap based 
metabolomics is regularly employed in clinical metabolomics analysis which had been 
applied successfully in the diagnosis of various inborn errors of metabolism such as aromatic 
L-amino acid decarboxylase deficiency, adenylosuccinate lyase deficiency (ADSL) 
deficiency, secondary ADA (adenosine deaminase) deficiency in sickle cell disease as well as 












Figure 0.2: Examples of biomarker development pipelines (Abbreviation: LC-MS/MS-Liquid 
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1.4. Metabolomics biomarker discovery pipeline  
The biomarker discovery pipeline uses a combination of technologies to capture the data, 
which is then translated to select for biomarkers that most reliably detect the disease as 
shown in Error! Reference source not found.. The pipeline begins with the analysis of a b
iospecimen on a targeted analysis platform using a method, which is robust and reproducible 
to ensure consistent performance. The biomarker candidates that emerge are further evaluated 
or validated across a large number of samples in the next stage of the pipeline. Validation 
must be sufficiently robust to achieve a high level of performance for routine clinical use and 
ensure that the data is of the highest quality regarding the clinical question posed. Biomarker 
candidates at this stage can be measured accurately with sensitive and reliable methods, 
which have been proven to distinguish patients from healthy subjects. Since mGFR 
(measured glomerular filtration rate) is an impractical procedure in routine clinical practice, 
serum creatinine and eGFR (estimated glomerular filtration rate) were the only traditional 
metabolic biomarkers of renal function regardless of the specific underlying kidney disease. 
Hence, despite their distinct molecular causes, acute, and chronic renal injuries were 
recognized by the same biomarkers which do not inform the pathophysiology of these 
disorders. 
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Alternatively, a metabolome wide association study done in kidney function and disease 
identified six relevant analytes “C- mannosyltryptophan, pseudouridine, N-acetylalanine, 
erythronate, myoinositol, and N-acetylcarnosine,” which together have been referred to as 
“accuGFR”TM. (86) The discovery of anti-phospholipase A2 receptor antibodies which are 
also used as a prognostic biomarker of membranous nephropathy already impacted on the 
management of patients with this kidney disease.(87) Biomarkers evaluation in different 
matrices in patients with complex disorders that lack specific diagnostic markers may allow 
accurate and more confident diagnosis. For example, in Alzheimer disease, cholesterol, and 
sphingolipids transport are perturbed in both CSF and plasma, in contrast to perturbed lysine 
and Krebs cycle metabolism found in individuals with mild cognitive impairment.(88)  
A metabolomics study can be performed either in a targeted or untargeted manner depending 
on the MS platform, and the data processing strategy as summarized in Error! Reference s
ource not found. . Untargeted analysis covers and attempts to identify all detected peaks above 
the noise threshold using scan mode and utilizes both annotated and unannotated peak 
information for statistical analysis. The comprehensive analysis of the detected metabolites in 
a biological sample using this approach is used mainly for “clinically relevant” biomarker 
discovery. On the other hand, the targeted analysis seeks only known metabolites detected by 
selected reaction monitoring (SRM) using triple quadruple tandem mass spectrometry or 
selected ion recording (SIR) by GC-MS to validate a biological hypothesis regarding levels 
of known and expected endogenous metabolites. 
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Since the targeted strategy is based on the prior biochemical knowledge of the endogenous 
metabolites, and the sample content, biomarker discovery is achieved by mapping the 
absolute metabolic changes to the pathophysiological knowledge or integrated with other 
“omics” datasets.(22, 89, 90) Performing an untargeted metabolomics study requires an 
advanced analytical method, automated spectral data processing, and biological data 
interpretation and hypothesis generation.(90) High resolution tandem mass spectrometers 
such as QTOF, FTICR, and Orbitrap are preferred instruments for untargeted metabolomics 
studies due to their ability to elucidate structural information and speed of data acquisition, 
whereas QqQ and conventional ion trap mass spectrometers have been used for targeted 
metabolomics studies.(92) 
In an illustrative study of Chinese men with infertility and renal insufficiency, a metabolomic 
signature of 41 differentially expressed, potential biomarkers related to aromatic amino acids, 
tri carboxylic acid cycle, and sphingolipid biosynthesis and metabolism were identified. 
Therefore this panel of metabolites helped in the understanding of the pathogenesis of kidney 
disease associated with male infertility.(43) Also, multivariate analysis of an untargeted 
metabolomics study of urine samples from 41 atopic asthmatic children showed reduced 
excretion of urocanic acid, methyl imidazole acetic acid and an unknown metabolite 
resembling the structure of an Ile-Pro fragment.(93) 
1.4.1.  Chemometric untargeted profiling 
The metabolomics data obtained from patient samples and the relevant disease 
pathophysiology are highly complex and require computational approaches to convert the 
raw data into biological knowledge and connect them in a meaningful way. Data mining of 
this vast array of metabolites is a major challenge, and various statistical techniques are 
required to manage the data and follow a defined workflow to avoid any misinterpretations 
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Error! Reference source not found.. (94)Processed data obtained from metabolomics run has to b
e uploaded to a web based or in-house built software program where data processing occurs 
in which various forms of raw data are converted into data matrices suitable for statistical 
analysis. Data normalization corrects any unwanted systematic variations and adjusts the data 
by identifying outliers and missing values. The choice of pretreatment method depends on the 
biological question that needs to be answered. The goal of data analysis is to determine 
relevant features and detect unique patterns, to assess differences between the phenotypes and 
facilitate classification/prediction. Multivariate or univariate analyses are usually performed 
for statistical analysis, where the multivariate analysis simultaneously analyzes all the 
variables, whereas univariate analysis is best suited for two groups of variables. Principal 
Component Analysis (PCA) is the most frequently used approach for data mining as an 
unsupervised approach and forms the basis of multivariate analysis.(95-97) 
Pathway analysis helps to enhance metabolite set enrichment analysis for pathways by 
considering the structures of pathways and dynamic pathway visualization. Pathway analysis 
along with bioinformatics study helps greatly in biological interpretation and validation of 
computationally derived results.(98) The purpose of enrichment analysis is to test the validity 
of the biological groups (pathways, genotype) of metabolites that are significantly enriched in 
the queried data. Ingenuity Pathway Analysis (IPA) (QIAGEN bioinformatics, Redwood city, 
CA), is a software application that enables analysis, integration, and understanding of the 
complex “Omics” datasets, which in turn provides vital information on the candidate 
biomarkers in the context of metabolomics and proteomics experiments 
1.4.2. Targeted metabolomics profiling 
In the chemometric approach for data interpretation, PCA is unsupervised and multivariate 
analysis is based on projection methods. Each principal component (PC) is a linear 
combination of original data parameters, and the successive PC explains the maximum 
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amount of variance possible, not accounted for by the previous PCs. The principle of Partial 
Least Squares (PLS) is very similar to PCA, except for a labeled set of class identities being 
added. The PLS algorithm maximizes the covariance between the X variables and the Y 
variables. The orthogonal Partial Least Squares (OPLS) method is a recent modification of 
the PLS method that helps overcome pitfalls; as it separates systematic variation in X into 
two parts, one linearly related to Y and and one unrelated (orthogonal).(41, 49) Targeted 
metabolomics profiling is fundamentally different from chemometric approaches where the 
compounds in a given biofluid or tissue extract are identified and quantified by comparing the 
spectrum of interest to a library of reference spectra of pure compounds. The advantage of 
targeted metabolomics profiling is that it does not require the collection of an identical set, 
and is more amenable to human studies or studies that require less day to day monitoring. The 
main disadvantage is the relatively limited size of most current spectral libraries available for 
metabolite identification and interpretation. There are many free web based tools for data 
interpretation; some of which are summarized in Table 0.2. 
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Table 0.2: Web-based tools for targeted metabolomics data analysis.  
 
Name of the web-





Comprehensive analysis of quantitative 
metabolomics data, which includes data 
processing, data normalization, statistical 
analysis and high levels functional 
interpretations. Heat maps generated show 
fold changes of small metabolic compounds 
in different study groups which are involved 
in the cohort 
(99) 




Web-based tool to interpret patterns of 
human or mammalian metabolite 










 Capable of extracting semi-quantitative data 
from raw data files which allow rapid 
biological insight 
(101) 
MetaQuant  Bioinformatics.org/metaquant. 
Java-based program for the automatic 




Allows users to upload easily and process 
liquid chromatography/mass spectrometry 
data for untargeted metabolomics 
(103) 
MZmine https://omictools.com/mzmine-tool  
Standalone Java application software, which 
implements solutions for several stages of 
data processing, including input file 
manipulation, spectral filtering, peak 
detection, chromatographic alignment, 
normalization, visualization and data export 
(104) 
MBRole  csbg.cnb.csi.es/mbrole/ 
Web server for carrying out over 
representation analysis of biological and 
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Together, with the results of the metabolic pathways analysis and other omics data, identified 
biomarkers are used to explain individual variations in disease and treatment responses. Also, 
individual or multiple biomarkers can be used for diagnostic purposes. Hence, metabolomics 
can be a valuable tool for precision medicine, for example; in the management of cancers like 
acute myeloid leukemia, the overexpression of 2-hydroxyglutarate has a therapeutic and 
multiple sclerosis.(106, 107) Table 0.3 
1.5. Clinical Metabolomics towards Personalized Medicine  
Personalized or precision medicine is a tool for disease prevention and management, which 
takes into consideration the individual's genomic variations, biochemical profile, 
environment, and lifestyle and aims at enabling advanced clinical decision-making. The 
introduction of President Obama's “Precision Medicine Initiative” in January 2015 has 
significantly popularized personalized medicine since then. As the percentage of patients for 
whom a drug is ineffective is quite significant in some groups such as cancer drugs (75%), 
Alzheimer's drugs (70%), personalized medicine is expected to help clinicians provide the 
most efficient management which requires personalized diagnosis and treatment.(106) In 
principle, the concept of personalized medicine originally focused on genotype guided 
prescription of drugs safely and efficiently. Empirical switching between drugs to find a 
desirable one with the satisfactory therapeutic response and least toxicity profile is not an 
ideal clinical practice. Thus, finding biomarkers that inform the understanding of disease 
pathophysiology should help in personalizing the diagnosis and management stratification. In 
addition, MS-based metabolomics has high potential to detect the molecular footprints of 
human disease, where ideally, the discovered biomarkers can be validated for use in routine 
clinical practice.  




Table 0.3: Comparison between the analytical techniques in metabolomics (NMR, GC-MS and 
LC-MS) 
 
Techniques NMR GC-MS LC-MS 
Target 
molecules 
Amino acids, organic acids 
and sugars (water soluble) 
Water soluble and some non-
water soluble 
Amino acids, organic 





bacterial, animal tissue 
extracts and food 
Bio-fluids, plants, bacterial , 
animal tissue extracts and 
food 
Bio-fluids, plants 
,bacterial, animal tissue 














Juvenile idiopathic arthritis 







Breast and pancreatic 
cancer(48), Mild 











30-120 120-360 30-60 
Run time 
( min/sample) 20-90 30-60 2-30 
Data analysis 
( min/sample) 30-60 30-60 2-30 
Limit of 




20-50 20-50 2-500 
Overlapping 
metabolites 10-15 10-15 10-15 
Cross checking 
(%) 10-30 10-30 10-30 
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Thus, there is a need for rigorous, standardized protocols, and pipelines for biomarkers 
discovery, analysis, validation, and reporting. Ultimately, these metabolic biomarkers may 
also lead to the development of novel therapeutics biomarkers that can be used to determine 
disease predisposition, such as BRCA1 and BRCA2 genes in breast cancer, diagnosis, 
prognosis or therapeutic responses. On the other hand, a diagnostic biomarker such as sweat 
chloride is used in combination with the clinical presentation to confirm a suspected 
diagnosis compatible with cystic fibrosis (surrogate). Oncotype Dx, a 21 mRNAs expression 
profile, is used clinically as a prognostic biomarker in patients with early stage, estrogen 
receptor positive breast cancer to predict recurrence risk as well as the likelihood of benefit 
from chemotherapy after breast cancer surgery. IL-17F, a predictive biomarker, could predict 
poor response to interferon-beta therapy in some patients with relapsing remitting multiple 
sclerosis.(106, 107) 
1.5.1. Personalized medicine in cancer 
Cancer is a major public health concern and a leading cause of death worldwide, accounting 
for 7.6 million deaths in 2008. Deaths from cancer are projected to rise to over 11 million by 
2030. Since early diagnosis will improve the prognosis, the discovery of sensitive cancer- 
related biomarkers through a personalized approach has become a priority in cancer research 
and is used as a detection tool for therapeutic targeting of metabolic enzymes. The successful 
translation of such strategies to the treatment of cancer would allow earlier intervention to 
improve survival. For example, in patients with non small cell lung cancer, targeted drugs are 
available to treat these tumors that harbor EGFR and ALK mutations.(111) The central 
carbon metabolism varies between cancer and normal cells as described by Warburg in 1930, 
when he demonstrated that cancerous cells exhibit glucose fermentation (glycolysis) as an 
oxidation mechanism over oxidative phosphorylation even when enough oxygen is usually 
present.(112)This effect could result in a significant metabolic perturbation, which is tumor 
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specific. Several key metabolic enzymes might be secondarily affected by the alteration of 
oncogenes (i e, RAS, PTEN, ERK) and onco- transcription factors (i e, HIF, p53, c-MYC), 
which contribute to metabolic shifts as observed in cancer. An LC-MSMS-based 
metabolomics study showed that shift in blood lysophosphatidylcholine metabolism might 
drive tumorigenesis in breast, prostate, and colorectal cancer. These biomarkers were 
validated to show the clinical predictive value of cancer status with 69% sensitivity and 94% 
specificity.(53) Using LC/MS-Q-TOF, Bannur et al demonstrated differential expression of 
metabolites in patients with acute lymphoblastic leukemia undergoing treatment compared to 
those in relapse. Hence, these differences in metabolomic expression could be used to 
monitor disease progression, and potentially guide additional therapeutic interventions.(113) 
Slamon et al, first described the role of amplification of the oncogene ERBB2 (HER2), a cell 
surface tyrosine kinase non-ligand binding EGF receptor, in human breast and ovarian 
cancer.(114) Herceptin (Trastuzumab), an anti-ERBB2 (HER2) was developed to suppress 
the oncogenic effects of HER2 protein overexpression, which then served as a precision 
medicine, FDA approved diagnostic and therapeutic biomarker in HER2 positive metastatic 
breast cancers. However, Trastuzumab is not beneficial and may harm patients with cancers 
that do not overexpress HER2, as it is directed only to 30% of breast cancers with over 
expression of HER2. Tenori (et al), analyzed 579 serum samples from women with metastatic 
breast cancer being treated with paclitaxel plus either anti-HER2 treatment (lapatinib) or 
placebo. The metabolic profiles were compared with the time to progression, overall survival 
and treatment toxicity. The subgroup of patients with HER2 positive disease treated with 
paclitaxel plus lapatinib were found to be statistically significant compared to the other 
group, indicating the importance of the applicability of metabolomics in personalized 
response to medicine.(115) 
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Liesenfeld et al in 2013 published a literature review on metabolomics in cancer research, 
which included 106 studies reporting on 21 different types of cancer in seven different 
sample types. Alternations in metabolites in various types of cancer and standardization of 
data analysis showed that metabolomics could emerge as a tool for future applications in 
epidemiology and translational cancer research.(116) More recently, the introduction of 
iKnife, a metabolomics biomarker based device, has created a sensation in the field of cancer 
surgery.(117) This device combines an established technology “Electro- surgery,” which was 
invented in the 1920s, and the new emerging technology “Rapid Evaporative Ionization Mass 
Spectrometry (REIMS).” This new technology promises to almost instantly identify and 
personalize the clinically relevant, tumor related metabolites present in human tissue  by 
analyzing the smoke (heat generated from the current vaporized tissue) that is released during 
electro surgery. Once the REIMS technology is validated clinically, the “smoke based” 
metabolomics profiling of healthy and cancerous cells can instantly inform the surgeon 
whether the tissue is healthy or cancerous. 
1.5.2. Personalized medicine in diabetes 
Diabetes mellitus (DM) is a chronic disease characterized by hyperglycemia, caused by the 
autoimmune mediated failure of pancreatic β- cell function and resulting lack of insulin 
production (type 1 or insulin dependent DM) or by insulin resistance (type 2, non- insulin 
dependent DM). Fasting plasma glucose and hemoglobin A1c (HbA1c) along with oral 
glucose tolerance test are the traditional tests done to diagnose people with diabetes mellitus 
as well pre-diabetes. Since HbA1C levels reflect glycemic control over the previous several 
months, there has been ongoing interest in developing newer more precise disease specific 
biomarkers.(118, 119) Insulin resistance (IR), is a known early major risk marker for 
metabolic and cardiovascular disease and can precede dysglycemia in prediabetes and type 2 
diabetes mellitus (T2DM) by some years. In contrast to the traditional glycated hemoglobin 
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(HbA1C), new non- glycemic (α-hydroxybutyrate, linoleoyl-glycerophosphocholine (LGPC), 
oleic acid) biomarkers, in combination with insulin, provide a novel and comprehensive 
measure of insulin resistance in a single assay. (Quantose IR™).(119, 120) Alpha 
hydroxybutyrate is positively correlated with insulin resistance and is indicative of early beta 
cell dysfunction, while L-GPC, is negatively correlated with IR shows impaired glucose 
tolerance and oleic acid is positively correlated with increasing lipolysis and IR.  
Lastly, increase insulin level is characteristic of IR and is an independent risk factor for type 
2 diabetes and cardiovascular disease. Quantose IR is a clinically validated fasting blood test 
for insulin resistance and pre-diabetes. The Quantose IR Score is based on the combined 
levels of these four biomarkers. Unlike the known T2DM related metabolomic biomarkers 
like branched chain amino acids, Wang-Sattler et al showed significant perturbations in 
glycine, lysophosphatidyl cholione (C18:2) and aceltycarnitine levels in pre-diabetic 
individuals with impaired glucose tolerance when compared to those with normal glucose 
tolerance. Metabolite protein interaction networks analysis linked these three biomarkers to 
seven known T2DM related genes (PPARG, TCF7L2, HNF1A, GCK, IGF1, IRS1, and IDE) 
through related enzymes or proteins and was confirmed by demonstrating altered 
transcription levels.(121) Suhre et al showed that perturbations of metabolic pathways linked 
to kidney dysfunction (3-indoxyl sulfate), lipid metabolism (glycerophospholipids, free fatty 
acids) and interaction with gut microflora (bile acids) might detect diabetes related 
complications under sub-clinical conditions.(47) 
Patients with T2DM enjoy the clinical availability of several classes of antidiabetes drugs 
including sulphonylureas, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor 
agonists, thiazolidinediones, sodium- glucose cotransporter-2 inhibitors, and biguanides 
(metformin). Given the complex genetics underlying the etiology of T2DM, it is not 
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surprising to note varying degrees of benefit and harm of these drugs in such patient 
population. Therefore, application of a personalized medicine approach based on recently 
discovered pharmacogenetics data is becoming increasingly useful. This is most evident in 
patients with sulphonylurea sensitivity, with HNF1A maturity-onset diabetes of the young 
(MODY) and patients with T2DM in combination with reduced function alleles at CYP2C9. 
This resulted in reduced metabolism of sulphonylureas, therefore increasing the risk of 
related side effects and severe metformin intolerance associated with reduced function 
organic cation transporter 1 (OCT1) variants, exacerbated by drugs that also inhibit OCT1. 
1.5.3.Inborn errors of metabolism 
Inborn Errors of metabolism (IEM) are inherited disorders typically caused by recessive 
mutations in the genes encoding metabolic enzymes. There are hundreds of IEMs and they 
have wide clinical spectrum. In a proof of concept study, untargeted metabolomic profiling 
was used efficiently in biomarker identification in patients with disorders of propionate 
metabolism. Out of 3500 segregated metabolites, propionyl carnitine was identified as 
distinguishing biomarker between methylmalonic and propionic acidemias. Perturbations in 
γ-butyrobetaine (despite normal free carnitine), isovalerylcarnitine and unsaturated 
acylcarnitines were associated with these two diseases and contributed to their improved 
understanding, disease diagnosis, and clinical patient evaluation.(72) Recently, 
phenylketonuria pathogenesis was studied using metabolomics approaches, where patient’s 
urine samples were profiled using GC-MS and NMR. Through multivariate and univariate 
statistical analyses, additional pathophysiological perturbations were found in arginine, 
proline, alanine, aspartate, and glutamate metabolism pathways.(123) 
Miller et al, studied 120 individual plasma samples and demonstrated the possibility of 
prospective screening of IEMs that might otherwise require ordering multiple confirmatory 
Introduction to Metabolomics 
36 
 
tests. This semi quantitative method detects 900 compounds, including 500 human analytes in 
a single human plasma sample.(124) These and other related studies formed the basis for the 
commercial launching of the two comprehensive targeted metabolomics based screens: 
Global Metabolomic Assisted Pathway Screen (GMAPS™) and MetaIMD™.(85) (84) 
In summary, the current clinical practice approach works for the majority of the population, 
but misdiagnosis, symptoms relapse, and unfortunate side effects that occur in some people 
limit the clinical efficacy in disease control. By comparing the metabolomic profiles of two 
or more disease phenotypes, biomarkers related to the disease specific perturbations can be 
investigated to develop a personalized approach used in treating and monitoring disease 
progression.(125) Since metabolomics can be performed on various biological matrices 
including CSF, urine, plasma, and sweat, standardized procedures are critical to rule out 
external interferences originating from those matrices. The time gap between sample 
collection and sample preparation, if not controlled, can result in significant variability in the 
metabolomics profile. Furthermore, improper storage and repeated freeze-thawing cycles hurt 
the quality of the obtained data.  
Dealing with the simultaneous analysis of different classes of metabolites, the chemical 
complexity, and molecular heterogeneity can pose technical challenges in analyzing them in a 
single assay. Choosing a single sample preparation method that provides both adequate 
sample clean up and universal extraction properties is also challenging.(126) Studies have 
shown that it is not practical to utilize a single stationary phase for the separation of a wide 
range of metabolites with different polarities.(127) Furthermore, unknown exogenous 
metabolites can be observed in the metabolome, where uncertainty can be avoided by 
generating larger databases to enable better separation from “normal” routine samples.(128) 
In GC-MS, the type and amount of derivatization reagent need to be optimized carefully 
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otherwise it may introduce additional interfering compounds, produce unexpected derivatives 
and by-products, and may even damage the column. 
Metabolomics data are vast and complex; however, the use of multivariate analytical 
techniques for data processing and availability of high-quality analysis software has made the 
data less complex. Improved methods for metabolomics data analysis are regularly published, 
making it difficult to choose the most appropriate approach. Nonetheless, metabolomics is 
still somewhat lagging behind other “omics” due to limited technical development, database 
challenges, training, and costs. More collaborations and exchanges with scientists in other 
disciplines need to be encouraged. Metabolomics has influenced pharmacological research to 
a great extent and made personalized health care increasingly possible. In silico models are 
increasingly used to elucidate the effect of drugs on metabolic phenotypes before moving on 
to in vivo testing. Gut microbiota associated with specific diseases can be better understood 
with the help of metabolomics, which can contribute to drug development.(129) Despite all 
these challenges, metabolomics along with the other “omics” facilitates the development of 
more efficient and precise biomarkers important for the understanding of disease progression 
and drug development. 
Van der Greef et al, recommend a one case clinical trial approach, wherein patients are 
evaluated by a challenge test approach like the oral glucose tolerance test (OGTT) routinely 
done to test for early onset of T2D, and is evaluated against an extensive database of 
information on environment, lifestyle, nutrition, psychological recommendations and also 
genotype/phenotype information related to health and disease. A Metabolomics study of the 
phenotype along with the challenge test will help to diagnose the disease quite earlier and 
also improve the health care system.(130) Due to the considerable improvements in health 
care delivery for individuals with acute health conditions, the incidence of chronic diseases is 
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rising sharply. It is estimated that by 2020, chronic diseases are likely to account for three-
quarters of deaths worldwide. Hence, there is a need to develop new effective approaches for 
personalized diagnostics with impact on therapeutic intervention and monitoring. 
Metabolomics contributes significantly to the characterization of various disease phenotypes 
and the identification of personalized metabolic features that can predict response to 
therapeutic interventions.  
The contribution of metabolomics to personalized health care and biomedical sciences, is 
immeasurable and has enabled the discovery of biomarkers specific enough to distinguish 
patients in various health states from healthy subjects. Differentiating DOCK8 deficient 
patients from those with atopic diseases at an early stage is significant in a child’s 
development, as treatment modalities differ considerably. To date, no metabolomics data is 
available to differentiate between DOCK8-deficient and AD patients, which present with 
similar clinical profiles. Therefore using metabolomics to understand the metabolic 
fingerprinting in this study cohort may help investigate the inflammatory responses that 
develop during disease pathogenesis. 
1.6.  Summary and Research synopsis of the Thesis 
In this chapter, a detailed review of current metabolomics literature has been highlighted, to 
understand the metabolomics strategies and analytical approaches that focus on the discovery 
of biomarkers. The literature was derived from metabolomics biomarker studies in the field 
of cancer, diabetes, obesity, inborn errors of metabolism and personalized medicine.  
The work presented in this PhD thesis provides a comprehensive biomarker discovery study 
in DOCK-8 deficient and AD patients. Particular emphasis was laid on building a 
comprehensive metabolomics panel and in discovery of cytokine and metabolomics 
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biomarkers. Since these patients have food allergies in common, food sensitization patterns 
were also studied. 
In Chapter 2, an extensive Quantitative profiling of Cytokines and Chemokine was 
generated and the comprehensive cytokine profile in HIES patients revealed distinctive 
biomarkers that differentiate between the DOCK8 deficient and AD patients. The unique 
expression profile of various inflammatory cytokines in patients with DOCK8 deficiency vs. 
atopic dermatitis likely reflects disease-specific perturbations in multiple cellular processes 
and pathways leading to a predisposition to infections and allergies seen in these patients. 
Chapter 3, details a robust comprehensive metabolomics method using tandem mass 
spectrometry for identification of the biomarker metabolites involved in DOCK-8 deficient 
and AD patients. 
In Chapter 4, in-depth metabolomics technologies including CIL LC-MS targeting the 
amine/phenol sub-metabolomes was used to study and explore differentially expressed 
biomarkers in DOCK8-deficient and AD patient groups. These biomarkers potentially reflect 
upon the disease pathogenesis and may contribute towards improved disease monitoring and 
ultimately novel clinical interventions.  
In the final Chapter 5, Sensitization patterns and cross reactivity of food and aero-allergens 
was analysed using the ImmunoCAP ISAC in correlation with the metabolomics and 
cytokine profiles from chapter 2 and 4. The distinct metabolic fingerprinting in food allergy 
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The work presented in this thesis provides an important contribution towards the discovery of 
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Hyper‐IgE (IgE) syndromes [HIES] are primary immunodeficiency disorders, characterized 
by elevated IgE levels, recurrent staphylococcal skin abscesses, eczema, and pulmonary 
infections.(1) They are genetically heterogeneous inherited syndromes, first described by 
Davis et al.(1966) and linked mainly to mutations in signal transducer activator of 
transcription 3 (STAT3) or dedicator of cytokinesis 8 (DOCK8), either in an autosomal 
dominant or recessive pattern, respectively.(2-4) Recently, additional mutations in 
phosphoglucomutase 3 (PGM3), involved in the glycosylation pathway, ZNF341 (5, 6) and 
IL6ST have been identified in the autosomal recessive forms of HIES.(7, 8) In contrast to 
STAT3 mutations, DOCK8‐deficient patients have severe T‐cell dysfunction associated with 
severe inflammation and allergic manifestations.(9, 10) Common pathogens include herpes 
simplex virus (HSV), human papillomavirus (HPV), molluscum contagiosum virus (MCV) 
and varicella zoster virus (VZV). Susceptibility to recurrent sinopulmonary infections is also 
caused by a wide variety of pathogens including streptococcus pneumoniae, haemophilus 
influenzae, pneumocystis jirovecii histoplasma capsulatum, and legionella pneumophila. 
CD8 T cells play an important role in immunity, (11) Randall et.al (2011) showed that 
DOCK8 plays a critical and intrinsic role in peripheral CD8 T cell survival and function.(12) 
Most of DOCK8 patients have low absolute counts of both CD4 and CD8 T cells, indicating 
a T cell immunity defect.Cancers related to cutaneous viral infections and T‐cell lymphoma 
had been described in DOCK8 deficiency, which is thought to be related to impaired CD8 T 
cell functions suggesting that DOCK8 has a tumor suppressor function.(9) DOCK8 is mainly 
expressed in cells of the immune system and controls many cellular processes including 
migration, phagocytosis, and adhesions.(10) A study by Su Hu et al. emphasized the 
regulatory role of DOCK8 on lymphocytes, where DOCK8 is essential for the activity of 
these immune cells, and its absence leading to susceptibility to infection.(8) 
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DOCK8 is one of eleven members of the DOCK 180 superfamily, (14) and has a typical 
guanine nucleotide exchange factor (GEF) for small G proteins, of Rho family such as Rac 
and Cdc42.  DOCK8 mainly has two related conserved protein domains DHR1 and DHR2, 
wherein the DHR1 domain binds to phosphatidylinositol-3, 4, 5-triphosphate (PtdIns 3,4,5)P3 
and mediates the recruitment of DOCK proteins to the plasma membrane. (15, 16) DOCK8 
acts as an adapter connecting Toll like receptor 9(TLR9) to the signalling cascade of B cell 
antigen receptor (BCR). DOCK8 also connects TLR9 signalling to the activation of STAT3 
and activation of TLR9 by its ligand CpG induces the formation and stabilization of a 
trimeric signalling complexes consisting of MYD88, PYK2 and DOCK8. This leads to the 
activation of src kinases which together with syk phosphorylate, activates STAT3, whose 
target genes are linked to the survival of B cells and production of immunoglobulin. This 
pathway indicates that DOCK8 is essential for TLR9-driven B cell proliferation and 
immunoglobulin production. (17, 18)  
DOCK8 patients are prone to autoimmune diseases; autoimmunity has been linked to defects 
in B cell tolerance sites involved in the elimination of auto reactive B cells. Janssen et.al 
(2014) showed that DOCK8 plays a crucial role in Treg cell homeostasis function and 
peripheral B cell tolerance.(19) Natural killer T( NKT) cells are a group of immunoregulatory 
T lymphocytes that play a important role in many diseases including viral infections, cancer, 
autoimmunity and allergy.(20) DOCK8 deficiency results in weak development of NK T 
cells thereby affecting their formation, development and survival, resulting in susceptibility 
to infections and malignancy.(21, 22) 
 Atopic dermatitis (AD) is a pervasive pediatric, chronic, highly pruritic inflammatory skin 
disorder, commonly associated with high IgE level. Eczematous skin lesions and pruritus are 
common overlapping clinical features in all subtypes of HIES and AD suggesting immune 
dysregulation. Through Endothelial Per-Arnt-Sim (PAS) domain protein 1 (EPAS1) 
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dependent activation of the IL‐31 promoter, CD4+ T cells from DOCK8‐deficient mice were 
recently shown to produce large quantities of IL‐31, a significant pruritogen associated with 
AD.(11) 
 It is speculated that the severity of infection and the skin hypersensitivity could be due to an 
altered cytokine production pattern in DOCK8 deficient and AD patients. The clinical 
management of patients with moderate-severe AD and DOCK8 deficiency can be challenging 
and quite complex, as they share many clinical features in common. A study by Janssen et.al 
(2014) has distinguished DOCK8 deficiency from AD using flow cytometry. CD3 and CD4 
lymphopenia and decreased CD8 T cells coupled with decreased memory B cells is strongly 
suggestive of DOCK8 deficiency rather than AD in a patient with severe eczema.(24) Patient 
and family education, avoidance of known contact, food and aero-allergens, controlling 
pruritis (using antihistamines) and proper skin hygiene and hydration using emollients and 
moisturizers are important first steps of treatment. Topical therapy includes using 
corticosteroids of varying potencies, calcineurin inhibitors, phosphodiesterase 4 (PDE4) 
inhibitor. (crisaborole) 
Acute exacerbations of chronic AD may require systemic corticosteroids. Phototherapy as 
well as immune suppression (such as oral cyclosporin) is more frequently and regularly used 
in adults compared to children. More recently, systemic (subcutaneous) immunomodulation 
using dupilumab, an (IgG4) anti-IL‐4 and IL‐13 receptor blocker, became available as an 
alternative option for patients with very difficult to control moderate to severe atopic 
dermatitis. Viral and bacterial cutaneous infections also require special attention and prompt 
management. As DOCK8 deficiency is a complex systemic disorder, these patients require 
additional supportive therapies and ultimately a definitive curative treatment with 
hematopoietic stem cell therapy (HSCT). Adequate nutritional support (to prevent failure to 
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thrive and secondary nutritional deficiencies), pulmonary and liver function assessments and 
monitoring, prophylactic antibacterial, antiviral as well as antifungal (cryptosporidial 
infections) and immunoglobulin prophylaxis are frequently required. Due to the high 
morbidity and mortality associated with DOCK8 deficiency, and as several clinical reports 
have demonstrated high survival, robust cellular and humoral immune reconstitution and 
improvements in both infections and atopy post‐ transplant, HSCT became the preferred 
definitive therapy for this and many other disorders.(25-30) 
Cytokines and their receptors play an essential role in the development, homeostasis as well 
as pathogenesis of tumors in HIES. High levels of IgE seen in these patients signal cytokine 
dysregulation and an imbalance in Th1/Th2 cytokine profile contributing toward the 
pathogenesis of the disease.(31) Altered or dysregulated cytokine expression leads to 
pathologies such as inflammation, tumorigenesis, and autoimmunity. Patients with DOCK8 
deficiency have increased Th2 cells (expression of IL‐4, IL‐5, IL‐10, IL‐13), which indicate 
its role in T‐cell regulation of allergic disease.(32) IL‐31 produced by Th2 cells is involved in 
promoting dermatitis and epithelial responses that characterize allergic and nonallergic 
diseases.(33) Renner et al. (2005) reported that despite the imbalance in T cell responses in 
HIES patients there is no defect in toll-like receptor signalling, (34, 35) These studies have 
led to the hypothesis that HIES might be a disease of impaired inflammatory responses rather 
than a disease of pathologic IgE production. Elevated IgE levels, eczema, asthma, food, and 
environmental allergies are common to HIES and AD, although warts, severe bacterial and 
viral infections, and pneumonia are exclusively seen in DOCK8-deficient patients.(3, 35, 36) 
Therefore, measurement of immune‐related proteins in serum may help in characterizing the 
local inflammatory responses that develop during HIES pathogenesis. Differentiating 
DOCK8‐deficient patients from those with atopic diseases at an early stage is significant in a 
child's development, as treatment modalities differ considerably.  





The aims of this study were as follows 
1) Comprehensive cytokine/chemokine profiling, in patients with DOCK8 deficiencies and 
Atopic dermatitis. 
2) To analyze the cytokine data using metabolomics to find distinct cytokine biomarkers, to 
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2.3  Methods 
2.3.1  Study Design and ethics 
Symptomatic patients with confirmed pathogenic DOCK8 mutations (n = 10), moderate to 
severe AD (n = 9) diagnosed based on the Hanifin and Rajka clinical criteria (37) and healthy 
Controls (ctrls) (n = 15) were enrolled in this study (Table 0.1). All recruited subjects 
attended the Allergy/Immunology Clinics at King Faisal Specialist Hospital and Research 
Centre (KFSHRC). Samples from the study participants were collected after signed informed 
consent was provided. Clinical and laboratory findings, as well as a comprehensive baseline 
questionnaire, were completed for each patient by the recruiting clinician. The consent form 
and baseline questionnaire were reviewed and approved by the Institutional Review Board's 
(IRB) ethics committee at KFSHRC (RAC No.  2160015). The Severity Scoring of AD 
(SCORAD) and Visual analogue scale (VAS) pruritus scores were determined for the 
DOCK8‐deficient and AD groups.(38) 
2.3.2  Cell lines 
The lymphoblastoid cell lines were established by transformation of peripheral blood 
mononuclear cells (PBMCs) with Epstein‐Barr virus as per standard protocols. Blood 
collected in an anti-coagulated sodium heparin tube was processed for lymphocyte 
separation, by adding Ficoll-paque, (GE Healthcare, Sigma Aldrich) followed by 
centrifugation at 3000 revolution per minute (RPM) for 20 minutes. Lymphocytes were 
transferred and washed with PBS and centrifuged at 3000 RPM for 10 minutes. Lymphocytes 
were re-suspended in Roswell Park Memorial Institute (RPMI) 1640 media supplemented 
with 15% fetal bovine serum (FBS), 50 units/mL penicillin, a mixture of 1% glutamine. 
(Gibco, Life Technologies). This was followed by addition of 0.5ml of Epstein Barr Virus 
(EBV) and 5µl of phytohaemagglutinin (PHA) to the re-suspension media. The lymphocytes 
were incubated at 37ºC in 5% CO2-humidified tissue culture incubator. The lymphocytes 
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were re-fed and cells were harvested during the logarithmic growth phase. After the 
incubation period, the cell media was centrifuged and supernatants were separated and stored 
at -80⁰C. 
2.3.3 Multiplex cytokine/chemokines analysis 
The human magnetic bead panel array was used to quantify the cytokine/chemokine levels in 
patient’s sera. The MILLIPLEX MAP kit (Millipore) was used according to the 
manufacturer’s instructions. Color code microspheres coated with a specific capture antibody 
were incubated with 100 uL of serum. The phycoerythrin-conjugated detection was used to 
form sandwich complexes, and the fluorescence data was acquired on the Luminex appliance, 
FLEXMAP 3D where one laser excites the phycoerythrin and measures the analytes whereas 
the other laser detects the fluorophores inside the bead and measures its expression in the 
sample. The targeted cytokines (n= 39) are listed in supplementary Table A1.1.1. Serum 
samples were assayed in duplicates, and analyte concentrations were calculated by 
constructing a standard curve to convert the optical density values into concentrations (pg/ml) 










    Age    IgE Levels Hgb Hct WBC Eosinophils CD4/CD8
 (Y) (KU/L) 110-160g/L 0.370-0.520L/L 10^9/L 10^9/L Ratio
P1 NM_203447.3:c.[2606-1G>A; c.405_827del] 21 F 25000 114 0.341 9.2 24.8 2.1 15 68.7
P2 NM_203447.3:c.[2606-1G>A; c.405_827del] 16 M 9140 86 0.264 3.72 35 0.8 13 67
P3 NM_203447.3:c.5625T>G:p.Y1875* 16 F 1690 121 0.36 4.63 50.3 1 14 59.8
P4 NM_203447:c.827+6T>C 16 F 11240 128 0.395 4.9 11.4 0.73 15 77.4
P5 NM_203447.3:c.5962_6068del (exon 46) 7 M 10170 103 0.312 9.93 26.4 0.7 17 79.5
P6 NM_001193536:c.3949+1G>T 14 M 15550 178 0.549 4.46 11.7 1.3 15 62.5
P7 NM_001193536:c.1593+1G>T 4 M 86940 85 0.29 24.9 31.4 9 17 70.6
P8 NM_001193536:c.1593+1G>T 9 F 44630 103 0.354 12.49 34.8 8.1 9 58.2
P9 NM_001190458:c.1905_1905+1delGG 8 F 26340 99 0.328 21.42 35.1 3.2 14 58.8
P10 NM_203447.3:c.5625T>G:p.Y1875* 21 M 265 119 0.386 9.7 12 1.1 12 70.1
Average±SEM 13.2±5.9 5/5 
(M/F)
19817.30±4772.6 113.6±8.4 0.357±0.02 10.53±2.3 27.29±4.02 2.8±0.99 14.1±0.75 67.26 ±2.37
P1 6 M 6540 124 0.368 10.6 16.5 0.9 16 64.4
P2 15 M 16500 142 0.419 3.72 15.6 1.4 14 71.3
P3 10 M 1612 102 0.32 8.01 13.9 1.2 16 73.3
P4 3 M 839 124 0.392 6.59 6.7 _ 13 56.1
P5 8 M 1221 119 0.388 5.09 13 1.5 9 40.8
P6 13 M 659 110 0.371 5.15 13 1.2 10 54.9
P7 15 F 1387 115 0.364 9.63 12.3 1.4 15 75
P8 16 M 365 133 0.372 2.71 7.9 2.3 14 65.1
P9 12 M 4587 127 0.417 9.2 5.1 1.5 16 70.6
Average±SEM 10.8±1.4 8/1 
(M/F)











2.3.4  IL-31 measurement using ELISA 
An ELISA kit (R&D Systems Minneapolis, USA) was used to quantify IL‐31 in human sera. 
The samples were incubated with an anti‐human IL‐31 primary antibody and then with the 
biotinylated secondary antibody. A streptavidin‐labeled horseradish peroxidase (HRP) was 
coupled to the sandwich complex for color development. Fluorescence intensity was 
measured at 450 nm and 570 nm wavelengths of excitation and emission, respectively, using 
Varioskan Flash multimode reader (Thermo Fisher Scientific Pandan crescent, Singapore). 
2.3.5  Immunoblotting  
Cells were centrifuged at 500 RPM for 5 min at 4ºC in ice cold phosphate buffered saline 
(PBS). After removing the supernatant, cells were lysed in Radio Immuno Precipitation 
Assay (RIPA) buffer and the cell pellet were allowed to agitate in a micro-centrifuge tube for 
30 min at 4ºC. The tubes were centrifuged at 13000 RPM for 30 minutes and the supernatant 
containing the protein was collected into a tube and protein was quantified using a 
spectrophotometer. Thirty micrograms of protein was loaded separated by SDS-PAGE 
(National Diagnostics, Atlanta, USA). for separation. The protein bands were transferred onto 
a Poly vinylidene fluoride (PVDF) membrane (GE Healthcare Waukesha, WI, USA) and to 
prevent the antibodies from binding to the membrane non-specifically, nonfat dried diluted 
milk solution was used. The membrane was incubated with HRP-conjugated antibodies, anti-
DOCK8 (Santa Cruz Biotechnology Dallas, TX, USA) and mouse anti-beta actin (Abcam 
Cambridge, MA, USA). The complex was detected using the SuperSignal West Pico 
Chemiluminescent (Thermo Fisher Scientific) and visualized on an ImageQuant LAS 4000 
(GE Healthcare Life Sciences). 




2.3.6 DOCK8 mutation analysis 
DOCK8 mutations were confirmed by Sanger sequencing of gDNA isolated from peripheral 
blood.(35) 
2.3.7 Data and statistical analysis 
The cytokines/chemokines global data analysis was performed using MetaboAnalyst version 
3.0 (McGill University). The raw data were normalized to the sample total median to ensure 
all samples were normally distributed. To visualize the difference among the study groups 
and make individual features more comparable, data were log transformed, and Pareto scaled, 
respectively. As the data were Gaussian distributed, the unpaired two‐tailed Student's t test 
was used for binary comparison between any two study groups, where the significance levels 
for cytokines data were considered at an false discovery rate (FDR) corrected p‐value<0.05, 
and values were presented as mean ± SEM. The targeted statistical analysis of multiple study 
groups (data in Figures 1 and 2) was carried out using GraphPad Prism (version 6.0, 
GraphPad software LA Jolla, CA). Analysis of variance (ANOVA) was performed by 
choosing column mean type analysis. Post hoc Tukey's method of analysis was used for more 
binary analysis and information such as adjusted p‐values for each comparison. These 
differences between the groups contributed to the significance of an ANOVA test. In all 
experiments, a calculated p‐value<0.05 was considered to be statistically significant. 
2.4  Results 
2.4.1 Clinical profile of HIES patient  
DOCK8 deficiency and AD patients were recruited through the allergy and immunology 
clinics at KFSHRC. In DOCK8‐deficient patients group, 50% were females and the mean age 
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was 13.2±5.9 years, whereas for the AD group (8 males and 1 female) the mean age was 10, 
and for the Ctrl group 23± 1.03 years (8M/7F). Eosinophilia was noticeable in both groups, 
whereas the median WBCs were 1.93±0.6 10^12/L) and 11.29±2.44 (10^9/L), whereas the 
Hgb counts were 113.6±8.4 and 121.7±4 (110-160g/L) respectively.The Hct median were 
almost same in both the cohort: 0.356±0.02 and 0.379±0.01 (0.370-0.520 L/L) respectively. 
The median of the CD4/CD8 ratio in DOCK8 patients was 2.8±0.99, compared to 1.43±0.14 
in the AD. (Table 0.1 ). DOCK8 mutations were confirmed by standard Sanger sequencing of 
peripheral blood gDNA. Dermatitis and food allergies were the most common clinical 
manifestations in both groups, followed by bronchial asthma. Staphylococcus infections and 
pneumonia were the most common clinical features seen in the DOCK8 patients, while four 
patients presented with thrush candidiasis and warts. (Table 0.2) In conjunction with severe 
skin infections, itching, and rashes, DOCK8 patients (50%) developed cutaneous abscesses. 
In addition, four DOCK8‐deficient patients acquired viral infections caused by molluscum 
contagiosum, and two had sclerosing cholangitis, whereas AD patients had fungal infections 
of the scalp (22%) and rhinitis (50%). Furthermore, three AD patients developed ear and 
chest infections (Table 0.2) sinusitis was seen in four DOCK8‐deficient patients. Owing to 
recurrent infections, six DOCK8‐deficient patients showed retardation in their physical 
growth. Additional features of DOCK8 deficiency include cataract and seizures in two 
patients each, congestive heart failure in one patient and one who developed fatal Hodgkin 
lymphoma. Both cohorts demonstrated elevated serum IgE levels compared to Ctrls. The IgE 
levels were significantly higher in DOCK8 patients (p-value<0.05) than AD ranging from 5-
500 KU/L (IU/ml) (Error! Reference source not found.A) In DOCK8, splicing mutations were t
he most common (70%), followed by stop gain (20%) and deletion (Error! Reference source 
not found.B) Mutations in DOCK8 were excluded in all AD patients except one. Immunoblot 
based DOCK8 expression analysis of cell line extracts using an N-terminus specific antibody 
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(Error! Reference source not found.C) showed near complete loss of DOCK8 protein e
xpression in all tested patients (n = 7) regardless of their mutation type. In three patients (P7, 
8, 9), immunoblot analysis could not be performed due to inadequate sample.  
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Findings DOCK8 (n=10) (%) 
AD (n=9) 
(%) 
Dry skin/itching  100 100 
Atopic dermatitis/eczema 100 100 
Food allergies 100 100 
Pneumonia 100 0 
Staphylococcal infection 100 11 
Bronchial asthma 90 44 
Bronchiectasis 50 0 
Molluscum contagiosum 40 0 
Sclerosing cholangitis 20 0 
Thrush candidiasis 40 0 
Warts 40 0 
Abscesses 50 0 
Otitis media 30 0 
Sinusitis 40 0 
Rhinitis 0 50 
Hodgkin lymphoma 9 0 
Failure to thrive 60 0 
Seizures 20 0 
Cataract 20 0 
Congestive heart failure 10 0 
Deceased (Hodgkin lymphoma) 10 0 
   






Figure 0.1: DOCK8 mutations and protein expression.(A) Serum IgE levels in patients with 
DOCK8 deficiency, atopic dermatitis (AD) and healthy controls (Ctrl) measured at collection point 
(One way ANOVA, Post hoc Tukey’s * p-value <0.05, ** p-value <0.001). (B) Distribution of 
DOCK8 gene mutations in HIES patients with DOCK8 deficiency. (C) Western blot analysis of 
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2.4.2 Changes in Serum cytokines 
In this study, a full analysis of the 39 analytes revealed only seven that were differentially 
expressed among the three comparative groups at p‐value <0.05.(Table 0.3) As shown in  
 
A , CXCL10 was up-regulated in DOCK8‐deficient patients compared to AD and Ctrl groups 
(P‐value <0.001). TNF‐A, GCSF and MDC were significantly upregulated only in DOCK8‐
deficient patients when compared to ctrl. ( 
 
B, C, E) CX3CL1 was significantly downregulated in DOCK8‐deficient patients (p‐value 
<0.05) compared to Ctrl groups ( 
 
D), whereas EGF was downregulated in AD (p‐value <0.05) and not significant when 
DOCK8 group was compared to Ctrl. ( 
 
F) However, IL‐31 was significantly upregulated in both patient groups compared to ctrls ( 
 
G). 
2.4.3 Biomarker evaluation  
For evaluating these cytokines for potential biomarker discovery, the data were combined and 
globally analyzed using MetaboAnalyst software version 3.0 (http://www.metaboanalyst.ca). 
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The raw data were normalized, transformed, and scaled by a median, log, and Pareto, 
respectively, to make sure all the data are visualized under Gaussian distribution. For paired 
analysis, a combination of the t test and fold change analyses is represented in a volcano plot. 
(Figure A2.1). The comparison between DOCK8‐deficient and Ctrl groups was demonstrated 
in a orthogonal projections to latent structures discriminant analysis (OPLS‐DA) 
 
  






Figure 0.2: Significant cytokines in serum of individuals with DOCK8 
deficiency, atopic dermatitis and healthy ctrl.(A) CXCL10, (B) Tumor 
necrosis factor alpha (TNF-A) (C) Granulocyte-colony stimulating 
factor, GCSF (CSF3), (D) CX3CL1 (fractalkine) (E) Macrophage-
derived chemokine ,MDC(CCL2), (F) Epidermal growth factor (EGF) 
and (G) Interleukin-31(IL-31) {DOCK8 (n=8) and AD (n=7). The 
statistical analysis was performed using one way ANOVA, post hoc 
Tukey’s,method where * Indicates significance  with p-value <0.05, ** 
p-value <0.001, and otherwise  are not significant (ns)}. 
 
 




Figure 0.3: Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) for binary 
comparisons and area under the curve (AUC) in DOCK8 deficient patients.(A) Comparison between 
DOCK8 deficient patients and healthy controls with a calculated space Q2=0.864 that represents the 
level of differential expression of the panel analytes (B) CXCL10 is up-regulated with AUC: 1 in 


















The separation between the two groups represents the degree of random relative expression in 
the whole panel due to DOCK8 deficiency (Q2 = 0.864) (Error! Reference source not found.A). A
nalytes are ordered in Error! Reference source not found.B based on their contribution in 
separating the two groups. Among CXCL10, TNF-A, CSF3, CCL22, CX3CL1, IFNG, and 
TGFA that were above the volcano plot's cutoff values, CXCL10 was evaluated as a potential 
biomarker using the support vector machine (SVM) model ,to generate a receiver operating 
characteristic (ROC) curve, where the area under the curve (AUC) amounted to 1(Error! R
eference source not found.B) . Another OPLA-DA based binary comparison between Ctrl and 
AD groups showed a Q2 of 0.32. (Error! Reference source not found.C) The relatively narrow 
spacing between the two groups indicates the lower ability of this profile to distinguish 
between the AD and ctrl individuals. As suggested by the volcano plot, the detected unique 
cytokine, EGF, which was downregulated in AD patients, had a ROC and AUC of 0.859 
(Error! Reference source not found.D). 
Since in this chapter, the strategy was to find disease‐specific biomarker(s) able to 
differentiate between DOCK8 deficiency and AD, the binary comparison was performed 
which revealed clear cluster separation in OPLS‐DA with a Q2 value of 0.693 ( 
 
 
Figure 0.4A). Comparison between all three groups also showed comparable separation but 
some overlapping was observed between the AD group and ctrl ( 
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Figure 0.4B) may be due to mild eczema seen in the ctrl group. Interestingly, CXCL10 and 
TNF‐A were the only signature cytokines, which were above the volcano plot's cutoff values 
and were significantly upregulated in DOCK8‐deficient patients. The typified linear 
combination of these cytokines will be a potentially robust differentiating tool between 
DOCK8 and AD with AUC 0.978 ( 
 
 
Figure 0.4C, D) 
  







Figure 0.4: Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) for binary 
comparison and area under the curve (AUC) in patients with DOCK8 deficiency, atopic dermatitis (A) 
Score plot comparison between AD patients and DOCK8 patients. (B) Overall comparison between 
AD patients, DOCK8-deficient patients and ctrl. (C) CXCL10 is up-regulated in DOCK8 deficient 
patients compared to AD patients, with AUC 0:978. (D) Tumor necrosis factor alpha (TNF-A) is up- 
regulated in DOCK8 patients compared to AD patients, AUC- 0.978. 
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Mean SEM Mean SEM Mean SEM p-value p-value p-value
EGF 119.81 28.36 91.53 28.36 244.52 35.50 0.14 0.02 0.67
FGF-2 52.35 13.25 114.48 44.90 117.31 27.74 0.31 1.00 0.43
CCL-11 152.58 23.96 97.61 19.15 162.67 22.01 1.00 0.13 0.19
TGF-A 9.18 3.79 9.16 3.04 6.48 1.74 0.06 0.23 0.81
GSF3 124.30 15.07 104.37 26.07 55.66 9.30 0.01 0.13 0.48
FLT3LG 32.01 18.97 22.32 19.28 20.14 8.57 0.88 0.47 0.68
CSF2 33.29 5.18 56.44 20.02 35.25 4.45 0.99 0.32 0.46
CX3CL1 57.60 12.94 207.51 55.06 251.22 53.88 0.02 0.81 0.14
IFNA 30.33 9.99 42.59 22.61 36.74 12.33 0.85 0.86 0.60
IFNG 16.35 5.09 62.98 27.87 53.77 14.62 0.20 0.87 0.13
CXCL2 7894.64 1249.41 5663.77 1652.69 5520.44 1482.61 0.57 1.00 0.68
IL-10 26.70 6.31 12.68 4.17 2.26 1.24 0.28 0.79 0.51
CCR3 23.15 11.95 142.41 63.59 75.96 43.04 0.72 0.84 0.46
IL12B 3.00 2.05 20.41 8.29 3.86 2.75 0.99 0.32 0.25
CCL22 2720.43 573.68 1838.89 223.77 1220.57 107.58 0.01 0.43 0.20
IL-12p70 6.64 4.82 42.04 28.78 47.11 20.37 ns ns ns
IL-13 14.15 6.64 135.06 76.43 62.41 39.07 0.64 0.39 0.15
IL-15 6.71 2.87 3.57 1.46 2.83 1.59 0.87 0.91 0.64
CD40LG 3205.41 1103.50 1354.48 360.54 4358.72 803.22 0.77 0.05 0.26
IL-17A 7.49 2.06 23.80 10.93 19.44 5.73 0.34 0.43 0.07
IL-1RA 93.87 42.57 213.46 103.00 109.94 67.94 0.52 0.96 0.35
IL-1A 290365.91 161683.29 801859.10 474855.45 2400302.99 2034028.62 0.58 0.74 0.97
IL-9 3.86 1.12 6.40 2.72 1.33 0.51 0.80 0.42 0.77
IL-1B 0.02 0.00 9.98 8.10 1.30 0.79 ns ns ns
IL-2 0.06 0.05 2.83 1.35 2.97 1.50 ns ns ns
IL-3 0.61 0.15 0.88 0.40 0.12 0.07 ns ns ns
IL-4 0.06 0.06 2.86 2.43 5.11 4.56 ns ns ns
IL-5 7.40 2.45 30.99 14.31 23.91 10.20 0.16 0.70 0.07
IL-6 28.78 12.96 31.04 24.42 5.92 2.60 0.73 0.69 0.99
IL-7 15.85 2.96 15.57 8.79 3.61 1.08 0.59 0.23 0.59
IL-8 24.20 2.39 29.27 8.70 26.00 6.14 1.00 0.93 0.91
CXCL10 1480.32 476.60 230.42 55.11 143.01 18.21 0.00 0.75 0.00
CCL-2 739.58 211.76 393.15 47.52 513.91 81.36 0.29 0.80 0.14
CCL-3 13.32 2.33 24.72 7.19 23.99 3.99 0.14 0.83 0.08
CCL-4 47.13 6.59 76.52 25.48 62.52 15.07 0.75 0.60 0.29
TNF-A 32.98 7.95 20.77 6.65 14.82 3.20 0.03 0.74 0.22
TNF-B 17.80 9.11 290.57 152.81 153.60 98.51 0.39 0.99 0.43
VEGF 319.24 59.76 339.93 122.33 338.44 70.57 0.97 > 0.99 0.98
IL-31 4363.38 1297.52 3780.75 1450.86 648.83 158.36 0.02 0.01 0.26
The statistical analysis was performed using one way ANOVA, post hoc Tukey’s method,stastical s significance with p-value <0.05 and ns= not significant 
DOCK8 (n=10) Ctrl (n=15)AD (n=9) 
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2.5  Discussion 
While significant progress has been made, the molecular mechanisms underlying specific 
cytokine functions remain largely unknown. The last decade has witnessed accumulating 
evidence supporting the central role of cytokines in immune surveillance as it relates to 
autoimmune diseases. It is essential to identify DOCK8 deficiencies before serious life‐
threatening complications arise. Diagnosis can be difficult in infants and young children 
because of coinciding laboratory findings and clinical profiles with AD and other types of 
HIES. There is global interest in identifying biomarkers that are disease‐specific for the 
various clinical and molecular subtypes of HIES. The combination of recurrent viral 
infections, atopy, food allergies, consanguinity, and hyperactivity strongly suggests the 
diagnosis of DOCK8 deficiency. Supportive treatments including prophylactic antibiotics, 
nutritional support, and immunomodulatory agents remain unsatisfactory, and patients 
usually have very short life expectancy. Due to high morbidity and mortality associated with 
DOCK8 deficiency, curative treatment using hematopoietic stem cell transplantation is 
becoming the last preferred choice, resulting in successful immune reconstitution. (39) In this 
study, among the 39 cytokines, seven (CXCL10, TNF‐A, GCSF, CX3CL1, MDC, EGF, and 
IL‐31) were differentially expressed ( 
 
A-G) CXCL10 is a chemokine which is known to be highly expressed in various 
diseases,(40) pneumonia triggered by viral and bacterial infection (41) as well as in 
asthma.(42, 43) Upregulation of this cytokine in the DOCK8‐deficient cohort seems to be 
associated with the commonly seen asthma, infections, allergies, and pneumonia phenotypes 
seen in these patients. ( 
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A) In contrast, TNF‐A is a multifunctional pro inflammatory cytokine, known to mediate 
tumor initiation, psoriasis. In contrast, TNF-A is a multifunctional pro inflammatory 
cytokine, known to mediate tumor initiation, psoriasis, AD and autoimmune diseases and 
participates in cell survival/death, and cancer.(44) Upregulation of TNF-A ( 
 
B) seems to be contributing towards the pruritus and immune dysregulation observed in 
DOCK8 patients. Furthermore, CSF3 is a glycoprotein linked with proliferation and 
maturation of neutrophils. (45) The role of CSF3 is evident in various cancers.(46, 47) 
Dehqanzada et al. in 2006 demonstrated that CSF3 was significantly overexpressed in breast 
cancer patients.(48) Higher expression of CSF3 ( 
 
C), demonstrated in those studies supports the role of immune responses, favoring tumor 
growth and progression which is in agreement with disease phenotypes seen in the DOCK8 
cohort. Moreover, CX3CL1 is known to be associated with various inflammatory conditions 
like AD (49) and allergic asthma.(50) It was downregulated in DOCK8 patients when 
compared to ctrls ( 
 
D). CCL2 was shown to be involved in various immune responses and elimination of 
pathogens (51), allergic reactions (52)and inflammation in the lungs.(53) Hence upregulation 
of CCL2 ( 
 
E) is consistent with the clinical features (infections, allergies, and pneumonia) seen in the 
DOCK8‐deficient patients. 
Atopic dermatitis is a chronic inflammatory skin disease with frequent recurrences, and 
cytokines appear to play a significant role in its complex pathogenesis.(54, 55) EGF is 
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reported to regulate fundamental functions in mammalian cells including survival, migration, 
proliferation, and homeostasis. This cytokine is expressed at the site infection, and its primary 
function is the protection of the skin against bacterial colonization mediated through the 
EGFR signaling. (56-58) It has been shown that, EGF shows to be significantly down- 
regulated in AD patients, but not in DOCK8‐deficient patients, when compared with ctrls ( 
 
F), hence, low levels of EGF may impair proliferation and anti‐inflammatory immune 
response in the skin. IL‐31 is a recently discovered cytokine produced by Th2 cells, 
and elevated levels of IL‐31 are correlated with increased serum IgE levels and 
disease severity and are responsible for the induction of pruritus in the AD 
patients.(54) Recently, it has been shown that topical administration of EGF 
suppresses immune response and protects skin barrier in Dinitrochlorobenzene 
(DNCB) induced AD in NC/Nga mice This effect appeared to be the result of EGF up 
regulation of epidermal proteins and down regulation of thymic stromal 
lymphopoietin (TSLP) mediated mast cell and Th2 cell activation.(56-59) Therefore, 
we propose that in subsets of patients with EGF deficiency, replacement therapy with 
topical or systemically administered EGF may be of clinical value. CXCL10 and 
TNF-A were identified as potential biomarkers differentiating DOCK8 deficient and 
AD patients ( 
 
 
Figure 0.4). The reliability of these cytokines as diagnostic markers should be confirmed by 
questioning more massive datasets, to assess whether these cytokines are specific to DOCK8 
gene expression or resulting from secondary disease complications.  
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A binary analysis was performed in DOCK8‐deficient patients with and without one of the 
following clinical manifestations: asthma, bronchiectasis, molluscum contagiosum infection, 
sclerosing cholangitis, thrush candidiasis, warts, sinusitis, rhinitis, and malignancy. For 
instance, CSF3 was upregulated in DOCK8 patients with warts and molluscum contagiosum, 
while CX3CL1 and IFNG were downregulated in the DOCK8 patient with malignancy. 
Moreover, Figure A2.3 represents volcano plots for binary comparisons between AD vs ctrl 
and DOCK8 vs AD, also demonstrates the potential biomarkers EGF, CXCL10, and TNF‐A. 
As shown in Error! Reference source not found., neither of the potential biomarkers, CXCL10 a
nd TNF, was over expressed in any of these binary analyses. Instead, they were 
downregulated in association with bronchiectasis and malignancy, suggesting that these 
biomarkers are very likely to be related mainly to the disease mechanism caused by DOCK8 
deficiency.  
These findings should be further studied in other HIES to determine their specificity. 
CXCL10 is one of the CXCR3 ligands secreted by CD4+, CD8+ T cells, natural killer (NK), 
or NK‐T cells in response to INFG. The average CD4+/CD8+ ratio in DOCK8 patients was 
higher (2.8 ± 0.99) than AD groups (1.43 ± 0.14) The C‐terminal of CXCL10 has a high 
affinity for cell surface heparan sulfate glycosaminoglycan (HS‐GAG), which is expressed on  
epithelial, endothelial, and hematopoietic cells. The higher circulated level of CXCL10 in 
blood is due to either a higher competitive binding with a viral protein inflammation, (60) as 
it attracts the activated T lymphocytes, which are the only inflammatory cells expressing the 
chemokine receptor CXCR3), or DOCK8 inhibition of HS‐GAG synthesis. From the clinical 
data collected for this study (Table 0.2), the spectrum of infections observed in DOCK8‐
deficient patients such as pneumonia (100%), staphylococcal infections (100%), and 
bronchiectasis (50%) suggests a connection between pathogens binding to HS‐GAG, and the 
degree of inflammation, which increases the circulated CXCL10.(61) CXCL10 levels in AD 
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patients were not as high as in DOCK8 patients, probably because AD patients lack this 
severe and complex spectrum of infections usually seen in DOCK8-deficient patients. 
However, Brunner et.al (2017) showed in his studies that CXCL10 levels were up-regulated 
in AD patients, which could be the contributing factor for the atopic diseases seen in both 
cohorts, as they share many symptoms, especially eczema.(62) 
Th2 cells producing IL-4, IL-5 and IL-13 are involved in humoral immunity against parasites 
and in allergic reactions. (63, 64). IL-5 plays a crucial role r in innate and acquired immune 
response and eosinophilia. (65) Although IL-4 and IL-13 are similar cytokines, they have 
some differences for example, IL-13 does not cause proliferation of T cells or differentiation 
of naïve T cells towards Th2 cells as IL-4 does, but the activation of mast cells by IL-13, is 
weaker, compared to IL-4.(66) Th2 cells are known to play an important role in the 
pathogenesis of allergic asthma, (67) IL-4, IL-5 and IL-13 produced by allergen specific Th2 
cells probably contribute in our study population to immune response directed against 
specific environmental antigens. This could be the reason that these cytokines were not 
statistically significant in both our cohorts. 
Th17 cells are essential for host defence against extracellular pathogens distinct from those 
targeted for Th1 and Th2 cells including pathophysiology of immune inflammatory 
disorders.(68) Few studies have been reported connecting severity in inflammation and Th17 
cell mediated immune responses.(68, 69) Th17 cells have shown to exhibit both pro and anti-
tumor functions. These cells have been shown to grow tumors by inducing immune effector 
cell recruitment within the tumor and they also produce IFNg in the tumor that will result in 
inhibition of tumor growth.(70) IFNg is also critical for innate and adaptive immunity against 
viral, intracellular bacterial infections and tumor control.(71) In this study, IFNg was down-
regulated in the DOCK8 cohort when compared to AD, suggesting poor immunity in these 
patients. 
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In summary, significant differential expression of cytokines CXCL10 compared to both AD 
and ctrl cohorts and CSF3, CCL22, CX3CL1, and TNF‐A compared to the ctrls were 
identified in DOCK8 deficiency, which possibly contributes to increased susceptibility to 
infection and cancer. CXCL10 and TNF‐A seem to be important biomarkers in differentiating 
between DOCK8‐deficient and AD patients, whereas EGF was found to be a useful 
biomarker in AD patients. Cytokine IL‐31 expression was comparable in both cohorts thus 
contributing toward pruritus, which is common to both groups. The unique expression 
profiles including CXCL10, CSF3, CCL22, CX3CL1, and TNF‐A that were detected in 
patients with DOCK8 deficiency probably reflect disease‐specific perturbations in multiple 
cellular processes and pathways leading to a predisposition to infections, allergy, and 
malignancy seen in these patients. Hence, the linear combination of three “CXCL10, TNF‐A, 
and EGF” typified biomarkers signature could lead to a unique scoring system for early 
effective diagnosis and distinction of DOCK8 deficiency vs atopic dermatitis. 
More broader cytokine profiling may reveal additional biomarkers linking these disorders 
with their clinical phenotypes thus facilitating improved understanding of disease 
pathogenesis. Scientific and clinical approach together will be required to gain novel insight 
into fundamental immunological mechanism in DOCK8 deficiencies. Complex phenotype 
and a broad range of combined immunological abnormalities are a major challenge in 
providing the proper optimal treatment to these patients. Since DOCK8 and AD patients have 
overlapping symptoms, their treatment management is also similar. These patients were on 
curative treatments like use of prophylactic antibiotics, antihistamines and topical steroids. 
Since samples were collected while they were clinically stable, there is no expected effect on 
the metabolome or the results. In summation, such imbalanced events may have a major 
impact on the development and progression of the disease. Further studies on the mechanism 
by which these cytokines promote the genesis of this disorder may yet further apply to the 
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ongoing molecular cellular and network reorganization that follow other types of immune 
deficiencies. Apart from the cytokine biomarkers, metabolomics biomarkers, were studied 
and discussed in chapter 4. Hypotaurine, 3-hydroxyanthranillic acid and glycyl-phenyalanine 
were identified as potential biomarkers specific for DOCK8 deficiency; perturbations in 
tryptophan degradation and increased availability of aspartate suggest a link of DOCK8 
deficiency to oncogenesis. Additionally, perturbations in taurine and dipeptides metabolism 
suggest altered antixidation and cell signaling states in DOCK8 deficiency.In the next 
chapter, a comprehensive metabolomics method was built for metabolomics biomarker study 
in DOCK8 deficiency vs atopic dermatitis. 
 
  




2.6  Reference list 
 
1. Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodeficiency 
diseases associated with increased susceptibility to viral infections and malignancies. 
The Journal of allergy and clinical immunology 2011;127:1329-41 e2; quiz 42-3. 
2. Davis SD, Schaller J, Wedgwood RJ. Job's syndrome. Recurrent, "cold", 
staphylococcal abscesses. Lancet 1966;1:1013-5. 
3. Renner ED, Puck JM, Holland SM, Schmitt M, Weiss M, Frosch M, et al. Autosomal 
recessive hyperimmunoglobulin e syndrome: A distinct disease entity. The Journal of 
pediatrics 2004;144:93-9. 
4. Grimbacher B, Holland SM, Gallin JI, Greenberg F, Hill SC, Malech HL, et al. 
Hyper-ige syndrome with recurrent infections--an autosomal dominant multisystem 
disorder. The New England journal of medicine 1999;340:692-702. 
5. Beziat V, Li J, Lin JX, Ma CS, Li P, Bousfiha A, et al. A recessive form of hyper-ige 
syndrome by disruption of znf341-dependent stat3 transcription and activity. Sci 
Immunol 2018;3. 
6. Frey-Jakobs S, Hartberger JM, Fliegauf M, Bossen C, Wehmeyer ML, Neubauer JC, 
et al. Znf341 controls stat3 expression and thereby immunocompetence. Science 
Immunology 2018;3:eaat4941. 
7. Schwerd T, Twigg SRF, Aschenbrenner D, Manrique S, Miller KA, Taylor IB, et al. 
A biallelic mutation in il6st encoding the gp130 co-receptor causes immunodeficiency 
and craniosynostosis. The Journal of experimental medicine 2017;214:2547-62. 
8. Sassi A, Lazaroski S, Wu G, Haslam SM, Fliegauf M, Mellouli F, et al. Hypomorphic 
homozygous mutations in phosphoglucomutase 3 (pgm3) impair immunity and 
increase serum ige levels. The Journal of allergy and clinical immunology 
2014;133:1410-9, 9 e1-13. 
9. Aydin SE, Kilic SS, Aytekin C, Kumar A, Porras O, Kainulainen L, et al. Dock8 
deficiency: Clinical and immunological phenotype and treatment options - a review of 
136 patients. Journal of clinical immunology 2015;35:189-98. 
10. Su HC. Dedicator of cytokinesis 8 (dock8) deficiency. Current opinion in allergy and 
clinical immunology 2010;10:515-20. 
11. Sarkar S, Teichgraber V, Kalia V, Polley A, Masopust D, Harrington LE, et al. 
Strength of stimulus and clonal competition impact the rate of memory cd8 t cell 
differentiation. Journal of immunology 2007;179:6704-14. 
12. Randall KL, Chan SS, Ma CS, Fung I, Mei Y, Yabas M, et al. Dock8 deficiency 
impairs cd8 t cell survival and function in humans and mice. The Journal of 
experimental medicine 2011;208:2305-20. 
13. Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al. Combined 
immunodeficiency associated with dock8 mutations. The New England journal of 
medicine 2009;361:2046-55. 
14. Meller N, Merlot S, Guda C. Czh proteins: A new family of rho-gefs. Journal of cell 
science 2005;118:4937-46. 
CXCL10 cytokine as a biomarker for DOCK8 deficiency 
80 
 
15. Caracciolo S, Moratto D, Giacomelli M, Negri S, Lougaris V, Porta F, et al. 
Expansion of ccr4+ activated t cells is associated with memory b cell reduction in 
dock8-deficient patients. Clinical immunology (Orlando, Fla) 2014;152:164-70. 
16. Cote JF, Motoyama AB, Bush JA, Vuori K. A novel and evolutionarily conserved 
ptdins(3,4,5)p3-binding domain is necessary for dock180 signalling. Nature cell 
biology 2005;7:797-807. 
17. Jabara HH, McDonald DR, Janssen E, Massaad MJ, Ramesh N, Borzutzky A, et al. 
Dock8 functions as an adaptor that links tlr-myd88 signaling to b cell activation. 
Nature immunology 2012;13:612-20. 
18. Harada Y, Tanaka Y, Terasawa M, Pieczyk M, Habiro K, Katakai T, et al. Dock8 is a 
cdc42 activator critical for interstitial dendritic cell migration during immune 
responses. Blood 2012;119:4451-61. 
19. Janssen E, Morbach H, Ullas S, Bannock JM, Massad C, Menard L, et al. Dedicator 
of cytokinesis 8&#x2013;deficient patients have a&#xa0;breakdown in peripheral b-
cell tolerance and defective&#xa0;regulatory t cells. Journal of Allergy and Clinical 
Immunology 2014;134:1365-74. 
20. Diana J, Lehuen A. Nkt cells: Friend or foe during viral infections? European journal 
of immunology 2009;39:3283-91. 
21. Crawford G, Enders A, Gileadi U, Stankovic S, Zhang Q, Lambe T, et al. Dock8 is 
critical for the survival and function of nkt cells. Blood 2013;122:2052-61. 
22. Mizesko MC, Banerjee PP, Monaco-Shawver L, Mace EM, Bernal WE, Sawalle-
Belohradsky J, et al. Defective actin accumulation impairs human natural killer cell 
function in patients with dedicator of cytokinesis 8 deficiency. The Journal of allergy 
and clinical immunology 2013;131:840-8. 
23. Yamamura K, Uruno T, Shiraishi A, Tanaka Y, Ushijima M, Nakahara T, et al. The 
transcription factor epas1 links dock8 deficiency to atopic skin inflammation via il-31 
induction. Nature communications 2017;8:13946. 
24. Janssen E, Tsitsikov E, Al-Herz W, Lefranc G, Megarbane A, Dasouki M, et al. Flow 
cytometry biomarkers distinguish dock8 deficiency from severe atopic dermatitis. 
Clinical immunology (Orlando, Fla) 2014;150:220-4. 
25. Yanagimachi M, Ohya T, Yokosuka T, Kajiwara R, Tanaka F, Goto H, et al. The 
potential and limits of hematopoietic stem cell transplantation for the treatment of 
autosomal dominant hyper-ige syndrome. Journal of clinical immunology 
2016;36:511-6. 
26. Patel NC, Gallagher JL, Torgerson TR, Gilman AL. Successful haploidentical donor 
hematopoietic stem cell transplant and restoration of stat3 function in an adolescent 
with autosomal dominant hyper-ige syndrome. Journal of clinical immunology 
2015;35:479-85. 
27. Bittner TC, Pannicke U, Renner ED, Notheis G, Hoffmann F, Belohradsky BH, et al. 
Successful long-term correction of autosomal recessive hyper-ige syndrome due to 
dock8 deficiency by hematopoietic stem cell transplantation. Klinische Padiatrie 
2010;222:351-5. 
CXCL10 cytokine as a biomarker for DOCK8 deficiency 
81 
 
28. Gatz SA, Benninghoff U, Schutz C, Schulz A, Honig M, Pannicke U, et al. Curative 
treatment of autosomal-recessive hyper-ige syndrome by hematopoietic cell 
transplantation. Bone marrow transplantation 2011;46:552-6. 
29. Qian C, Wang Y, Reppel L, D'Aveni M, Campidelli A, Decot V, Bensoussan D. 
Viral-specific t-cell transfer from hsct donor for the treatment of viral infections or 
diseases after hsct. Bone marrow transplantation 2018;53:114-22. 
30. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. 
Hematopoietic stem cell transplantation in europe 2014: More than 40 000 transplants 
annually. Bone marrow transplantation 2016;51:786-92. 
31. Netea MG, Schneeberger PM, de Vries E, Kullberg BJ, van der Meer JW, Koolen MI. 
Th1/th2 cytokine imbalance in a family with hyper-ige syndrome. The Netherlands 
journal of medicine 2002;60:349-53. 
32. Lambe T, Crawford G, Johnson AL, Crockford TL, Bouriez-Jones T, Smyth AM, et 
al. Dock8 is essential for t-cell survival and the maintenance of cd8+ t-cell memory. 
European journal of immunology 2011;41:3423-35. 
33. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell 
SR, et al. Interleukin 31, a cytokine produced by activated t cells, induces dermatitis 
in mice. Nature immunology 2004;5:752-60. 
34. Renner ED, Pawlita I, Hoffmann F, Hornung V, Hartl D, Albert M, et al. No 
indication for a defect in toll-like receptor signaling in patients with hyper-ige 
syndrome. Journal of clinical immunology 2005;25:321-8. 
35. Alsum Z, Hawwari A, Alsmadi O, Al-Hissi S, Borrero E, Abu-Staiteh A, et al. 
Clinical, immunological and molecular characterization of dock8 and dock8-like 
deficient patients: Single center experience of twenty-five patients. Journal of clinical 
immunology 2013;33:55-67. 
36. Zhang Q, Davis JC, Dove CG, Su HC. Genetic, clinical, and laboratory markers for 
dock8 immunodeficiency syndrome. Disease markers 2010;29:131-9. 
37. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. 
Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and 
assessment of atopic dermatitis. Journal of the American Academy of Dermatology 
2014;70:338-51. 
38. Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual 
analogue scale: Evaluation of the instrument for the assessment of pruritus. Acta 
dermato-venereologica 2012;92:497-501. 
39. Al-Herz W, Chu JI, van der Spek J, Raghupathy R, Massaad MJ, Keles S, et al. 
Hematopoietic stem cell transplantation outcomes for 11 patients with dedicator of 
cytokinesis 8 deficiency. The Journal of allergy and clinical immunology 
2016;138:852-9 e3. 
40. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (c-
x-c motif) ligand (cxcl)10 in autoimmune diseases. Autoimmunity reviews 
2014;13:272-80. 
41. Hoffmann J, Machado D, Terrier O, Pouzol S, Messaoudi M, Basualdo W, et al. Viral 
and bacterial co-infection in severe pneumonia triggers innate immune responses and 
specifically enhances ip-10: A translational study. Scientific reports 2016;6:38532. 
CXCL10 cytokine as a biomarker for DOCK8 deficiency 
82 
 
42. Ragusa F, Fallahi P. Ip-10 in occupational asthma: Review of the literature and case-
control study. La Clinica terapeutica 2017;168:e151-e7. 
43. Medoff BD, Sauty A, Tager AM, Maclean JA, Smith RN, Mathew A, et al. Ifn-
gamma-inducible protein 10 (cxcl10) contributes to airway hyperreactivity and airway 
inflammation in a mouse model of asthma. Journal of immunology 2002;168:5278-
86. 
44. Patel HJ, Patel BM. Tnf-alpha and cancer cachexia: Molecular insights and clinical 
implications. Life sciences 2017;170:56-63. 
45. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-
macrophage colony-stimulating factor (1). The New England journal of medicine 
1992;327:28-35. 
46. Tachibana M, Miyakawa A, Tazaki H, Nakamura K, Kubo A, Hata J, et al. Autocrine 
growth of transitional cell carcinoma of the bladder induced by granulocyte-colony 
stimulating factor. Cancer Res 1995;55:3438-43. 
47. Takami K, Miura K, Takeuchi H, Egawa S, Moriya T, Nakamura Y, et al. 
Granulocyte-colony stimulating factor-producing pancreatic cancer: Report of a case. 
Surgery today 2008;38:453-7. 
48. Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, et al. 
Assessing serum cytokine profiles in breast cancer patients receiving a her2/neu 
vaccine using luminex technology. Oncology reports 2007;17:687-94. 
49. Ferretti E, Pistoia V, Corcione A. Role of fractalkine/cx3cl1 and its receptor in the 
pathogenesis of inflammatory and malignant diseases with emphasis on b cell 
malignancies. Mediators of inflammation 2014;2014:480941. 
50. Julia V, Staumont-Salle D, Dombrowicz D. [role of fractalkine/cx3cl1 and its receptor 
cx3cr1 in allergic diseases]. Medecine sciences : M/S 2016;32:260-6. 
51. Godiska R, Chantry D, Raport CJ, Sozzani S, Allavena P, Leviten D, et al. Human 
macrophage-derived chemokine (mdc), a novel chemoattractant for monocytes, 
monocyte-derived dendritic cells, and natural killer cells. The Journal of experimental 
medicine 1997;185:1595-604. 
52. Mantovani A, Gray PA, Van Damme J, Sozzani S. Macrophage-derived chemokine 
(mdc). Journal of leukocyte biology 2000;68:400-4. 
53. Richter JR, Sutton JM, Belizaire RM, Friend LA, Schuster RM, Johannigman TA, et 
al. Macrophage-derived chemokine (mdc/ccl22) is a novel mediator of lung 
inflammation following hemorrhage and resuscitation. Shock (Augusta, Ga) 
2014;42:525-31. 
54. Wang AX, Xu Landen N. New insights into t cells and their signature cytokines in 
atopic dermatitis. IUBMB life 2015;67:601-10. 
55. Yamanaka K, Mizutani H. The role of cytokines/chemokines in the pathogenesis of 
atopic dermatitis. Current problems in dermatology 2011;41:80-92. 
56. Heck DE, Laskin DL, Gardner CR, Laskin JD. Epidermal growth factor suppresses 
nitric oxide and hydrogen peroxide production by keratinocytes. Potential role for 
nitric oxide in the regulation of wound healing. The Journal of biological chemistry 
1992;267:21277-80. 
CXCL10 cytokine as a biomarker for DOCK8 deficiency 
83 
 
57. Pastore S, Mascia F. Novel acquisitions on the immunoprotective roles of the egf 
receptor in the skin. Expert review of dermatology 2008;3:525-7. 
58. Pastore S, Mascia F, Mariani V, Girolomoni G. The epidermal growth factor receptor 
system in skin repair and inflammation. The Journal of investigative dermatology 
2008;128:1365-74. 
59. Kim YJ, Choi MJ, Bak DH, Lee BC, Ko EJ, Ahn GR, et al. Topical administration of 
egf suppresses immune response and protects skin barrier in dncb-induced atopic 
dermatitis in nc/nga mice. Scientific reports 2018;8:11895. 
60. Luster AD, Greenberg SM, Leder P. The ip-10 chemokine binds to a specific cell 
surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell 
proliferation. The Journal of experimental medicine 1995;182:219-31. 
61. Belperio JA, Keane MP, Burdick MD, Londhe V, Xue YY, Li K, et al. Critical role 
for cxcr2 and cxcr2 ligands during the pathogenesis of ventilator-induced lung injury. 
The Journal of clinical investigation 2002;110:1703-16. 
62. Brunner PM, Suárez-Fariñas M, He H, Malik K, Wen H-C, Gonzalez J, et al. The 
atopic dermatitis blood signature is characterized by increases in inflammatory and 
cardiovascular risk proteins. Scientific reports 2017;7:8707. 
63. Murphy KM, Reiner SL. The lineage decisions of helper t cells. Nature reviews 
Immunology 2002;2:933-44. 
64. Miahipour A, Haji-Fatahaliha M, Keshavarz H, Gharavi MJ, Mohamadi H, Babaloo 
Z, et al. T helper 1 (th1), th2, and th17 responses to leishmania major 
lipophosphoglycan 3. Immunological investigations 2016;45:692-702. 
65. Takatsu K, Nakajima H. Il-5 and eosinophilia. Current opinion in immunology 
2008;20:288-94. 
66. E. dVJ. - molecular and biological characteristics of interleukin-13. 
67. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. 
Annual review of immunology 1999;17:255-81. 
68. Singh RP, Hasan S, Sharma S, Nagra S, Yamaguchi DT, Wong DT, et al. Th17 cells 
in inflammation and autoimmunity. Autoimmunity reviews 2014;13:1174-81. 
69. Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: Biology, pathogenesis of 
autoimmune and inflammatory diseases, and therapeutic strategies. The American 
journal of pathology 2012;181:8-18. 
70. Guéry L, Hugues S. Th17 cell plasticity and functions in cancer immunity. BioMed 
research international 2015;2015:314620-. 
71. Ikeda H, Old LJ, Schreiber RD. The roles of ifn gamma in protection against tumor 









2.7  Summary of Chapter 2 
 The aim of this study was to identify cytokine biomarkers in DOCK8-deficient and 
AD patients 
 Significant differential expression of cytokines CXCL10, CSF3, CCL22, CX3CL1, 
and TNF-A were identified in DOCK8 deficiency, which possibly contributes to increased 
susceptibility to infection and cancer 
 CXCL10 and TNF-A seem to be important biomarkers in differentiating between 
DOCK8‐deficient and AD patients 
 EGF was established to be a good biomarker in AD patients.  
 Cytokine IL-31 expression was comparable in both cohorts thus contributing toward 
pruritus, which is common to both groups 
 The linear combination of three typified signature biomarkers, “CXCL10, TNF-A, and 
EGF” could lead to a unique scoring system for early effective diagnosis and distinction of 
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Metabolomics signifies the comprehensive assessment of endogenous and exogenous small 
molecules, (metabolites) and systematically identify and quantify them in various biological 
systems under consideration.(1, 2) Since the metabolome is responsive to changes induced by 
a diverse array of genetic and non-genetic factors including nutrition and therapeutics, it is an 
ideal approach to track, monitor and understand the connection of these influences to 
phenotype. (3, 4) The sensitivity of metabolic profile is the primary challenge that hampers 
the quality of data and biological interpretation.(5) Integrating the data set of metabolomics 
with genomics, transcriptomics, and proteomics, adds a more reliable and informative 
dimension to the phenotype, leading to a better understanding of the disease pathophysiology. 
(3, 4) The association between the metabolic changes, patient phenotype, pathological status 
and treatment, is well established and has enhanced the application of metabolomics in 
various medical fields. (6-9) Since every molecule has a metabolic fate, there is a panel of 
metabolites that represents the end products of known biochemical pathways. Thus, any 
biological disturbance should potentially have a distinct metabolic imprint indicative of the 
current state, reflecting the net effects of endogenous and exogenous molecules on  anabolism 
and catabolism.(10) 
The chemo-physical diversity of metabolites makes global metabolomics profiling an 
analytical challenge. Sample pretreatment is crucial in metabolomic studies, as metabolism is 
dynamic by nature metabolomic profiling is influenced by sample type, gender, diet, lifestyle, 
sample collection conditions, storage conditions, metabolism quenching and extraction 
because any contamination or degradation will adversely affect degradation will adversely 
affect the analytical results.(11) Hence these factors should be controlled, and an appropriate 
number of samples should be used in pilot studies.(12) In Gas chromatography-mass 
spectrometry (GC-MS), the degradation of thermo labile compounds can have a significant 
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impact on the data quality; hence it is advisable to use liquid-based techniques for such 
analytes. Matrix effect can be solved with the utilization of an internal standard and by proper 
evaluation of matrix effect during method development .(12) Several analytical platforms are 
used in metabolomics, but none fulfills the criteria of being an ‘ideal global metabolic 
profiling technique' as biological samples include thousands of metabolites that vary, not only 
in concentration but also in their physical and chemical properties .(1, 13). 
Recently, various metabolomics methods have been introduced for analyte detection and 
clinical biomarker discovery. Miyamoto et al. (2015), used GC-TOF-MS based metabolomic 
profiling to evaluate the prognosis in patients with lung cancer and showed up regulation of 
certain sugars and amino acids in affected individuals when compared with ctrls.(14) Also, 
analysis of a wide range of metabolites, ranging from high to low molecular weight and from 
hydrophilic to hydrophobic was demonstrated using LC-MS/MS. (15, 16) A nuclear magnetic 
resonance (NMR) based combined breathomics and metabolomics study revealed a marked 
difference between healthy and asthmatic children.(17)  
Recent advances in instrument development in NMR, MS, and Ultra Performance Liquid 
Chromatography (UPLC) combined with bioinformatics has paved the way for sophisticated 
and more robust metabolomics studies over the last decade.(18, 19) Diagnostic metabolic 
profiles to identify candidate biomarkers in animal and human tissue was made possible by 
combining the separation analytical technology of UPLC with MS.(20) Liquid 
chromatography-mass Spectrometry (LC-MS/MS) has been widely used for global metabolic 
profiling, as indicated in some published studies.(21, 22) 
Several hundred inborn errors of metabolism (IEM), which are primary genetic disorders and 
involve intermediary metabolism of small and large molecules have been characterized 
clinically and biochemically. Most IEMs have a severe impact on affected individuals leading 
to varying degrees of developmental and physical retardation, organ function derangement 
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and even death, as especially seen in severe mitochondrial and urea cycle disorders.The 
implementation of newborn screening for an increasing number of IEM showed birth 
prevalence as high as 1 in 500 live births in some populations. Enzyme deficiencies, the 
hallmark of IEMs, usually lead to the accumulation of toxic (precursor) compounds and 
depletion of certain product compounds, thereby affecting proximal and distal cellular 
processes and resulting in a unique combined clinical and biochemical disease phenotype. 
The unique metabolic profiling can be useful in clinical care, biomarker discovery for several 
common and rare human diseases, as well as in understanding disease mechanisms and 
response to therapy. Currently, clinical metabolic profiling of acylcarnitines, amino acids, 
very long chain fatty acids, steroids and organic acids are routinely performed in newborn 
screening and biochemical genetics laboratories worldwide.(23, 24) These assays are targeted 
to a group of disorders and are performed individually using different platforms. Few 
laboratories have already developed and adopted limited clinical metabolomics assays useful 
in the evaluation of patients suspected of having metabolic diseases. (7, 9, 25) However, 
conventional IEM diagnosis procedures are based on a series of sequential and segmented 
biochemical assays on various analytical platforms. This diagnostic strategy is slow, time 
consuming and complex, whereas optimal patient management requires an improved speed of 
biochemical tests to allow early diagnosis for better monitoring and management of IEMs.  
Comprehensive and quantitative metabolomics is increasingly assuming a more significant 
role in exploring novel ways to diagnose, treat and prevent nutrition-related diseases such as 
obesity, diabetes mellitus, and some IEMs. (26, 27) like phenylketonuria(PKU),maple syrup 
urine disease(MSUD),very long chain acid dehydrogenase deficiency(VLCADD), glutaric 
type-1(GA-1), glutaric type-2(GA-2), tyrosinemia type-1(TYR-1) and tyrosinemia type 2( 
TYR-2). 
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 For example, insulin resistance (IR) is a known significant early risk marker for metabolic 
syndrome and cardiovascular disease and can precede dysglycemia in prediabetics and 
patients with type 2 diabetes mellitus (T2DM) by some years. In contrast to the traditional 
glycated hemoglobin (HbA1c), new non-glycemic {a-hydroxybutyrate, linoleoyl-
glycerophosphocholine (L-GPC), oleic acid} biomarkers, in combination with insulin, 
provide a novel comprehensive and more robust measure of insulin resistance in a single 
assay (Quantose IR™). These biomarkers (alpha hydroxybutyrate, L-GPC, and oleic acid) 
correlate with early beta cell dysfunction, impaired glucose tolerance and increasing lipolysis 
respectively. In addition, increased insulin level is characteristic of IR and is an independent 
risk factor for type 2 diabetes and cardiovascular disease.(28, 29)Recently, additional insight 
into the pathogenesis of phenylketonuria was gained using GC-MS and NMR based 
metabolomics. Analysis of urine samples from these patients demonstrated multiple 
perturbations in arginine, proline, alanine, aspartate, and glutamate metabolism pathways. (9)  
This chapter details the development of an LC-MS/MS-based comprehensive targeted 
metabolomics panel which encompasses a broad range of clinical and biochemical genetic 
disorders (such as disorders of metabolism of amino acids, organic acids, bile acids, 
polyamines, neurotransmitters, sugars, and mitochondrial fatty acid oxidation). The method is 
applicable for different biological matrices such as whole blood, serum, dried blood spots 
(DBS) and tissues. The sensitivity, selectivity, and linearity of this LC-MS/MS method were 
evaluated, including the stability of the measured metabolites under defined preparation and 
analysis conditions. (15, 30, 31) Since DBS represent the maximum metabolic level of 
analytes that remain stable and are quantifiable, (32, 33) the method was validated on DBS 
from eight different groups of patients with a known diagnosis of IEM.  
 
 





The aims of this study were as follows: 
1) To develop and standardize a metabolomics method, utilizing LC-MS/MS for 
metabolomics profiling in DOCK8 deficient and Atopic dermatitis patients. 
2) Validate this method, as per the United States Food and Drug Administration (US FDA) 
regulations. 
3) Test the applicability of this method on three different matrices: DBS, serum and 
tissues. 
4) Validate the developed method on eight known diagnosis of IEM. 
5) Validate the method on DBS with eight known IEM. 
6) Build a reference range for DBS. 
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3.3  Materials and Methods 
3.3.1 Chemicals and reagents 
Metabolite standards and reagents were obtained from Sigma Chemicals (St. Louis, MO) at a 
minimum purity of 98%). All organic solvents and water used in sample and mobile phase 
preparations were LC-MS/MS grade and obtained from Fisher Scientific (Fair Lawn, 
NJ).Isotope labeled internal standards were purchased as follows: 
Isotope labeled 
standards   
Pterin  Schricks  Laboratories (Postface, Switzerland).  
L-Monapterin   Schricks  Laboratories (Postface, Switzerland).  
2-Amino 1,6-Hexandioc-
D3   Cambridge Isotope, Inc (Woburn, MA). 
Guanosine-15N5 Cambridge Isotope, Inc (Woburn, MA). 
Inosine-15N4 Cambridge Isotope, Inc (Woburn, MA). 
D-Fructose (2e13C) Cambridge Isotope, Inc (Woburn, MA). 
Citric acid-D4 Cambridge Isotope, Inc (Woburn, MA). 
L-Citrulline-D7 Cambridge Isotope, Inc (Woburn, MA). 
Adenosine-C13 Cambridge Isotope, Inc (Woburn, MA). 
Methylmalonic acid-D3 Cambridge Isotope, Inc (Woburn, MA). 
Alanine-D1 Cambridge Isotope, Inc (Woburn, MA). 
2- Deoxyadenosine-C13 Cambridge Isotope, Inc (Woburn, MA). 
GlucoseeD7 Cambridge Isotope, Inc (Woburn, MA). 
Alanine-D4 ChromSystems (Grafelfing, Germany 
Arginine- D7 ChromSystems (Grafelfing, Germany 
Aspartic acid-D3 ChromSystems (Grafelfing, Germany 
Citrulline-D2 ChromSystems (Grafelfing, Germany 
Glutamic acid-D5 ChromSystems (Grafelfing, Germany 
Leucine-D3 ChromSystems (Grafelfing, Germany 
Methionie-D3 ChromSystems (Grafelfing, Germany 
Ornithine D6 ChromSystems (Grafelfing, Germany 
Phenylalanine-D5 ChromSystems (Grafelfing, Germany 
Tyrosine- D4 ChromSystems (Grafelfing, Germany 
Valine-D8 ChromSystems (Grafelfing, Germany 
C0-Carnitine-D9 ChromSystems (Grafelfing, Germany 
C2-Carnitine-D3 ChromSystems (Grafelfing, Germany 
C3-Carnitine-D3 ChromSystems (Grafelfing, Germany 
C4-Carnitine-D3 ChromSystems (Grafelfing, Germany 
C5-Carnitine D9 ChromSystems (Grafelfing, Germany 
C6-Carnitine-D3 ChromSystems (Grafelfing, Germany 
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C8-Carnitine- D3 ChromSystems (Grafelfing, Germany 
C10-Carnitine-D3 ChromSystems (Grafelfing, Germany 
C12-Carnitine-D3 ChromSystems (Grafelfing, Germany 
C14-Carnitine-D3 ChromSystems (Grafelfing, Germany 
C16- Carnitine-D3 ChromSystems (Grafelfing, Germany 
C18-Carnitine-D3  ChromSystems (Grafelfing, Germany 
 
3.3.2 LC-MS/MS analysis 
In this LC-MS/MS method, an Acquity UPLC-XEVO TQD tandem mass spectrometer 
(Waters Corporation, USA) was used, where analytes were separated by reversed phase 
chromatography using Acquity UPLC C18, 1.7 mm, 2.1 mm x 100 mm column (at ambient 
temperature). Each sample was analyzed twice; in positive and negative ionization modes. In 
positive mode analysis, the mobile phase consisted of (A) 0.1% acetic acid and (B) 50% 
acetonitrile (ACN) and 50% Methanol (MeOH). The mobile phase, for the positive mode, 
was ramping from 2% to 95% for 10 min, held for 1 min at 95% then mobile phase A was 
ramped back to 2%, to regenerate the column for the next run. In negative mode, the mobile 
phase was composed of (A) 0.1% tributylamine (TBA), 0.03% acetic acid, 10% MeOH and 
(B)100% ACN. Subsequently, mobile phase for negative mode was ramping from 5% to 70% 
for 13 min, held for 1 min at 70% and then the mobile phase A, ramped back to 5%, to 
regenerate the column for the next run. The samples were run in the positive mode, first and 
then run on the negative mode, with an intermediate automated washing step to avoid any 
sample carryover. The total run time for each sample in each mode was 15 min at a flow rate 
of 0.3 mL/min. The samples were stored in the auto sampler at 4oC, and the injection volume 
was 10 ml. 
The targeted compounds were prepared in 50% methanol (400 mM) and infused into XEVO 
TQD (Waters Corporation, USA) for optimization. The source and desolvation temperatures 
were set at 150 oC and 250o C, respectively, while the desolvation gas was set at 500 L/h to 
tune molecules in both (positive and negative) polarity modes. The specific tuning 
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parameters, such as ionization polarity, precursor and product ions, cone voltage and collision 
energy (CE) were obtained for each analyte. The eluted metabolites were analyzed under the 
optimal MS conditions listed in Table A1.2 using an electrospray ionizing. The cone voltage 
ranged from 18 to 170 V, and the collision energy ranged from 7 to 65 eV. Common MS 
parameters were the same as the tuning conditions described above except the desolvation 
temperature and gas flow at 500 ⁰ C and 1000 L/h, respectively. A chromatographic method 
was developed to accommodate the best baseline separation for the targeted metabolites 
within 15 min of retention time, the gradient started at injection (zero dead volume). A 
mixture of all of these compounds was used to prepare a wide range of calibration curve 
(1e1000 nM) and a set of analytical quality control (QC) samples (25, 250,750 nM). The MS 
was maintained using a calibration kit and protocol as recommended by the manufacturer 
(Waters Corporation, USA). 
3.3.3 Assay validation 
Validation of the analytical method was performed according to the United States Food and 
Drug Administration (US FDA), and International Conference on Harmonization (ICH) 
guidelines.(15, 34, 35) 
3.3.3.1 Specificity and sensitivity 
For the metabolites listed in Table A1.2, calibration curves were prepared daily in serial 
dilution and spiked with standard internal mixture (IS). In each detection mode, a set of IS 
compounds were used to correct for the sample preparation and LC-MS/MS fluctuations as 
detailed in Table A1.3. The calibration curve linearity was evaluated over three consecutive 
days. A blank with internal standard (IS) mixture̊, a standard metabolites mixture, and 7-10 
points calibration curves were analyzed using the developed method. The calibration curves 
were generated by plotting the peak area ratio (area analyte /area IS) of the metabolite versus 
the nominal concentration of each analyte. The lower limit of quantification (LLOQ) was 
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defined as the lowest point in the calibration curve, where the signal was at least ten times 
greater than the standard deviation of the blank. The LLOQ accuracy should be within 80 to 
120%, and day-to-day variation less than or equal to 20%. During optimization, target analyte 
fragmentation was  minimized and the fragmentation of the isobaric matrix components was 
maximized, hence the precursor ion of the analyte passed through the collision cell with a 
minimum intensity loss, while the isobaric matrix components were eliminated by 
fragmentation in the collision cell. The minimal difference between retention times in matrix-
free (solvent) and (serum) spiked samples (<0.1%) allowed confident, highly specific, peak 
identification. Also in the chromatography method, the first minute was excluded for eluting 
compounds to overcome the possible ion-suppression. Finally, to avoid any other potential 
source of signal fluctuation, only significant fold change at a cut off 2 with false discovery 
rate (FDR) corrected p-value <0.05 was considered. 
3.3.3.2 Intra and inter-day precision 
The intraday variability was evaluated by preparing three independent fresh replicates (n ¼ 6) 
of each QC sample, a mixture of standard metabolites and internal standards prepared in the 
lab to yield concentrations of 25, 250, 750 nM. Over three different days, the inter-day 
validation was accomplished similarly. The accuracy was calculated as (mean measured 
concentration/nominal concentration) x 100%, and the variability was represented as the 
percent relative standard deviation (percentage RSD). 
3.3.3.3 Stability 
To study the metabolite solution stability, under different sample preparation and analysis 
conditions, a set of three QC samples (25, 250, 750 nM) were prepared and treated under the 
following conditions: room temperature (RT), at bench top for 6 h, 7 days in the auto sampler 
or refrigerator (4⁰C), 30 days storage in the freezer (-20⁰C) and 30 days storage in liquid 
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nitrogen (recognized as fresh). The long-term stability of these metabolites in DBS was 
evaluated by running a batch of 20 DBS of controls, at 0 times (fresh), 2 months and 4 
months. The molecular stability was calculated as (area ratio of examined sample/area ratio 
of the fresh sample) x 100%. 
3.3.3.4 Recovery 
The recovery of the metabolites was studied through extraction, where plasma samples were 
spiked with a mixture of labeled internal standard extracted and then analyzed on this 
analytical platform. The recovery percentage was calculated as (area ratio of extracted 
metabolites from plasma/area ratio of metabolites in solution) x100%. 
 
3.3.4 Biological sample collection and metabolite extraction. 
3.3.4.1 Animal tissue samples 
Heart, liver, kidney, muscle, and brain tissue samples were collected from five healthy male 
Sprague Dawley (SD) rats by following the protocol approved by the animal care and use 
committee (ACUC) at King Faisal Specialist Hospital and Research Center (KFSH&RC) 
(Study number: 2150,016). Upon sacrifice, the rat tissue samples were excised and washed 
quickly with cold phosphate buffered saline (PBS), snap frozen in liquid nitrogen, and then 
stored at 80⁰ C. All tissues were processed together at the same time as detailed in a previous 
study, where ~100 mg of tissue was pulverized in a cell crusher under liquid nitrogen for 
metabolic extraction.(36) The polar metabolites were extracted by adding 1.0 ml of IS (250 
nM) mixed with the extraction solvent (40% ACN, 40% MeOH and 20% water). The mixture 
was shaken at 1000 round per minute (RPM) for 1 h at 4 ⁰ C in a thermomixer (Eppendorf, 
Germany). Following extraction, samples were spun down at 14,000 RPM on an Eppendorf 
centrifuge (Hamburg, Germany) for 10 min at 4⁰C, and the supernatant was transferred to 
fresh tubes to be evaporated in Savant™ SpeedVac Concentrator (Thermo scientific, USA). 
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This step was performed twice to enhance the extraction recovery. Then after the extracted 
solvent was evaporated to dryness in the concentrator, the dry extract was reconstituted in a 
100 ml mixture consisting of the mobile phase (95% of 0.1% acetic acid and 5% of mixture 
of 50% ACN and MeOH) and stored at 4ºC for LC-MS/MS analysis. 
3.3.4.2 Biological matrix: whole blood and serum 
Whole blood samples were collected from 20 healthy adult individuals: 100 ml was aliquoted 
into Eppendorf tubes, 100 ml was spotted on Guthrie cards (Perkin Elmer) and the rest of the 
blood sample was centrifuged to obtain 100 ml serum. The polar metabolites were extracted 
from blood and serum with a mixture of IS (250 nM) and extraction solvent (50% ACN, 50% 
MeOH) as per the developed extraction protocol in section 3.2.4.1 
3.3.4.3 Dried blood spots (DBS) 
Initially, DBS samples from the same 20 healthy adult volunteers (Section 3.2.4.2) were 
punched (5 discs, 3.1 mm each) into a 96-well plate, and then metabolites were extracted 
using a mixtureof IS (250 nM) and extraction solvent (40% ACN, 40% MeOH and 20% 
water). The extraction procedure was completed as detailed in (section 3.2.4.1).The potential 
clinical usefulness of this method was further evaluated by running additional 200 random 
DBS samples obtained from the Newborn Screening & Biochemical Genetics Laboratory 
(NSBGL) at the KFSHRC, as per the ethics committee approval (Project# 2160027). As a 
part of the routine newborn screening panel, in Saudi Arabia, all of these 200 DBS samples 
were previously reported to be negative for 17 inborn errors of metabolism.(Phenylketonuria, 
Maple syrup urine disease, Arginosuccinase deficiency, Citrullinemia, 3-hydroxy-3-
methylglutaryl-CoA lyase deficiency, Isovaleric acidemia, Methymalonic acidemia, 
Propionic acidemia, Beta ketothiolase deficiency, Glutaric type-1, Medium chain acyl CoA 
dehydrogenase deficiency, Glutaric type-3, 3-MethylcrotonylCoA carboxylase deficiency, 
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Galactosemia, Congenital hypothyroidism, congenital adernal hyperplasia, Biotindase 
deficiency )  
In addition, 56 abnormal DBS samples from patients with 8 IEM disorders were collected; 
[phenylketonuria(PKU),maple syrup urine disease(MSUD),very long chain acid 
dehydrogenase deficiency(VLCADD), glutaric type-1(GA-1), glutaric type-2(GA-2), 
tyrosinemia type-1(TYR-1) and tyrosinemia type 2( TYR-2)]. In addition, 56 abnormal DBS 
samples from patients with eight different inborn errors of metabolism were collected. These 
samples failed the routine MS/MS-based newborn screening pipeline and were then 
confirmed as having one of the 8 disorders listed in Table 0.1. These samples were evaluated 
using this method to study the potential capability of this panel to detect and profile various 
IEMs.  
3.3.5 Data and statistical analysis 
3.3.5.1 Data acquisition, processing, and visualization 
The sample delivery to the mass spectrometer was managed through the LC-MS/MS software 
of MassLynx, version 4.1 (Waters Corporation, Massachusetts, USA), which was also used 
for tuning and data acquisition. The peak integration and data analysis were performed using 
TargetLynx (Waters Corporation, Massachusetts, U S A). The area under the peak was used 
as the analytical signal for quantitative measurement of assay performance regarding 
linearity, sensitivity, and reproducibility. The tuning parameters and the retention times for 
the compounds are represented in Table A1.2. 
3.3.5.2 Stastical Analysis. 
The raw data was analyzed using MetaboAnalyst software version 3.0 (McGill University, 
Montreal, Canada). Features with more than 50% missing values were removed, while others 
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with missing values were replaced with small values (half of the minimum positive values in 
the original data) assumed to be above the detection limit. The data was then normalized to 
the equivalent internal standard's area under the peak, and then to the sample total sum to 
ensure normal distribution. To adjust for the differences among the study samples, data log 
transformation, and Pareto scaling approaches were used to make individual features more 
comparable. As the vast majority of the study analytes were Gaussian distributed, an unpaired 
two-tailed Student’s t-test was used to compare the differences between two study groups 
(treated, non-treated), where the significance levels for metabolomics data were considered at 
a FDR corrected p-value < 0.05, and values were presented as mean ± SEM. The Sample Size 
Calculator for designing clinical research (http://www.sample-size.net) was used for the 
Mean-effect size analysis which was performed along all statistical analyses. The 
chemometric analysis was carried out using principal component analysis (PCA) and 
orthogonal partial least-squares projection to latent structure-discriminant analysis 
(orthoPLS-DA) (33).Orthogonal projection of Latent structures-discrimination analysis 
(OPLS-DA) is a supervised multiple regression analysis for identifying the discrimination 
between different datasets. The bar-graphs were generated using Graph Pad Prism V. 6 (34, 
35). The FDR-corrected p values are represented on the figures as 0.0001 (***), 0.001 (**), 
and 0.05 (*). The statistically significant features between the study groups were used for 
pathway analysis and molecular mapping. Metabolic enrichment and pathway analyses were 
based on MetaboAnalyst (http://www.metaboanalyst.ca). The Rattus norvegicus pathway 
library was used. Cytoscape 3.4.0 on MetScape (http://www.cytoscape.org)  was used for 
large-scale network analysis and the visualization of the integrated metabolism pathways 
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3.4 Results and discussion. 
3.4.1 Method development and MS optimization 
A library of 225 targeted and clinically relevant metabolites was obtained from commercial 
sources and used to optimize the LC- MS/MS instrument in multiple reactions monitoring 
(MRM) mode as shown in Error! Reference source not found..The compound specific c
hromatographic and mass spectrometric parameters such as RT, precursor ion, product ion, 
collision energy (CE) and cone voltage are summarized in Table A1.2. The chromatographic 
parameters were developed in gradient reversed phase to obtain proper analytical peaks. The 
reproducibility of liquid chromatography is very important to distinguish between the 
molecules produced inside the ion source such as ATP dissociation to ADP and AMP causing 
endogenous artifacts. Representative over layed chromatograms in both positive and negative 
ionization modes are shown in Error! Reference source not found.A and B, respectively. The s
tock solution of the standard mix was prepared at a concentration of 10,000 nM. Standard 
solutions (1, 5, 10, 25, 50, 100, 250, 500, 750, 1000 nM) were prepared by serial dilution of 
the stock solution with mobile phase mix. (95% of 0.1% acetic acid and 5% of mixture of 
50% ACN and MeOH) 
  




Figure 0.1: Workflow for targeted LC-MS/MS analysis of metabolites extracted from Dried Blood 
Spot (DBS), plasma, whole blood, and tissues. Tissue samples were frozen on dry ice, stored at -80oC, 
and crushed in a crucible on liquid nitrogen just prior to extraction 
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Biochemical markers Sex Age 
(years±SD) Primary Secondary Male Female 
PKU 15 Phe Phe/Tyr 7 8 13.9±8.7 
MSUD 10 Leu, Ileu, Val Leu/Ala 6 4 6.7±5.2 
VLCADD 10 Tetradecenoylcarnitine (C14:1) C14/C16 5 5 3.0±1.58 
MMA/PA 8 Propionylcarnitine (C3) 




6 2 4.1±3.5 
GA-1 2 Glutarlycarnitine (C5DC) (urine glutaric & 3-hydroxyglutaric acids) 1 1 5±2.82 
GA-2/ 
MADD 1 C4, C5   1 22±0 
TYR-1 7 Tyr Succinylacetone 6 1 15.1±4.87 





2 1 21±12.7 
Abbreviations: PKU phenylketonuria , MSUD maple syrup urine disease,  VLCADD very 
long chain acyl-CoA dehydrogenase deficiency, MMA/PA methylmalonic acidemia , PA 
propionic academia ,GA-1 glutaric acidemia type1, GA-2 glutaric acidemia type2, MADD 
multiple acyl-CoA dehydrogenase deficiency, TYR-1 tyrosinemia type1, TYR-2 tyrosinemia 
type2. 





Figure 0.2: Metabolite quantification: Overlay chromatogram of 225 metabolites (A) Tryptophan in 
positive ion mode and (B) Methylmalonic acid in negative ion mode. 
(Each coloured peak represents the amount of metabolite in the analysed samples).  
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and the analyte area ratio (area analyte/area IS) versus its nominal concentration was 
analyzed for linearity. The mean Pearson correlation coefficient (R2), calculated over the 
course of several days was greater than 0.98 for all targeted metabolites (Table A1.3). 
Dealing with the simultaneous analysis of different classes of metabolites, the chemical 
complexity, and molecular heterogeneity can pose technical challenges in analyzing them in a 
single assay. For example, compared to LC-MS/MS, analysis of volatile organic compounds 
with high separation efficiency is possible using GC-MS, while it has some limitations in 
analyzing medium and highly polar metabolites requiring derivatization which can introduce 
additional substances resulting into overlapping signals, degradation of unstable metabolites 
and column damage. On the other hand, in LC- MS/MS analysis of non-derivatized polar and 
high molecular weight metabolites is possible. Hence often there is a demand to combine 
various analytical methods to obtain the best results.(39) 
3.4.2 Method validation 
3.4.2.1 Specificity and sensitivity 
The LC-MS/MS method specificity was evaluated, and showed no interfering peaks at the 
corresponding retention times for the extracted compounds from different biological matrices 
such as whole blood, serum, and tissue. The sensitivity of the method was evaluated as 
described before and the results were summarized in Table A1.3. The lower limit of 
quantification (LLOQ), values are the average of the lowest point in each valid linear 
calibration curve with the relative standard deviation (RSD) ranging from 80 to 120%. Some 
compounds were below the values are the average of the lowest point in each valid linear 
calibration curve with the relative standard deviation (RSD) ranging from 80 to 120%. Some 
compounds were below the LLOQ, indicating that they could be detected in low 
concentration but could not be quantified. Sensitivity for each metabolite varied over wide 
ranges, as it depends on the compound polarity, fragmentation and ionization pattern and 
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post-source chemical stability. Under the optimum chromatographic conditions, peaks of the 
targeted metabolites were separated at retention times ranging from 0.73 to 11 min. Most of 
the metabolites eluted within 6 min except for sodium glycodeoxycholate and 
tauroursodeoxycholate which eluted soon after 11 min of retaining in the column. 
3.4.2.2  Intra and inter-day accuracy and precision 
Inter and intraday precision and accuracy were evaluated for the listed metabolites at three 
levels of QC samples; low, medium, and high concentration. The inter-day variability was 
less than 20% and inter-day accuracy ranged from 80 to 120% (Table A1.4) for the QCs, 
which meet the criteria of a validated bio analytical method to be utilized routinely for 
quantitative metabolomic profiling.  
3.4.2.3  Stability 
The stability of targeted compounds was studied under different preparation and acquisition 
conditions using the low, medium and high levels of the QC samples. It was calculated 
relative to freshly prepared samples, stored in liquid nitrogen as summarized in Table A1.5. 
The stability of some compounds showed a slight reduction after 6h but was very poor after 
24 h, bench top storage (data not shown). Some compounds were unstable compared to the 
internal standard, which supports the need for having an isotopically labeled analog for each 
analyte. In general, the stability of most of the targeted metabolites under the operational 
conditions ranged between 60 and 150%, except under RT (6 h on the bench top) when it 
dropped below 60%. These stability ranges are considered valid for reporting because the 
area of LLOQ, as far as the method is concerned, is far above the noise and the RSD ranges 
between 80 and 120%. For DBS samples, metabolites long-term stability was evaluated 
relative to freshly prepared samples and is summarized in Table A1.6. Most metabolites 
including amino acids and carbohydrates were stable with minimal variance when analyzed 
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after 2 and 4 months. Itaconic acid, inosine 5’-diphosphate, L-carnitine, N-acetylspermine 
and 2-oxoglutaric acid showed no change when reanalyzed, whereas homocitrulline and 
sodium taurodeoxycholate showed significantly reduced stability. 
3.4.2.4 Recovery 
Recovery of the selected labeled internal standards (n=24) was used to evaluate the extraction 
recovery, where most of them were above 60% as summarized in Table A1.7 except for 
methionine-d3, arginine-d7, and valine-d8.Overall the recovery data ranged between 54% & 27%. 
3.4.3  Application of metabolomics analysis to biological samples 
The metabolites in a biological sample are complex and have different chemo-physical properties, 
such as hydrophobicity, acidity, charge, pKa, size (1, 40) and the efficiency of extraction also 
varies depending on the metabolite itself. Hence, simultaneous separation of all the metabolites in 
a single comprehensive assay is challenging, (13, 41) and the metabolic profile is very sensitive to 
the biological matrix. The library of 225 targeted metabolites in this study are clinically relevant 
to many biochemical genetic diseases and are directly involved in different biochemical pathways 
that regulate a variety of important functions in the body. Examples of these pathways include 
metabolism of nucleotides, lactate/pyruvate, nicotinate and nicotinamide, biotin, glutathione, 
steroids, amino acids, polyols, vitamins, mitochondrial fatty acids oxidation and electron 
transport, glycolysis and pentose phosphate intermediates, hexosamine biosynthesis, malate-
aspartate shuttle, as well as the “cancer related” Warburg effects. To evaluate the organ-specific 
metabolomic profile, tissue samples were collected from several organs (kidney, brain, heart, 
liver, skeletal muscle) of five male SD rats. As displayed in Error! Reference source not found.A, t
he overall metabolite levels varied but was highest in the kidney tissue (35%) in comparison to 
the liver (25%), brain (17%), heart (15%) and muscle tissue (8%) for the same amount of tissue. 
Although the rat tissues were collected without perfusion, it is interesting to note the higher levels 
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of metabolites in the kidney which is probably related to its physiological function in excreting 
various compounds intermediary to metabolism and being the recipient of almost one-quarter of 
the total cardiac output.(42, 43) ANOVA analysis was performed for statistical (p-value) and fold 
change (FC), a significant set of metabolites in each tissue. The PCA score plot showed clear 
cluster differentiation among the five tissues (Error! Reference source not found.B), which reflects t
he reproducibility and the sensitivity of the method to detect the metabolic differential 
perturbation among the different tissue samples.  
Pathway analysis of the significantly enriched metabolites was performed and (Error! Reference s
ource not found.C) shows significant perturbation in pathways, such as the metabolism of 
nucleotides, nicotinate and the amino acids (alanine, aspartate and glutamate). The level of 
metabolic perturbations mainly follows the unique physiology of the organ or tissue. As shown in 
the heat map (Error! Reference source not found.D), cluster analysis shows unique metabolic s
ignatures for the various tissues. For example, in contrast to the three other tissues studied, both 
skeletal and cardiac muscle showed perturbed levels of several nucleotides, creatine, and some 
hexoses. In the murine brain, creatinine and NANA (N- acetylneuraminic acid) was elevated 
relative to liver and kidney. The unusual dicarboxylic acid, itaconic acid (3-methylenesuccinic 
acid) was most abundant in murine brain, and to a much lower extent in skeletal muscle. 
Normally, decarboxylation of aconitate by aconitate decarboxylase (ACOD1) results in the 
formation of small quantities of itaconic acid.  So far, no human patient with ACOD1 deficiency 
has been described. The “non-oxidative” pentose monophosphate shunt related metabolites, 
erythrose-4- phosphate, ribose-5-phosphate, fructose-6-phosphate, and sedoheptulose-7-phosphate 
seem to have perturbed patterns which correlate with known related human disorders. In 
particular, metabolism of nucleotides, nicotinate and amino acids. are most expressed in skeletal 
and cardiac muscles while sedoheptulose-7-phosphate is expressed primarily in brain and cardiac 
muscle. Transketolase (TKT, MIM # 617044) and transaldolase (TALDO1, MIM # 606003) 
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deficiencies are rare autosomal recessive disorders involving this pathway and are clinically 
characterized by congenital heart disease, facial dysmorphism, short stature and elevated plasma 
and urinary polyols 
However, healthy neurological development, hepatosplenomegaly, and bone marrow 
dysfunction are features of TALDO1 deficiency, unlike TKT deficiency which had been 
associated with neuropsychiatric abnormalities. (44-46) Taken together; these observations 
suggest that accumulation of these pentose sugars may be causing cardiac dysmorphogenesis 
while the accumulation of sedoheptulose-7- phosphate, in particular, and may be neurotoxic. 
The polyamines, putrescine, spermidine, and spermine are multifunctional polycationic 
aliphatic amines that are involved in multiple vital cellular processes through translation 
initiation. Spermidine synthase (SRM, MIM # 182891) and spermine synthase (SMS, MIM # 
300105) are responsible for the synthesis of spermine from putrescine through the generation 
of spermidine. Polyamine catabolism utilizes the rate-limiting enzyme SAT1 (spermidine/ 
spermine N (1) acetyltransferase 1) which has a higher affinity for spermidine than spermine 
and SAT2 (spermidine/spermine N (1) acetyltransferase 2), which has an equal affinity for 
both substrates. 
  




Figure 0.3 : Targeted metabolomic analysis of normal murine tissues. (A) Distribution of 225 
targeted metabolites extracted from five different types of murine tissues (brain, heart, kidney, liver, 
muscle). (B) Principal component analysis (PCA) score plot of the five different murine tissues.(C) 









Figure 3.3(D) Heat map analysis of significantly enriched metabolites in 5 murine tissues (muscle, 
heart, liver, brain and kidney) 
A targeted metabolomics approach 
110 
 
Levels of N-acetylspermine were highest in rat cardiac muscle, liver, and the least in skeletal 
muscle while putrescine and spermine were probably depleted. (Error! Reference source not f
ound.D) (47) Recessive mutations in SMS, an X-linked gene, cause Snyder-Robinson mental 
retardation syndrome, which is characterized by developmental delay, facial dysmorphism 
and skeletal abnormalities.(48)To study the role of various biological matrices on the 
metabolic profile, whole blood samples from healthy individuals were collected and divided 
as blood, serum, and DBS. The metabolites levels were comparable in serum and whole 
blood as shown in the Figure 0.4A, but slightly higher in serum. Although both serum and 
plasma are commonly used to explore biomarkers in metabolomics studies, several studies 
have demonstrated that most metabolites are more stable and well expressed in serum.(49, 
50) Dried blood spots showed the maximum metabolic level of analytes included in this 
panel, as compared to serum and blood samples, which is supported by other studies, where 
the largest number of metabolites was quantifiable and stable in DBS (at -80⁰C under dry 
conditions).(51, 52) ANOVA analysis of metabolites in the three matrices (Figure 0.4B) 
showed high levels of 3-phosphoglycerate (DBS >serum> blood). Distinct cluster separation 
among the three matrices reflects the sensitivity of the method as shown in Figure 0.4C. 
Among the three matrices, pathway analysis of the significantly expressed metabolites shows 
amino acids metabolism to be most significantly perturbed (Figure 0.4D). The healthy 
control DBS samples (n=200) included in the study were selected randomly from the NBS 
platform after they had been confirmed to be negative for any of the 17 inborn errors of  
metabolism that we target routinely in the Saudi newborn screening program. 
 
  






Figure 0.4:(A) Distribution of metabolites expression in various matrix sources. (B) One way 
Anova comparison of differential expression of metabolites between serum, blood and DBS 
samples. Inset shows expression profile of 3-phosphphoglycerate (DBS>serum>blood). (C) PCA 
analysis separates samples based on their matrix. (D) Pathway analysis of significantly enriched 
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These samples were then analyzed on this targeted metabolomics panel to study the technical 
reproducibility of the method, and to build a reference range for the analytes seen in the 
healthy newborn population. The reference ranges for the detected metabolites in DBS were 
calculated using non- parametric percentile method 95% CI, in this study was (2153.5 ± 42.4 
nM), and for methionine 197.26 ± 5.39, the reference ranges for the rest of analytes are 
summarized in Error! Reference source not found. 
3.4.3.1 Inborn errors of metabolism (IEMs)  
In IEMs metabolomic profiling, using multiple biological matrices may represent the 
metabolic perturbations associated with these diseases.(7, 25) Early and accurate diagnosis of 
many of these disorders has proven to be critical in their management. In our study, samples 
from patients with known IEMs (n ¼ 56) were processed using this analytical platform, and 
the data were subjected to statistical analysis. Besides the focused diagnostic key MS/MS 
based markers used routinely and summarized in Table 0.1, several other metabolites were 
found to be differentially expressed in these patients compared to ctrl samples such as 
betaine, succinic acid, niacinamide, fructose 1,6-bisphopshate (Error! Reference source not f
ound.). All of these samples were diagnosed based on the gold standard key biomarkers such 
as branched-chain amino acids in patients with MSUD, propionyl/C3-carnitine and 
methylmalonic acid in MMA, tetradecadienoyl/C14:1 carnitine for VLCAD, glutarylcarnitine 
and 3-hydroxyglutaric aciduria for glutaric aciduria type 1 patients, and phenylalanine for 
PKU patients. As shown in Error! Reference source not found., several sugars (arabinose, r
ibulose, dextrose, fructose and mannose) appeared to be overexpressed, in all studied groups 
of inborn errors of metabolism more so in the disorders of mitochondrial metabolism 
(VLCAD and GA2 deficiency) compared to ctrls. Biotin deficiency was detected in patients 
with various inborn errors of metabolism suggesting dietary deficiency, the correction of 
which may have a positive clinical impact on these patients. Betaine (trimethylglycine) is a 
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dietary supplement abundantly present in seafood, plants (such as wheat germ, bran, spinach), 
and is important as an osmolyte that protects cells under stress and as a methyl group donor 
significant for the hepatic methionine cycle.(53, 54) Betaine supplementation appears to be 
adequate in these patients as shown in these metabolomics profiles.  
3.4.3.1.1  Methylmalonic acidemia (MMA) & propionic acidemia (PA) 
Methylmalonic aciduria is a biochemically, molecularly and clinically heterogeneous disorder 
which is caused by a deficiency of methylmalonyl CoA mutase (MCM), defects in the 
transport or synthesis of its cofactor, adenosyl-cobalamin (cblA, cblB, cblC, cblF, cblD and 
cblX), deficiency of methylmalonyl-CoA epimerase (MCEE). The biochemical hallmarks of 
MMA include high plasma propionyl/C3-carnitine and elevated urinary excretion of MMA 
and methylcitrate. On the other hand, elevated plasma propionyl carnitine, urine 
methylcitrate, propionic acid and propionylglycine characterize the metabolic profile of 
patients with propionic acidemia as shown in Error! Reference source not found.A Secondary h
yperglycinemia occurs in both disorders as well as in several other organic acidemias. For 
proper diagnosis and management, metabolic profiling in organic academia is essential, as 
they are almost clinically indistinguishable. 
The overall incidence in the Western population ranges from 1:48,000 to 1:51,000 births for 
MMA, (55) and from 1:50,000 to 1:500,000 births for PA, whereas in Saudi Arabia, the 
incidence is much higher at 1 in 2,000 to 5,000 live births.(56) Clinical symptoms are non-
specific and start as early as second day of life with deteriorating clinical conditions like 
vomiting, dehydration, weight loss, temperature instability, neurological involvement with 
muscular hypo of hypertonia, lethargy progressing to coma and seizures. Laboratory findings 
include metabolic acidosis and ketosis.(56, 57) Newborn screening for MMA and PA is 
possible using propionylcarnitine and methionine. (58, 59) 
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As shown in Error! Reference source not found., MMA (n=6) and PA (n=2) displayed distinct m
etabolomics profiles with minimal overlap including hyperglycinemia and related elevated 
glutamine levels. Interestingly, spermine appears to be markedly reduced, in MMA compared 
to PA suggesting a preferential toxicity to the synthetic polyamine pathway in such patients. 
Another intriguing observation is the lower level of ethanolamine in MMA patients (as well 
as patients with PKU, GA2, VLCADD) in comparison to PA. Ethanolamine is produced via 
the decarboxylation of serine and is essential for the synthesis of phospholipids. In the MMA 
group of samples (n= 6), MMA was significantly elevated as expected as in Error! Reference s
ource not found.B, whereas Error! Reference source not found.C summarizes some of the noted 
biochemical perturbations in connection with MMA metabolism. 
3.4.3.1.2 Phenylketonuria (PKU)  
Classical phenylketonuria is caused by a deficiency of hepatic phenylalanine hydroxylase 
(PAH) and results in the accumulation of phenylalanine (Phe) and its catabolites 
(phenylpyruvate, phenyllactate, and phenylacetate). Loss of PAH activity results in increased 
concentration of phenylalanine in blood and toxic concentrations in the brain. Untreated PKU 
is associated with progressive intellectual impairment, along with other symptoms like 
eczematous rash, autism, seizures and motor deficits. As the child grows up, other 
developmental problems, aberrant behavior and psychiatric symptoms become evident. 
Enzyme deficiency can lead to mild hyperphenylalaninemia, mild phenylketonuria, and 
classic phenylketonuria. Classic phenylketonuria is a result of complete deficiency of 
phenylalanine hydroxylase activity, leading to irreversible intellectual disability, whereas 
mild hyperphenylalaninemia and mild phenylketonuria are linked to a lower risk of impaired 
cognitive development if left untreated. In Europe, the prevalence of PKU is 1: 10,000 live 
births,(60) whereas in Saudi Arabia the prevalence ranges from 0.005% to 0.0167%. The 
highest prevalence was reported in Turkey at 0.0167%, whereas the lowest prevalence was 
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reported in the UAE, 0.005%.(61) Due to well advanced newborn screening (NBS) programs 
reported in many developed countries, classical phenylketonuria are rarely reported , as PKU 
can be diagnosed readily in blood specimens collected by heel-prick from newborns.(62) 
Early diagnosis and prompt interventions can help avoid mental disability and a lifelong Phe 
restricted diet is the basis of current management of PKU.(63)  
In the PKU group of samples (n=15), Phe level was significantly elevated as expected and 
shown in Error! Reference source not found.C.As shown in Error! Reference source not found.A Hy
perphenylalaninemia causes increased production and excretion of phenylpyruvic acid, an 
inhibitor of the mitochondrial enzyme pyruvate carboxylase, a key regulatory enzyme 
involved in  gluconeogenesis, lipogenesis, and neurotransmitter synthesis, which converts 
pyruvate to oxaloacetate.(64)As a result, most glycolysis intermediates such as PEP, F-1, 6-
BP are up-regulated along with down regulation of lactate as shown in Error! Reference source n
ot found.B. This perturbations leads to the accumulation of succinate, carnitine, and 
acetylcarnitine and reduces the conversion of acetyl-CoA through oxaloacetate to citrate 
(Error! Reference source not found.D).Hydroxyproline was found to be up-regulated in PKU p
atients suggesting altered bone metabolism. Several studies reported low bone mineral 
density (BMD) in patients with PKU, which is formula independent. (65, 66) 
3.4.3.1.3 Hereditary tyrosinemias (Type-1 and type 2) 
Tyrosinemia type-1 is caused by a deficiency of fumarylacetoacetate hydrolase (FAH), the 
last enzyme involved in the phenylalanine/tyrosine degradation pathway while tyrosinemia 
type 2 results from a deficiency of tyrosine transaminase (TAT).(67)These two tyrosinemia 
syndromes are quite distinct, both clinically and biochemically as succinylacetone (4, 6-
dioxoheptanoic acid) accumulates in patients with type 1 only. 
   




Figure 0.5: Targeted metabolomic profiling in DBS samples of patients with various known inborn 
errors of metabolism.(A) Metabolic perturbations in methylmalonic aciduria and (B) related 
pathways, where MMA is associated with multiple significant metabolic abnormalities 
includingbiotin deficiencyand hyperhomocysteinemia. (C) Characteristic metabolite profiles in 
selected inborn errors of metabolism. * denotes statistical significance. 
 
(Abbreviations: Methylmalonic acidemia- MMA, Maple syrup urine disease- MSUD, Very ling chain 
fatty acid dehydrogenase deficiency- VLCAD, Glutaric type-1- GA-1, Not remarkable- NR.) 
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The disease is characterized by progressive liver disease and renal tubular dysfunction that 
leads to hypophosphatemic rickets, cirrhosis and hepatocellular carcinoma.(68) Prevalence 
estimates from 1 in 250,000 births. (69) The presentation of the disease may occur in infancy, 
childhood or as adults and age of presentation broadly correlates with severity of the disease 
.(70) In 10 tyrosinemia samples (Tyr1=7, Tyr2=3), the metabolomics profiles were quite 
distinguishable from the control group (Error! Reference source not found.C, E) but not from e
ach other presumably because succinylacetone excretion was controlled under therapy. 
Tyrosinemia groups of samples when compared to controls (Figure. A2.6), Tyr and Phe, 
nucleotides, carnitine and betaine were upregulated while sugars, niacinamide, progesterone 
as well as amino acids were down-regulated. While both disorders share partially the same 
metabolic pathway, additional dietary and therapeutic interventions likely contributed to this 
pattern (Error! Reference source not found.E and Error! Reference source not found.).  
3.4.3.1.4 Maple syrup urine disease (MSUD) 
MSUD is an aminoacidopathy caused by recessive mutations in one of the lipoic acid 
dependent enzymes: branched chain keto acid dehydrogenase-E1 alpha polypeptide 
(BCKDHA); Branched Chain Keto Acid Dehydrogenase E1 Subunit alpha (BCKDHA); 
Branched Chain Keto Acid Dehydrogenase E1 Subunit beta (BCKDHB); dihydrolipoamide 
branched chain transacylase (DBT), responsible for the catabolism of the branched-chain 
amino acids leucine, isoleucine, and valine. Accumulation of these three amino acids and 
their corresponding ketoacids leads to encephalopathy and progressive neurodegeneration in 
untreated infants. 
Patients with severe forms of MSUD develop metabolic decompensation and encephalopathy 
within the first weeks of life and may lead to death if left untreated.(71) Continuous 
metabolic control of these patients is possible by DBS monitoring programs, (72) because if 
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the disease progress convulsion, hypoglycemia, coma and systemic failure may occur. Hence, 
early detection and treatment is essential for long-term disabilities. Restricted dietary 
management with low BCAAs (mainly leucine) has to be followed in these patients or the 
ultimate treatment is liver transplantation.(73) As expected, in our group (n=10) of patients 
with MSUD, the key diagnostic markers leucine, isoleucine, and valine were elevated when 
compared to the ctrls (Error! Reference source not found.B and Figure A2.6). In addition, p
anthothenic acid and 4-hydroxyproline were up regulated, whereas progesterone, 
niacinamide, and ethanolamine were down regulated. 
  




Figure 0.6: Comparison of targeted metabolomic profiles in patients with phenylketonuria (PKU) vs. 
tyrosinemia type 1 (TYR-1).(A) Metabolic pathway of phenylalanine and tyrosine metabolism. (B) 
Several glycolytic intermediates are almost equally overexpressed in both PKU and TYR-1 patients. 
(C) PCA score plots for PKU (n15) and TYR-1 (n=10) vs control subjects show clear separation of 
the three groups with partial overlap between the PKU and TYR1 subjects. (D) Significant 
perturbations in amino acids (especially homocysteine and glutathione) and carnitine metabolism 
were detected in both disorders.  
  









Figure 3.6E: Heat map analysis of enriched metabolites in PKU and TYR-1 shows distinct 
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3.4.3.1.5  Very-long-chain acyl-coenzyme A dehydrogenase deficiency (VLCADD) 
VLCADD, is an autosomal recessive disorder with a prevalence of about 1:85,000 (74) and 
results in impaired mitochondrial b-oxidation of long chain fatty acids. It presents with a 
disease specific acylcarnitine profile with elevated C14:1-carnitine as a unique blood marker.  
(75) Classically, two forms of VLCADD have been described: an early-onset, severe form 
which, if unrecognized and undiagnosed, may lead to extreme weakness of the heart muscles 
(cardiomyopathy) and may be life-threatening, and a later-onset, milder form that is 
characterized by low blood sugar (hypoglycemia). (76) Treatment consists in avoidance of 
fasting, prompt treatment of fever, other illnesses and supplementation of a diet low in long 
chain fatty acids and medium chain triglyceride.(77) In patients with secondary carnitine 
deficiency, L-Carnitine at low doses is recommended followed by monitoring including 
annual physical examination .(78) VLCADD can be detected through newborn screening 
programs, but there are chances to miss some cases as acylcarnitine profile can become 
normal during anabolic conditions. (79)(80) In the ten profiled samples, niacinamide, 
glycerol, ethanolamine were significantly under-expressed (Error! Reference source not found.). 
3.4.3.1.6 Glutaric acidemias: GA-1 and GA-2. 
Glutaric acidemias are autosomal recessive neurometabolic disorders with mutations in 
glutaryl-CoA dehydrogenase (GCDH) causing type 1 (GA-1) and mutations in ETFA, ETFB 
and Electron transfer flavoprotein dehydrogenase (ETFDH) causing type 2 (GA-2). Detection 
of glutarylcarnitine (C5DC) by tandem mass spectrometry is the primary biomarker used in 
newborn screening for for GA-1.(81) In contrast, elevation of plasma C4/butyrylcarnitine and 
C5/ isovalerylcarnitine mark the acylcarnitine profiles of patients with GA-2 
(MADD/multiple acyl-CoA dehydrogenase deficiencies).  
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GA-1 patients have a deficiency of glutaryl-CoA dehydrogenase enzyme (82) that is required 
to break down the amino acids lysine, hydroxylysine, and tryptophan and prevalence of GA-1 
is 1 in 56000. (83) Accumulation of these amino acids can cause cerebral atrophy and brain 
damage,(84) characterized by macrocephaly at birth or shortly after, dystonia, and seizures at 
the first episode. (85) Treatment includes carnitine supplementation, diet restricted in amino 
acids capable of producing glutaric acid, and prompt treatment of occurring illnesses.(86) 
GA-II represent three types of clinical phenotypes: the neonatal form with congenital 
anomalies, the neonatal form without congenital anomalies; and the late onset form with 
myopathic phenotype.(87) MADD is a disorder of fatty acid and amino acid oxidation and is 
a clinically heterogeneous disorder ranging from a severe neonatal presentation with 
metabolic acidosis, cardiomyopathy and liver disease, to a mild childhood/adult disease with 
episodic metabolic decompensation, muscle weakness, and respiratory failure.(88) These 
patients are advised a protein- and fat-restricted, carbohydrate-rich diet as well as riboflavin, 
glycine, and L-carnitine supplementation. (88) 
The metabolomic profiles of GA-1 (n= 2) and GA-2 (n= 1) showed upregulation of 
pantothenic acid, betaine, 3-phosphoglycerate, inosine and hypoxanthine in both GA-1 and 
GA-2 samples, whereas several sugars such as dextrose, ribose, and mannose were 
downregulated. Interestingly, spermine and (to a lower extent) alanine were preferentially 
downregulated in GA-2 but not in GA-1 (Error! Reference source not found.). This may c
ontribute to the pathogenesis of hypoglycemia in these disorders. 
In the last two decades, LC-MS/MS has become the main technique for analyzing DBS in 
newborn screening programs worldwide. To achieve maximum sensitivity, clinical 
laboratories apply conservative cut-off values resulting in decreased test specificity and 
consequently a higher rate of false-positive results. Consequently, second tier tests were 
developed, to improve the specificity of screening processes.(32, 33) The potential advantage 
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of “comprehensive” untargeted metabolomics over traditional limited targeted analysis 
depends on its scope of detection providing additional data that currently requires multiple 
clinical tests, including targeted panel assays for amino acids, acylcarnitines, organic acids, 
purines, pyrimidines targeted panel assays for amino acids, acylcarnitines, organic acids,  
purines, pyrimidines, acylglycines and others. 
The described metabolomics method, although is a pilot study with a limited 225 analytes, 
seems to be a promising assay in individuals at risk of having one of the common inborn 
errors of metabolism and is potentially clinically useful. The large number of analytes 
targeted in this single assay in three commonly used matrices, coupled with the reference 
ranges and average values in the control subjects may help facilitate identifying the optimal 
matrix for various analytes. For individuals with metabolic disorders caused by defects in the 
metabolism of large molecules such as lipids and glycosaminoglycans (GAGs), additional 
studies using lipidomics, for example will be needed. 
In summary, there is a strong clinical need to develop and validate quantitative methods 
capable of measuring the largest number of metabolites subject to wide and rapid dynamic 
changes present in a biological system.(15) This is particularly challenging since several 
important factors such as metabolite dilution, stability, low abundance, sample matrix, 
concentration and availability of internal standards may significantly impact the ability to 
quantify these analytes. In the present study, the effect of sample matrix on the expression of 
profiles of a large set of clinically oriented metabolites was demonstrated which may help to 
guide the choice of the optimal sample type and matrix in which it is collected. The 
developed method showed capability to detect common inborn errors of metabolism. In 
chapter 4, same approach was used and seven metabolites were positively identified in binary 
comparisons between DOCK8- deficient and AD patients. Aspartic acid and 3-
hydroxyanthranillic acid were up-regulated in DOCK8 compared to AD, whereas 
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hypotaurine is down-regulated compared to ctrl. Leucyl-phenylalanine, and glycyl-
phenylalanine were down-regulated in DOCK8 compared to AD, guanosine was upregulated 
in DOCK8 when compared to ctrl and 2- aminooctanoic acid was up-regulated in AD 
compared to ctrl. 
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3.6  Chapter 3 summary  
 The aim of this study was to develop a metabolomics method to analyze DOCK8 and 
AD patients for biomarker discovery. 
 A comprehensive metabolomics panel was built to accommodate 225 metabolites 
within a short run time of 15 minutes for both polarity modes (negative and positive). 
 The method was validated in regards to specificity, sensitivity, intraday accuracy and 
precision, stability and recovery as per US FDA regulations. 
 The developed method includes a list of optimized MS/MS parameters and can be 
potentially useful as a screening tool for different autoimmune and other disease categories. 
 This methodology can also be used in three different matrices (blood, serum and 











CHAPTER 4: METABOLOMICS DISTINGUISHES DOCK8 
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DOCK8 deficiency is caused by loss of function mutations in the dedicator of cytokinesis 8 
(DOCK8) gene,(1, 2) characterized by susceptibility to sinopulmonary infections, atopic 
eczema, asthma, food allergies, severe viral infections, increased incidence of malignancy 
leading to premature death. (2, 3)DOCK8 is a cytoskeletal protein which contains two related 
conserved protein domains DHR1 and DHR2 with bi-allelic DOCK8 mutations having both 
been reported with frequent large deletions and point mutations, leading to protein loss of 
function. (2, 4)It is highly expressed in the immune system especially in lymphocytes but is 
also expressed in placenta, kidney, lung and pancreas.(5) DOCK8-deficient patients develop 
atopic dermatitis, asthma, and severe allergies to food and environmental antigens in early 
infancy.(6) In addition, chronic viral infections are also distinctive features with the common 
pathogens being herpes simplex virus (HSV), human papillomavirus (HPV) molluscum 
contagiosum virus (MCV) and varicella-zoster virus (VZV).  In general, all DOCK8-deficient 
patients are susceptible to recurrent sinopulmonary infections caused by a wide variety of 
pathogens including Streptococcu spneumoniae, Haemophilus influenzae, Pneumocystis 
jirovecii, Histoplasma capsulatum and Legionella pneumophila. (7) 
Atopic dermatitis (AD) or eczema is a prevalent pediatric chronic inflammatory skin disease, 
and specific food-allergens and nutrients are closely related to the development and severity 
of this disease. AD is characterized by intense pruritus and occurs primarily in infants and 
children, with approximately 70% of cases starting before the age of 5 years. The eczema 
classically involves the face, scalp and extensor surfaces of extremities. Impaired innate and 
adaptive immunity, environmental changes and alterations in genes involved in epidermal 
barrier functions contribute towards the clinical manifestations of this disease.(8) These 
patients are susceptible to superficial infections with Staphylococcus aureus, but invasive 




shown flow cytometry biomarkers distinguishing DOCK8 from AD.(9) Whereas Boos et.al( 
2014) showed that DOCK8 mutation plays an important role in food allergies, and different 
IgE sensitization patterns in HIES and AD patients.(6) Treatment of AD is directed mainly 
towards prevention and management of infection and immunomodulation to control the 
associated rash and pruritus. Topical corticosteroids, systemic antibiotics, and antifungal 
agents are used for both prophylactic and symptomatic treatment in conjunction with topical 
therapy. Atopic dermatitis and DOCK8 deficiencies share similar clinical symptoms 
including eczema, eosinophilia, and characteristic elevated levels of serum IgE. 
As discussed in Chapter 1,Metabolomics is a rapidly growing and promising discipline 
enabling the quantification of the group of small molecules involved in intermediary 
metabolism encoded by genomic DNA. Over the last decade, both targeted and untargeted 
metabolomics studies have identified several relevant biomarkers involved in complex 
clinical phenotypes in diverse biological systems. Significant environmental and clinical 
disturbances can be monitored at the metabolomic level by examining an array of different 
pathways that are crucial for cellular homeostasis.(10, 11) Since the metabolome is complex 
and very dynamic, newer and more reliable quantitative technologies have enabled the 
discovery of biomarkers specific enough to distinguish patients in various health states from 
healthy subjects.(12) Chemical isotope labeling liquid chromatography-mass spectrometry 
(CIL LC-MS) is a robust and emerging analytical platform used in biomarker discovery, 
where different labeling reagents are used to target functional groups based sub-
metabolomes.(13, 14) 
Apart from cytokine biomarkers capable of distinguishing DOCK8-deficient (6,9, 15) from 
patients (16) definitive metabolomics biomarkers have not been identified yet. Therefore, in-
depth metabolomics technologies to study the metabolomics profiles of a cohort of patients 




disease pathogenesis and may contribute towards improved disease monitoring and ultimately 
novel clinical interventions. CIL LC-MS targeting the amine/phenol sub-metabolomes was 
used to find novel differentially expressed biomarkers in hereditary DOCK8-deficient and 









The aims of this study were as follows: 
 
1. To employ CIL LC-MS to study the metabolomics profiles in DOCK8 and AD 
patients to find novel and differentially expressed biomarkers  
2. To evaluate these biomarkers that potentially reflects disease pathogenesis and may 







4.3 Material and Methods: 
4.3.1 Chemicals 
The LC-MS grade reagents, including water, acetonitrile (ACN ), methanol and formic acid, 
were purchased from Fisher Scientific (Ottawa, ON)and13C-dansyl chloride was available 
from the University of Alberta)(http://mcid.chem.ualberta.ca). For cell culture, Rosewell Park 
Memorial Institute (RPMI) medium, penicillin, glutamine was obtained from Sigma 
Chemicals, (St. Louis, MO), and Fetal bovine serum (FBS) from Gibco, Life Technologies, 
(Saint-Aubin, France) 
4.3.2 Characteristics of the study population: 
 
As discussed in chapter 2, the metabolomics study cohort for DOCK8-deficient and AD 
patients were same.(17) This study was approved by the Research Ethics Committee at the 
Office of Research Affairs, at King Faisal Specialist Hospital and Research Center 
(KFSHRC) (RAC No. 2160015). 
4.3.3 Cell culture 
Lymphoblastoid cell lines were obtained by transformation of peripheral blood mononuclear 
cells (PBMCs) as discussed in chapter 2.(17)  
4.3.4  LC-MS 
In this CIL LC-MS metabolomics workflow (Error! Reference source not found.), each sample w
as labeled by12C-dansyl chloride (DnsCl), while a pooled sample was generated by mixing all 
individual samples then labeled by 13C- DnsCl.(13) The 13C-labeled pooled sample served as 
a reference for all the 12C-labeled individual samples. Each sample was normalized prior to 
LC-MS analysis. LC‐UV quantitation was performed to determine the total concentration of 




of 13C‐labeled pooled sample and injected into LC-MS. All labeled metabolites were 
identified as peak pairs on mass spectra, and the peak area ratios were used for quantitative 
metabolomic analysis. 
The serum and cell lysates processed samples were analyzed using a Thermo Fisher 
Scientific Dionex Ultimate 3000 UHPLC System (Sunnyvale, CA) linked to a Bruker Maxis 
II quadrupole time-of-flight (Q-TOF) mass spectrometer (Bruker, Billerica, MA). The LC 
column was an Agilent reversed phase Eclipse plus C18 column (2.1 mm × 10 cm, 1.8 μm 
particle size, 95 Å pore size), while the mobile phase A was 0.1% (v/v) formic acid in 5% 
(v/v) ACN, and solvent B was 0.1% (v/v) formic acid in acetonitrile. The LC gradient was: t 
= 0 min, 20% B; t = 3.5 min, 35% B; t = 18 min, 65% B; t = 21 min, 99% B; t = 34 min, 99% 
B, with a flow rate of 0.18 mL/ min. The MS conditions were as follows: polarity, positive; 
dry temperature, 230 °C; dry gas, 8 L/min; capillary voltage, 4500V; nebulizer, 1.0 bar; end 














4.3.5 Data collection, processing, and analysis  
 
The LC-MS spectra were first converted to csv files by Bruker Daltonics Data Analysis 4.3 
software. The peak pairs were extracted from csv files by IsoMS. Meanwhile the redundant 
pairs (e.g. those of Na+, NH3+adduct ions and dimers) were filtered out.(18) All data 
generated from multiple runs were aligned together based on the peak’s accurate mass and 
retention time. The missing values in the aligned file were filled by Zero fill software.(19) A 
univariate analysis (volcano plot) was performed for each binary comparison to identify 
significantly differentially expressed metabolites. A criterion of fold-change greater than 1.5 
or less than 0.67 with q-value (false discovery rate) less than 0.05 was used. The q-value is 
calculated by R script based on p-value from a t-test. In the volcano plot, the x-axis represents 
the fold change (FC) between two comparison groups, and y-axis represents the p-value. The 
principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) 
were performed using MetaboAnalyst (www.metaboanalyst.ca).(20) The metabolites were 
positively identified by searching against DnsID Library (www.mycompoundid.org) using 
retention time and accurate mass.(21) Putative identification was performed by searching 
accurate mass against My Compound ID library, which contains 8,021 known 
human metabolites and 375,809 predicted metabolites.(www.mycompoundid.org) (22) 
 Statistical analysis among the three groups was performed by Analysis of Variance 
(ANOVA) using post-hoc Tukey’s method of analysis, with multiplicity adjusted p-values for 
each comparison. This method was chosen not only because of the unequal group sizes, 
among the experimental and the ctrl groups but also because it reduces the probability of 
making a type 1 error and supports testing of pairwise differences. Further analysis was 
performed on GraphPad Prism (version 6.0, Graph Pad software, LA Jolle, CA). The 




method MetaboAnalyst software version 3.0 (McGill University, Montreal, Canada) 
(http://www.metaboanalyst.ca) for global analysis. The raw data was normalized, 
transformed, and scaled by a median, log, and Pareto respectively, to make sure all the data 
are visualized under Gaussian distribution. 
4.4 Results 
4.4.1 Clinical characterizations of DOCK8-deficient and AD patients 





Table A1.9 The mean age of the DOCK8-deficient and AD cohort were13.2±5.9 and 
10.8±1.4 years, respectively, where the Ctrl was 23± 1.03.Comparatively, the CD4/CD8 ratio 





Table A1.9) (17) 
Total IgE levels in both DOCK8-deficient and AD groups were elevated when compared to the ctrl group, with DOCK8-deficient patients 
showing significantly higher serum IgE levels (p-value <0.05) compared to AD patients and ctrls. (5-500KU/L) Eosinophil levels was seen to be 
significantly up- regulated in DOCK8-deficient patients compared to AD.(Error! Reference source not found.A) Among the DOCK8-deficient c
ohort splicing mutations were the most common (46%), followed by missense mutations (27%), deletion mutations (20%) and stop codon 

















Figure 0.2: Analysis of clinical and laboratory parameters in DOCK8 deficient and atopic dermatitis (AD) patients. (A) Eosinophil counts are significantly 
different between the DOCK8 deficiency and AD groups but not the serum IgE levels.(B) Distribution of mutations in DOCK8 deficiency patients (One way 






4.4.2 Metabolomics profiling 
Pathway analysis (Error! Reference source not found.A) identified nitrogen (global) amino acid metabolism pathways to be the most perturbed, f
ollowed by an amino acyl-tRNA biosynthesis when DOCK8 deficiency was compared with AD and Ctrl. The global metabolomics profiles was 
dissected in several binary analyses for a better understanding of the distinctive contribution of each gene in DOCK8 deficiency group compared 
either to AD or Ctrl groups. Partial least square discriminant analysis (PLS-DA) score plot demonstrates significant separation between the 
DOCK8 deficiency and Ctrl groups (Error! Reference source not found.B). The univariate and volcano plot analyses were also performed and a t
otal of 3442 metabolites features were detected, among them, a group of metabolites (n=481) was differentially expressed and visualized in the 
volcano plot (Error! Reference source not found.C). The cutoff p-value has a corresponding q-value of less than 0.05, and a fold change cut-off v
alue of 1.5. Among the 481dysregulated metabolites, 274 metabolites were up-regulated, while 207 metabolites were down-regulated in the 
DOCK8 deficiency group. However, only 40 metabolites were positively identified using the dansyl standard library based on exact mass and 





Similarly, the binary comparison between AD patients and Ctrl groups (Error! Reference s
ource not found.D), showed clear cluster separation between the two groups (Q2=0.962) and a 
total, of 418 metabolites were dysregulated including 232 up-regulated and 186 down-
regulated metabolites (Error! Reference source not found.E). In this group, only 37 metabolites w
ere positively identified using the dansyl standard library (Error! Reference source not found.) 
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Figure 0.3: Pathway analysis and binary comparisons (serum). (A) Pathway analysis for DOCK8 
deficient patients vs Ctrl comparison. (B) DOCK8 deficient patients (n=10 in duplicates) vs Ctrl 
(n=33 in duplicates): PLS-DA score plot with a calculated space Q2=0.971 and R2=0.997. (C) 
Volcano plots (DD vs. ctrl) with fold change > 1.5 (up-regulated=274 metabolites) and < 0.67 (down-
regulated=207 metabolites); q=0.049, p=0.107, 40 metabolites were positively identified. (D) Atopic 
dermatitis (AD) (n=9) vs Ctrls (n=33): PLS-DA score plot, with a calculated space Q2=0.962 and 
R2=0.998. (E) Volcano plots with fold change > 1.5 (up-regulated=232) and < 0.67 (down-
regulated=186), q=0.050, p=0.055, total 37 metabolites were positively identified. Abbreviations: 
DOCK8-Dedicator of cytokinesis 8, AD-Atopic dermatitis, PLS-DA-Partial least square 
discrimination analysis.  
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Seven metabolites were positively identified using the dansyl standard library after a binary 
comparison between DOCK8 deficiency and AD cohorts (Figure 0.4A, B) while, a total of 
147 metabolites were dysregulated (118 and 29 metabolites were up and downregulated in 
DOCK8 deficiency group, respectively). The seven positively identified metabolites are 
presented in Figure 0.4C-I. (Table A1.12) Among those, aspartic acid and 3-
hydroxyanthranillic acid were significantly upregulated in DOCK8 deficiency patients, 
whereas the dipeptides leucyl-phenylalanine and glycyl-phenylalanine were downregulated 
compared to the AD. Hypotaurine, guanosine, and 2-aminooctanoic acid were not found to be 
significantly differentially expressed in DOCK8 deficiency compared to AD after using one 
way ANOVA / post-Tukey's method (Figure 0.4 G-I). 
  








Figure 0.4: Positively identified serum metabolites in DOCK8-deficient patients  vs AD vs Ctrls. 
(A) PLS-DA score plot for binary comparison between DOCK8 deficient and AD, with a calculated 
space Q2=0.758 and R2=0.998. (B) Volcano plot with fold change > 1.5 (up-regulated=118) and < 
0.67 (down-regulated=29), total 7 metabolites were positively identified. (C) L-Aspartic acid is up- 
regulated in DOCK8 deficient compared to AD patients. (D) 3-Hydroxyxanthranillic acid is up- 
regulated in DOCK8 deficient patients. Dipeptides leucyl-phenylalanine and glycyl-phenylalanine are 
up-regulated in AD patients compared to DOCK8 patients (E, F respectively). (G) Hypotaurine is 
down-regulated in DOCK8 deficient patients compared to Ctrl.(H) Guanosine is up-regulated in 
DOCK8 deficient and AD patients while (I) 2-aminooctanoic acid is up-regulated in AD patients only. 
For paired analysis, a combination of t-test and fold change analyses is represented in this volcano 
plot, where the x-axis (FDR-corrected p.value), and y-axis is true positive. Statistical analysis was 
performed using one way ANOVA, post hoc Tukey’s, where * Indicates significance with p-value 
<0.05, ** p-value <0.001, and otherwise not significant (ns). Abbreviations: DOCK8-Dedicator of 
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4.4.3 Biomarker Evaluation 
As a result of the binary comparisons between DOCK8 deficiency vs Ctrl, AD vs Ctrl, and 
DOCK8 deficiency vs AD groups, receiver operating characteristics (ROC) exploring curves 
were generated (Error! Reference source not found.A). The 95% confidence interval was c
alculated for these curves using 500 bootstrappings, and the optimal cutoff was determined 
using the furthest to diagonal line (Youden) to evaluate the sensitivity and specificity of the 
potential metabolites for being differentiating potential biomarkers mainly between DOCK8 
deficiency and AD patients. The combination of the top metabolites in ROC curves, show 
AUCs ranging from 0.85-0.93(Error! Reference source not found.A). The significant features o
f the positively identified metabolites (Error! Reference source not found.B) shows aspartic 
acid and 3-hydroxyanthranillic acid are being up-regulated in DOCK8 compared to AD, 
whereas hypotaurine is down-regulated compared to ctrl. Leucyl-phenylalanine and glycyl-
phenylalanine, were down-regulated in DOCK8, compared to AD, guanosine is upregulated 
in DOCK8 when compared to ctrl and 2- aminooctanoic acid is up-regulated in AD compared 
to ctrl.The combination of all seven analytes gave the maximum confidence of differentiation 
and detection of DOCK8 deficiency from the AD with (AUC=0.922). ROCs for Hypotaurine, 









Figure 0.5: Receiver operating characteristics (ROC) curve and loading plots for positively 
identified serum metabolites in the comparison between DOCK8-deficient vs AD patients. (A) 
ROC generated by random forest model shows area under the curve (AUC)=0.931 for identified 
metabolites. (B) Loading plots for the 7 positively identified metabolites shows upregulation of 
aspartic and 3-hydroxyanthranilic acids in DOCK8 deficient patients. (C) Hypotaurine is not 
significantly differentially expressed in DOCK8 compared to AD patients, AUC- 0.567 and p value of 
0.41537. (D) 3-Hydroxyxanthranillic acid  is significantly upregulated in DOCK8 patients, AUC: 
0.882 and p value of 4.4491E5. (E) Glycyl-phenylalanine is downregulated in DOCK8 deficient 
patients compared to AD patients, AUC: 0.667 and p value of 0.04766. Data was normalized, 
transformed, scaled by median, log, and Pareto scaling to make sure all the data are under Gaussian 
distribution. For paired analysis, a combination of t-test and fold change analyses is represented, 
where the X-axis (FDR-corrected p. value), and Y-axis is true positive.Abbreviations: DOCK8-
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The PBMC cell line metabolomics profiles were generated using the same mass spectrometry 
platform. Metabolomics profiles were generated in cell lystates for DOCK8 deficiency, AD, 
and Ctrl groups which showed cluster separation among them (Figure 0.6) Pathway analysis 
revealed multiple perturbations. PLS-DA analysis showed cluster separation in the binary 
comparisons: DOCK8 (n=7) vs Ctrl (n=4), AD (n=4) vs Ctrl (n=4), DOCK8 deficiency vs 
AD.(Figure 0.6C) 4-Hydroxybenzoic and 3-hydroxymandelic acids were the common 
differentially expressed metabolites in both the PMBC and serum samples of DOCK8 
deficient patients when compared with controls. Whereas when AD cohort samples were 
compared to ctrls, glutamic acid, ornithine, serotonin, 1, 4-diaminobutane and aniline (a 
primary aromatic amine) were in common among the serum and cell line samples. No 
common metabolites were observed among the serum and cell lines samples for the binary 









Figure 0.6: Binary comparisons of cell lines lysates metabolomic profiles (run in triplicates) show 
distinct patterns in DOCK8 deficient vs. atopic dermatitis patients. (A) PLS-DA score plot in DOCK8 
deficient patients (DD) (n=7) vs Ctrl (n=4) with a calculated space Q2=0.782 and R2=0.991. (B) PLS-
DA score plot in AD (n=4) vs Ctrl. (n=4) with a calculated space Q2=0.758 and R2=0.999. (C) PLS-
DA score plot for binary comparison between DD and AD, with a calculated space Q2=0.493 and 
R2=0.996.(Abbreviations: DOCK8-Dedicator of cytokinesis 8, AD-Atopic dermatitis, Ctrl-healthy 








It is critical to recognize DOCK8 deficiency and differentiate its various clinical and 
molecular forms before severe life-threatening complications arise. For example, Aydin, et.al 
(2015) in a study on 136 DOCK8-deficient patients, reported malignancies in 17%, life-
threating infections in 58% and non-infections cerebral events in 10% of their 
patients.(23)Differentiating DOCK8-deficient from AD patients can be difficult in infants 
and young children because of overlapping clinical and laboratory findings. The DOCK8 
protein regulates intracellular signaling networks, proliferation, differentiation, migration, 
synapsis formation, adhesion and survival of cells affecting innate and adaptive immunity 
reflecting complex function.(3, 23, 24) 
The identification of predictive biomarkers to distinguish DOCK8-deficient from AD, based 
on serum metabolite changes, requires a highly sensitive platform to allow the detection of 
very low abundant (pmol to fmol) metabolites. Chemical isotope labeling LC-MS represents 
a robust method for metabolomics profiling and biomarker discovery, as the 13C- labeled pool 
served as an internal standard and compensated for the fluctuations in MS response.(25) In 
this study, seven metabolic features were found to significantly differentiate between 
DOCK8-deficient and AD patients. Taken together, these seven differentially expressed 
metabolites paint a distinctive metabolomics profile in DOCK8-deficient and AD (Figure 
0.4C-I). Upregulation of 3-hydroxyanthranilic acid was observed in DOCK8-deficient cohort 
compared to Ctrl and AD, while aspartic acid was upregulated in DOCK8-deficient cohort 
compared to Ctrl and hypotaurine was down-regulated in DOCK8 deficiency compared to the 
AD. 
The binary analyses between DOCK8 deficiency with and without various clinical 
complications (asthma, bronchiectasis, molluscum contagiosum, sclerosing cholangitis, 
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candidiasis, warts, sinusitis, or malignancy) failed to demonstrate a secondary role for these 
phenotypes on the overall DOCK8 deficiency specific metabolites (Figure 0.7), which 
suggests that these metabolites are primarily due to the underlying genetic deficiency, rather 
than its secondary medical complications. 
The hypotaurine-taurine metabolism pathway starts with cystamine production via cystine 
decarboxylation, which is then reduced to cysteamine followed by oxidation to hypotaurine 
(by the enzyme cysteamine dioxygenase). Hypotaurine is ultimately oxidized to the final 
product taurine by hypotaurine dehydrogenase, which is then excreted out of the body or used 
within. While very little is known about the physiological role of hypotaurine, taurine is 
known to have diverse cellular functions including neurotransmission, retinal photoreceptor 
differentiation through taurine-upregulated gene 1 (TUG1), a non-coding RNA that 
modulates the expression of photoreceptor-specific genes in the retina (27) , osmoregulation, 
calcium modulation and suppression of inflammation, as well as normal mitochondrial 
respiratory chain function.(28) Within the CNS, taurine exhibits an age dependent gradient 
expression and has its own synthesizing enzymes, receptors and transporters.(29) Taurine has 
also been implicated as a tumor marker in a number of different cancer types. (30-33) The 
exact mechanisms regulating taurine levels in tumors have not been established but may 
involve either regulation of its synthesis from hypotaurine and/or regulation of its uptake 
from the extracellular environment, mediated by the taurine transporter SLC6A6. Mammals 
oxidize hypotaurine to taurine using trace amounts of hydrogen peroxide (H2O2) produced by 
cellular metabolism, which is likely to be more frequent in the brain than the liver.(26) 
Holopainen et al.(1982) demonstrated the rapid uptake of hypotaurine into neuroblastoma 
cells suggesting that hypotaurine may have a function in the regulation of neuronal 
activity.(27) Other studies suggested a role for hypotaurine as an antioxidant and protective  
  





Figure 0.7 : Impact of DOCK8 phenotypes on metabolomic profiling. PLS-DA loading plots based 
on binary comparisons in DOCK8 deficient patients with (+) and without (-) various clinical 
phenotypes including (A) Asthma, (B) Bronchiectasis, (C) Molluscum contagiosum, (D) Sclerosing 
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agent under physiological conditions.(28, 29) Peng et al. (2016) also showed that under 
hypoxic signaling, hypotaurine behaves as an oncometabolite promoting tumor 
progression.(30) The observation of underexpression of hypotaurine in the DOCK8 deficient 
patients suggests potential loss of its antioxidant and protective effects. 
3-Hydroxyanthranillic acid (3-HAA), a tryptophan catabolism molecule produced through the 
kynurenine pathway, suppresses antitumor immunity in human malignancy, (31) has immune 
regulatory properties as it can inhibit Th1 and Th2 cells, increase the percentage of regulatory 
T-cells, and regulate leucocyte infiltration and plaque formation.(32) It is found in the human 
epidermis where it participates in multiple enzymatic reactions.(33, 34) In addition, 3-HAA 
appears to play an essential role in the pathogenesis of several inflammatory, infectious and 
degenerative diseases.(35) The increased tryptophan catabolism, in relation to infections 
during the course of the disease may lead to the increased levels of 3HAA as seen in our 
DOCK8 patients (Figure 3B). More recently, Hongjun et al.(2017) showed that homozygous 
germline deficiency in 3-hydroxyanthranilic acid 3,4-dioxygenase (HAAO) causes niacin 
deficiency, responsible for a complex human multiple congenital (cardiac, vertebral, renal) 
anomalies syndrome, which can be averted in affected mice via prenatal niacin 
supplementation.(36) Moreover, 3-HAA decreases Th1 and Th2 responses (37) and directly 
impair immune responses via different mechanism like the ability to induce the expression of 
hemeoxyhenase-1 (HMOX-1), (35) cell cycle control and inhibition of cytokine release 
through the depletion of intracellular gluthathione, (38) as well as the induction of antigen 
specific IL-10 producing T cells (32) and inhibiting PKD1, which is essential mediator of 
CD28 in inflammation.(39) Dietary aspartic acid down-regulates TLR 4, Nucleotide-binding 
oligomerization domain-containing protein 1 (NOD1) and Myeloid differentiation primary 
response 88 (MYD88) in the jejunum mediate the inflammatory response, thereby affecting 
the growth performance and inflammation in piglets.(40) Furthermore, intraperitoneal 
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injection of aspartic acid in mice has been found to have more beneficial effects on 
Experimental autoimmune encephalomyelitis, (EAE) a widely used model for multiple 
sclerosis, reflecting upon the role of aspartate in therapy.(41) 
Perturbations in amino acid metabolism had been also observed in some cancers as well as 
neurodegenerative disorders such as Alzheimer disease and Parkinson diseases.(40-42) 
Aspartic acid is a major excitatory neurotransmitter, which had been found to be increased in 
some epileptic and stroke patients, decreased in patients with depression and brain atrophy. In 
contrast, guanosine is a nucleoside that exerts important neuroprotective and 
neuromodulatory roles in the central nervous system, which may be related to inhibition of 
the glutamatergic neurotransmission activity. Glycyl-phenylalanine, a dipeptide produced by 
incomplete protein catabolism, consists of glycine and phenylalanine and is known to play an 
essential role in cell signaling effects by impacting specific amino acid degradation 
pathways.(43) It is transported intact by a cation independent facilitative diffusion 
mechanism during which the dipeptide is hydrolyzed to its component amino acids.(43) 
Some dipeptides have physiological or cell-signaling effects although most are simply short-
lived intermediates on their way to specific amino acid degradation pathways following 
further proteolysis. This dipeptide has not been identified yet, in human tissues or biofluids 
and so it is classified as an 'expected' metabolite. 2-aminooactanoic acid is shown to be 
perturbed in human colorectal cancers.(44) Taken together, these findings call for further 
analysis of the perturbed amino acid pathways for additional insight into its significance.  
In summary, DOCK8 deficiency appears to be associated with a distinctive metabolomics 
profile characterized by significant differential overexpression of 3-HAA and aspartic acid 
both of which have been linked to oncogenesis coupled with underexpression of hypotaurine, 
guanosine, and the dipeptides leucyl-phenylalanine, glycyl-phenylalanine, which together 
seem to contribute to some of the immune and malignancy-related phenotypes observed in 
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this disease. The complex nature of these diseases suggests that no single biomarker will be 
sufficient to meet the clinical needs of such patients; instead, a larger panel of biomarkers 
will ultimately be required. These findings may inform further mechanistic analyses in these 
diseases.  In the next chapter, Metabolomics and cytokines profiling of food allergy was 
studied in DOCK8-deficient and atopic dermatitis patients as both the cohort groups have 
food allergies in common. ISAC sensitization profiling showed differential and overlapping 
sensitization patterns.  
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4.7 Chapter 4 summary 
 Metabolomic profiling differentiated DOCK8 deficiency from atopic dermatitis and 
revealed distinct biochemical pathway perturbations .The aim of this study was to find 
metabolomics profiles distinguishing the study groups. CIL LC-MS targeting the 
amine/phenol sub-metabolomes was used to find novel differentially expressed biomarkers in 
DOCK8 and AD patient groups. 
 Seven metabolites were positively identified in binary comparisons between DOCK8- 
deficient and AD patients. Aspartic and 3-hydroxyanthranillic acids were upregulated in 
DOCK8 deficiency, whereas hypotaurine, leucyl-phenylalanine, glycyl-phenylalanine and 
guanosine were downregulated. 
 Hypotaurine, 3-hydroxyanthranillic acid and glycyl-phenyalanine were identified as 
potential biomarkers specific for DOCK8 deficiency 
 The complex nature of these diseases suggests that no single biomarker will be 
sufficient to meet the clinical needs of such patients; instead a larger panel of biomarkers will 
ultimately be required. Further validation of these biomarkers in larger cohorts is necessary 






CHAPTER 5: DISTINCT IgE BASED ALLERGEN ARRAY, 
METABOLOMICS AND CYTOKINE PROFILES IN DOCK8-

























Elevated serum IgE and eczema are indicators for most allergic diseases. However, this 
cannot be considered as very specific markers as these are also elevated in patients suffering 
from primary immunodeficiency disorders (PID), such as the Hyper IgE syndromes (HIES). 
Loss of function mutations in the dedicator of cytokine8 (DOCK8) gene causes the autosomal 
recessive HIES and are characterized by highly elevated serum IgE levels, recurrent 
staphylococcus skin abscesses and mucocutaneous infections, severe eczema and pulmonary 
infections. Furthermore, these patients suffer from autoimmunity and increased susceptibility 
to virus-induced malignancies and lymphomas.(1)Due to the high morbidity and mortality 
associated with DOCK8 deficiency, hematopoietic stem cell transplantation (HSCT) is the 
preferred definitive therapy for this disorder.(2) 
As discussed in chapters 2 and 4, atopic dermatitis (AD) is a chronic inflammatory disease 
with remission that commonly occurs in early infancy. Clinical manifestations in patients 
with AD include food allergy, asthma, and allergic rhinitis, probably in response to impaired 
innate and adaptive immunity as well as environmental stimuli.(3) Eczematous skin lesions, 
pruritus and food allergies are common overlapping clinical features in DOCK8-deficient and 
AD. Food allergy is a typical type 1 hypersensitivity reaction, occurring when patients 
develop specific IgE antibodies because of exposure to some food proteins via the skin, gut or 
respiratory system. In general, an active oral immune tolerance is generated against food and 
allergic reactions in humans are caused by a disruptive adaptive immune system that 
generates a specific immune response upon exposure to certain foods.(4) 
The immuno Solid-Phase Allergen Chip (ISAC) (Thermo Fisher, Uppsala, Sweden) 
microarray technique is preferred over routine allergen specific IgE testing using the 
ImmunoCAP, because the ISAC panel includes purified allergen components from 51 
allergenic sources allowing the determination of specific IgE against 112 allergen 
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components in the same serum sample. As detailed in Chapter 1, metabolomics, refers to a 
comprehensive and systematic characterization and quantification of endogenous and 
exogenous small molecules with molecular size <1500 Da (metabolites), using high 
throughput technologies. Interestingly, only few reports have documented the use of 
metabolomics in food allergy. Kong et.al (2015) used liquid chromatography MS analysis 
and showed that elevated levels of uric acid played a critical role in the induction of peanut 
allergy. The authors hypothesized that uric acid activates dendritic cells by increasing CD86 
and OX40 ligand expression.(5) To date, no data is available on the relationship between the 
IgE-mediated food sensitization in DOCK8 deficient and AD patients and the metabolomic 
expression.  
In this study chemical isotope labeling liquid chromatography-mass spectrometry (CIL LC-
MS) was used to understand the metabolic fingerprinting in food allergy in the study cohort, 
which may help to understand the inflammatory responses that develop during DOCK8 
pathogenesis. Since DOCK8-deficient and AD patients have detectable environmental, food 
and microbial antigen-specific IgE titers, the comprehensive evaluation of food and 
aerosolized allergens sensitization patterns in patients with DOCK8-deficient and AD 
patients was associated with perturbations in metabolites and cytokines expression. 
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5.2  Aims 
The aims of this study were as follows: 
1) To evaluate food and microbial antigen-specific IgE titers in DOCK8-deficient and 
AD cohorts, using ImmunoCAP Solid-Phase Allergen Chip (ISAC).  
2) To analyse and understand the metabolic fingerprinting in food allergy using  
chemical isotope labeling liquid chromatography-mass spectrometry (CIL LC-MS) 









5.3.1  Serum samples 
As discussed in chapter 2 and 4, the study cohort for DOCK8 and AD patients were same. (6, 
7)This study was approved by the Research Ethics Committee at the Office of Research 
Affairs, of King Faisal Specialist Hospital and Research Center (KFSHRC) (RAC No. 2160 
015). 
5.3.2 Allergy Microarray (ISAC) 
Serum samples from DOCK8-deficient (n=10), AD (n=9) and control samples (n=3) 
underwent testing for ISAC. (Thermo Fisher, Uppsala, Sweden) ISAC is a multiple allergen 
component assay based on a solid phase multiple immunoassays, containing immobilized 
protein, which detects and quantifies IgE antibodies to 112 allergen components. The 
ImmunoCAP ISAC IgE chip was placed in the humidity chamber with the reaction sites 
facing upwards, 20µl of each sample along with IgE control serum was aliquoted onto one 
reaction site and incubated at room temperature for 120 minutes. The chip was washed with 
220 ml of buffer for 10 minutes followed by a washing step with 220ml of purified water for 
5 minutes and the chip was allowed air dry. 20 µl of IgE detection antibody solution was 
added onto each reaction site of the chip, and incubated at room temperature for 60 minutes. 
The non-binding detection antibody was removed by rinsing gently under distilled water was 
removed by rinsing gently under distilled water. Finally, the chip was again washed with 220 
ml of buffer A and purified water and allowed to air dry.  The serum IgE antibodies bind to 
the immobilized allergen components and in turn the allergen-bound specific-IgE antibodies 
are detected by fluorescence signal, measured with a confocal laser scanner, and the 
microarray image data analyzed using ImmunoCAP ISAC Xplain software (Phadia).(6) The 




Table A1.13. Results are reported in ISAC standardized units (ISU) and categorized based on 
manufacturers cutoff levels (0.3 to 0.9= low, 1 to 14.9=moderate, >15=very high). 
5.3.3 Chemical Isotope Labeling Liquid Chromatography-Mass Spectrometry  
As discussed in chapter 4, CIL LC-MS metabolomics approach was used, serum samples for 
DOCK8 and AD cohorts were analyzed using a Thermo Fisher Scientific Dionex Ultimate 
3000 UHPLC System (Sunnyvale, CA) linked to a Bruker Maxis II quadrupole time-of-flight 
(Q-TOF) mass spectrometer (Bruker, Billerica, MA).(7)  
Cytokines/Chemokine profiling 
Patient samples were quantitatively profiled using the MILLIPLEX MAP kit, (Millipore) 
phycoerythrin-conjugated detection was used to form sandwich complexes, and the 
fluorescence data acquired on the FLEXMAP 3D as described in chapter 2.(6) 
Data and statistical analysis 
Metabolomics data were aligned based on peak’s accurate mass and retention time; the 
metabolites were positively identified by putative identification against DnsID Library 
(www.mycompoundid.org). Putative identification was performed by searching accurate 
mass against My Compound ID library, which contains 8,021 known human metabolites and 
375,809 predicted metabolites.(9, 10) Univariate analysis (volcano plot) for significant 
metabolites was performed based on a criterion of fold-change of greater than 1.5 or less than 
0.67 with q-value (false discovery rate) less than 0.05. The sparse partial least squares 
discriminant analysis (sPLS-DA) were performed using MetaboAnalyst 
(http://www.metaboanalyst.ca). The raw data were normalized to the sample total median to 
ensure all samples were normally distributed. To visualize the difference among the study 
groups and make individual features more comparable, data were log-transformed, and Pareto 
scaled respectively. Binary comparison between allergen positive and negative groups in 




DOCK8-deficient and AD patients were performed to find the significant metabolites 
followed by pathway analysis. 
Two-tier ID approach was used to perform metabolite identification. In tier 1, peak pairs were 
searched against a labeled metabolite library (CIL Library) based on accurate mass and 
retention time. The CIL Library (amine/phenol channel) contains 711 experimental entries, 
including metabolites and dipeptides. 190 peak pairs were positively identified in tier 1. In 
tier 2, linked identity library (LI Library) was used for identification of the remaining peak 
pairs. LI Library includes over 2000 human endogenous metabolites from 68 metabolic 
pathways, providing high-confidence putative identification results based on accurate mass 
and predicted retention time matches. 97 peak pairs were putatively identified in tier 2. The 
targeted statistical analysis of multiple study groups were carried out using Graph Pad Prism 
(version 6.0, Graph Pad software). As the data were Gaussian distributed, unpaired two-tailed 
Student’s t-test was used for binary comparison between any two study groups. In all 
experiments, a calculated p-value<0.05 was considered to be statistically significant. 
5.4  Results 
DOCK8- deficient and AD patients were recruited from the Allergy and Immunology clinic 
at KFSHRC, generally presented with increased serum IgE levels, eczema, and eosinophilia, 
as described earlier.(6) In DOCK8- deficient cohort, 50% were females and presented with 
higher median IgE levels (14355 KU/L) compared to AD patients (1387 KU/L). IgG and IgA 
median score was also higher in the DOCK8- deficient compared to AD cohort, 18.35g/L±3 
and 3.1g/L±1.3, respectively, whereas IgM median score was lower in DOCK8- deficient 
cohort (0.35 g/L), compared to AD (0.92g/L). Median scores for monocytes were found to be 
higher in DOCK8- deficient patients (9.5%10^9/) compared to AD (7.5%10^9/), in contrast 




to lymphocytes and basophils which showed a lower median score in DOCK8- deficient 
cohort of17 x10^9/L and 0.55x10^9/L, respectively. However, eosinophils showed a higher 
median score in DOCK8- deficient group (28.9%) compared to the AD. (13%) (Error! R
eference source not found.) 
5.4.1  Clinical manifestation 
Eczema, dry skin and food allergies were common to both groups of patients (Error! Reference s
ource not found.).Staphylococcus infections and pneumonia were the most common clinical 
features seen in the DOCK8-deficient patients, whereas rhinitis was only seen in the AD 
group. Seven of ten DOCK8-deficient patients, presented with asthma whereas only four of 
nine AD patients had asthma. DOCK8-deficient patients also presented with viral infections, 
warts, otitis media sinusitis, seizures, and cataract, as described in chapter 2.(6) The Severity 
Scoring of Atopic Dermatitis (SCORAD) and the Visual Analogue Scale (VAS), were 
comparable for both DOCK8-deficient and AD groups. (11) CXCL10, TNF-A, EGF 
cytokines were also calculated as they are typified signature biomarkers to distinguish 
DOCK8-deficient compared to AD. (6) The median value for CXCL10 and TNF-A were 
found to be higher in DOCK8-deficient patient, whereas in AD patients EGF levels were 
higher compared to DOCK8 patients. (Error! Reference source not found.) 
5.4.2 ImmunoCAP data 
ImmunoCAP data was obtained from patient records for seven out of nine of the DOCK8-
deficient patients. All DOCK8-deficient patients were allergic to milk, tree nut and wheat, 
followed by six patients who were allergic to egg and soybean. In contrast, among AD 
patients, eight patients were allergic to wheat, soybean and tree nut followed by seven 
patients allergic to milk and six patients allergic to egg. Only one patient from the DOCK8-




deficient and AD groups showed sensitization towards shellfish. There was no overall 
significance observed between the two cohorts in food-allergens or aero-allergen groups. 
(Figure 0.1) ( 
Table 0.1) 
Table 0.1: Quantitative IgE testing using ImmunoCAP 
 
 
Class: <0.35=0; 0.35-0.70=1; 0.71-3.50=2; 3.50-17.50=3; 17.51-50.4=4; 50-100=5; >100=6 
  
Patient name P1 P2 P3 P4 P8 P9 P10 P11 P12 P13 P14 P15 P16 P17 P18 P19
Food allergens
Egg white 1 6 3 0 1 3 5 5 2 0 2 1 0 3 0 3
Egg yolk 0 4 1 0 2 0 3 0 0 0 1 1 0 0 0 2
Milk 3 6 4 2 6 4 4 3 1 0 0 3 2 3 6 3
Wheat 2 5 3 1 6 5 4 6 3 1 1 2 0 2 4 3
Fish   0 0 0 0 1 1 0 3 0 0 0 1 0 0 2 2
Soyabean      3 5 3 1 4 5 0 6 2 1 3 2 0 3 6 3
Shellfish 0 1 0 0 0 0 0 0 4 0 0 0 0 0 0 0
 Peanut 4 6 4 0 5 5 0 6 3 1 4 1 0 3 6 5
 Brazilnut  3 0 0 0 6 0 0 0 1 0 4 1 2 3 0 3
 Cashewnut  0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 5
 Walnut 0 0 0 0 0 0 0 0 0 0 0 4 0 4 0 6
Pistachio 0 0 0 0 0 0 0 0 0 0 3 0 5 0 6
Hazelnut 3 0 0 0 6 5 0 0 2 1 4 3 0 3 0 5
DOCK8 (n=7) AD (n=9)









Figure 0.1: ImmnoCAP  profiling in DOCK8-deficient(n=7) and atopic dermatitis(n=9) patients 
shows no significance.(A) Averaged concentration of food-allergens in PAU/L (B) Averaged 
concentration of aero-allergens in PAU/L, p-value< 0.05,Abbreviations: AD-Atopic dermatitis, 






Table0.2 Clinical manifestations in DOCK8 deficient patients and AD patients 
Diagnosis Code Age(yr) Gender IgE levels (KU/L) 
IgM level               
(0.5-2.4 g/L) 
IgG level          
(6-15.7 g/L) 

















P1 21 F 25350 0.25 27.3 3.83 0.01 9.2 2.1 18.8 8.6 0.6 24.8 
P2 16 M 7530 NA NA NA NA NA 0.8 6 4 NA 35 
P3 16 F 1829 0.47 27.3 0.3 4.2 4.63 1 15.3 6.3 0.3 50.3 
P4 16 F 7250 0.25 13.6 2.54 5.9 4.9 0.73 21.4 10.5 0.2 11.4 
P5 5 M 16780 0.31 9.9 1.06 4.8 9.3 2.2 23 14.7 0.7 26.4 
P6 7 M 13160 0.45 15.4 5.6 5.29 9.93 0.7 18.7 13.5 0.5 11.7 
P7 14 M 15550 0.52 21.3 4.3 6.82 4.46 1.3 14 8.6 0.7 31.4 
P8 4 M 70.4 NA NA NA 5.3 24.9 9 8 1 1 34.8 
P9 9 F 21680 0.3 24.9 11.9 5.26 12.49 8.1 4 11  35.1 
P10 8 F 61060 0.25 4.5 0.5 3.81 21.42 3.2 34.4 16.5 0.4 12 
Median   11.5   14355 0.305 18.35 3.185 5.26 9.3 1.7 17 9.55 0.55 28.9 
AD 
P11 21 M 6540 0.92 10 0.79 4.7 9.7 1.1 38.2 4.7 1 16.5 
P12 6 M 16500 0.62 20 2.63 5.2 10.6 0.9 33 7.7 0.5 15.6 
P13 15 M 1612 2.23 26 0.3 6.39 3.72 1.4 26.8 10.7 1.4 13.9 
P14 10 M 839 1.68 15 1.2 5.48 8.01 1.2 70.5 7 0.2 6.7 
P15 3 M 1221 0.88 16 0.98 5.3 6.59 1.3 57 5 4 13 
P16 8 M 659 1.64 15 1.3 5.22 5.88 1.2 57 5 4 13 
P17 13 F 1387 1.43 12 1.39 4.9 5.09 1.5 40.3 11.8 0.9 13 
P18 15 M 365 0.7 12.9 1.3 5.2 5.15 1.2 36.2 7.5 0.6 12.3 
P19 12 M 4587 0.7 8 0.3 4.71 9.63 1.4 53.2 9.3 0.5 7.9 
Median   12   1387 0.92 15 1.2 5.2 6.59 1.2 40.3 7.5 0.9 13 
 





5.4.3 IgE sensitization profiling 
In order to have a standard allergic profile on all study patients, IgE sensitization profiling 
using ISAC revealed different sensitization patterns for food and aerosolized allergens. In our 
cohort, both aerosolized and food-allergens showed differences in IgE sensitization pattern 
within different food groups. The statistical analysis was performed on ISAC data by taking 
the sum of the respective allergens in each group (DOCK8-deficient, AD) and analysis of 
overall food and aerosolized allergen groups together showed differential expression pattern 
among the groups. The overall significance for both the groups is represented in Figure A2 6. 
Food allergen sensitisations were not different between groups, whereas aero-allergens were 
up- regulated in AD compared to the DOCK8-deficient cohort. 
As represented in Table A1.144, among the food-allergens, DOCK8-deficient patients 
showed maximum sensitization towards cow milk (80%) and tree nut (70%), followed by egg 
(60%), soybean (60%), peanut (60%) and wheat (40%). In contrast, the DOCK8-deficient 
patients did not show any sensitization to shellfish, unlike the AD group (n=2). Within the 
food allergen group, the calculated highest median value for peanut allergens was observed in 
the AD cohort compared to DOCK8-deficient. A similar pattern was followed in egg and tree 
nut allergens, where egg allergen group showed higher IgE sensitization in the AD (P2, P7, 
and P9) compared to DOCK8-deficient patients (P18 and P11) (Figure 0.2A-D). Whereas for 
milk allergens, higher sensitization was seen in DOCK8-deficient patients, (P2, P8 and P9) 
compared to AD patients. (P11, P18 and P19) (Figure 0.2D-H) For overall peanut allergens 
(rAra h1, rAra h2, and rArah6), a slightly higher sensitization was observed in DOCK8-
deficient (P7, P1, and P2) compared to AD patients. (P11 and P19) Figure 0.3 (A-D) Similar 
pattern were observed for soybean (Figure 0.3 E-F) and tree nut allergens.Figure 0.4 (A-E) 
In contrast, sensitization was slightly higher in AD patients for sesame (Figure 0.3G) (P11, 




P12 P18 and P19) and for shellfish allergens (Figure 0.5 ) compared to DOCK8-deficient 
















Figure 0.2: Egg (A-D) and milk (E-H) allergens sensitization pattern in DOCK8-deficient (n=10) and 
atopic dermatitis (n=9) patients using ISAC analysis. No stastical significance was observed in both 
the cohorts, P1-P10 are DOCK8-deficient, while P11-P19 are AD patients,p-value< 0.05, 
(Abbreviations: AD-Atopic dermatitis, ISAC-ImmunoCAP Solid-Phase Allergen Chip)  
  








Figure 0.3: Food and aero-allergens sensitization pattern in DOCK8-deficient (n=10) and atopic 
dermatitis (n=9) patients using ISAC analysis: Cat allergen was up-regulated in AD in comparison to 
DOCK8 deficient patients. No significance was observed among the other allergens.* Indicates 
significance. Not specified ones are not significant) p-value< 0.05, P1-P10 are DOCK8-deficient, 
while P11-P19 are AD patients Abbreviations: (AD-Atopic dermatitis, ISAC-ImmunoCAP Solid-






Table 0.3: Clinical profiles and key cytokine levels in DOCK8-deficient and AD patients  






(pg/ml) VAS SCORAD 
DOCK8 
P1 Yes Yes No Yes Yes Yes 35.8 343.6 22.7 15.0 68.7 
P2 Yes No No Yes Yes Yes 34.3 323.5 28.9 13.0 67.0 
P3 Yes Yes No Yes Yes Yes 42.3 739.0 27.3 14.0 59.8 
P4 Yes Yes No Yes Yes Yes 0.0 584.0 23.9 15.0 77.4 
P5 Yes Yes No Yes Yes Yes 142.8 295.1 32.5 17.0 79.5 
P6 Yes Yes No Yes Yes Yes 450.9 3724.0 32.1 15.0 62.5 
P7 Yes NA No Yes Yes Yes 182.6 1229.0 23.7 17.0 70.6 
P8 Yes Yes No Yes Yes Yes 225.7 2157.0 39.0 9.0 58.2 
P9 Yes Yes No Yes Yes Yes 102.4 5127.0 107.9 14.0 58.8 
P10 Yes No No Yes Yes Yes 64.2 994.3 20.8 12.0 70.1 
Median               83.3 866.7 28.1 14.5 67.9 
AD 
P11 Yes NA NA Yes No Yes 27.9 163.5 9.3 16.0 64.4 
P12 Yes NA NA Yes No No 102.7 251.4 6.8 14.0 71.3 
P13 Yes NA NA Yes No No 123.2 108.1 28.6 16.0 73.3 
P14 Yes NA NA Yes No No 134.9 92.6 14.0 13.0 56.1 
P15 Yes NA NA Yes No No 10.1 204.1 16.5 9.0 40.8 
P16 Yes Yes Yes Yes No No 7.6 124.1 3.1 10.0 54.9 
P17 Yes Yes Yes Yes No No 4.9 286.4 16.9 15.0 75.0 
P18 Yes Yes Yes Yes No No 165.4 208.0 69.7 14.0 65.1 
P19 Yes Yes Yes Yes No No 247.1 635.6 22.2 16.0 70.6 
Median               102.7 204.1 16.5 14.0 65.1 
 







Figure 0.4: Treenut allergen sensitization pattern is not significantly different between 
DOCK8(n=10),atopic dermatitis(n=9)patients and ctrl( n=3).(A-E) 
p-value< 0.05, P1-  P10 are DOCK8-deficient, while P11-P19 are AD patients. 














Figure 0.5: Sensitization profiles for Shellfish between DOCK8-deficient (n=10) ,atopic 
dermatitis(n=9)patients and ctrl( n=3) shows no significant difference.(A-C) p- value< 0.05, P1-P10 




















Figure 0.6: Wheat (A-B) and Soyabean (C-D) allergens sensitization pattern in DOCK8-deficient 
(n=10) and atopic dermatitis (n=9) patients using ISAC analysis. No stastical significance was 
observed in both the cohorts, p-value< 0.05, (Abbreviations: AD-Atopic dermatitis, ISAC-









Noticeably among the aeroallergens, AD patients (78%) showed significantly higher 
sensitization to cat allergen rFeld1, compared to DOCK8-deficient patients (p-value<0.05). 
(Figure 0.3H). DOCK8-deficient patients showed moderate sensitization to latex (60%), 
plane tree (50%), and Timothy grass pollen (50%). AD patients also developed a higher 
sensitization to Bermuda grass (56%), Timothy grass (55%), Aspergillus (44%), Cypress 
(33%) and Cedar (33%) compared to DOCK8-deficient patients. Similarly, as seen among the 
food-allergens, the median and interquartile ranges (IQR) were comparable within the 
groups. (Table A1.15). Three AD patients showed sensitization to cockroach and one AD 
patient (P15) showed sensitization towards dog, goosefoot and saltwort (P11), compared to 
no sensitization of these allergens in AD patients. Sensitization towards plane tree (50%) 
allergens was slighly higher in DOCK8-deficient (n=5) compared to AD (n= 4) patients.  
5.4.4 Cytokine profiling 
Cytokine/chemokine profiling for the same patients was performed for biomarker discovery 
as reported before.(6) Herein, we re-analyzed the same data based on the patients' food 
allergy profile. Multiple binary analyses were performed for IgE sensitization on the 
cytokines/chemokine data using the patient allergic vs. non-allergic status to a particular food 
or aero-allergen as a classifier. The significantly expressed cytokines/chemokines within each 
food group are summarized Table 0.4. In the DOCK8-deficient cohort, univariate analysis on 
cytokine profiling was performed between high and low sensitized allergen groups. For 
example, egg allergens (nGal d1 and nGal d3) profiling is represented in Figure 0.7A-F. IL-4 
was up-regulated, in contrast to Scd40L (Soluble CD40-ligand) being down-regulated in high 
sensitized nGal d1 allergen group, whereas CCL11 and colony-stimulating factor3 (CSF3) 
were down-regulated in high sensitized nGal d3 allergen group. Among the milk allergens 




(nBos d5 and Bos d8), CCL11and CSF3 were downregulated in high sensitized group. 
(Figure 0.8: A- F) Similarly, in peanut allergens (rAra h1), transforming growth factor 
(TGF-A) and fibroblast growth factor 2 (FGF-2) were upregulated in high sensitized group 
were observed. (Figure 0.9 : A-C) and in soybean allergen (rGlym5) CCL11 and CSF3 
(Figure 0.9: D-F) were differentially expressed in DOCK8-deficient cohort. No significant 
cytokines were detected in the sesame food group for patients. Among the AD patients, 
significant cytokines/chemokines expression were observed only for peanut and sesame 
allergen sensitisation. FGF-2(Figure 0.10 : A, B) was significantly upregulated in IgE 
sensitized patients to peanut allergen (rAra h3), and IL-3(Figure 0.10: C, D) was seen to be 
significant in sesame allergens. 
  








Figure 0.7: Sensitisation to specific egg allergens induces differential cytokine expression in 
DOCK8-deficient patients (n=10) (A-C) Volcano plots show IL-4 was up-regulated in association 
with nGal d1 sensitization(H) while Scd40l was down-regulated with nGal d1(L) (D-F)Volcano plots 














(Abbreviation: CSF3-colony stimulating factor, FGF-2-fibroblast growth factor, TGFA-transforming 
growth factor,AD- Atopic dermatitis,NS-Not significant,NA-Not applicable) 
  








Figure 0.8: Milk allergy is associated with down-regulated expression of cytokines CCL11and CSF3 











Figure 0.9 : Peanut and soy allergy in DOCK8-deficient patients(n=10) induces up regulation of 















Figure 0.10: Peanut and Sesame allergens induce down regulation of cytokine FGF2 and  up 











5.4.5 Metabolomics profiling: 
Metabolomics profiling for our patients was also performed for biomarker discovery as 
discussed in chapter 4.(7) Multiple binary analyses were performed on each disease group, 
sub classified based on certain IgE binding to food-allergens (i.e. DOCK8-deficient allergic 
to egg vs DOCK8 deficient patients not allergic to egg). The metabolomics profile for the 
significant food-allergens, (egg, milk, peanut, sesame and soybean) were analyzed using 
MetaboAnalyst software version 3.0(http://www.metaboanalyst.ca) as described before in the 
method section. 
In the DOCK8 cohort, the metabolomics binary comparison for egg allergen sesitisation 
showed cluster separation as demonstrated for sPLS-DA (Figure 0.11A), and the volcano plot 
showed 17 significantly expressed metabolites. (11downregulated and 6 upregulated) (Figure 
0.11B) The same analysis revealed a distinctive metabolic profile for each food allergen such 
as milk (6 downregulated and 1 upregulated) (Figure 0.12 : A-B), peanuts (10 downregulated 
and 6 upregulated) (Figure 0.13: A-B), sesame (10 downregulated and 15 upregulated) 
(Figure 0.14: A-B) and soy (6 downregulated and 2 upregulated). (Figure 0.15: A-B) 
Significantly, expressed metabolites in the DOCK8-deficient cohort, for five food groups, 












Figure 0.11:sPLS-DA score plot analysis for significant metabolites in DOCK8-deficient (n=10) and 
atopic dermatitis (n=9) patients with(+) and without(-) egg allergy (A,C) with the corresponding 
volcano plots respectively.(B,D) Fold change=1.2, p-value<0.05{Abbreviations: AD-Atopic 













Figure 0.12: sPLS-DA score plot analysis for significant metabolites in DOCK8-deficient (n=10) and 
AD (n=9) patients with (+) and without (-) milk allergy (A,C) with their corresponding volcano plots 
respectively.(B,D) Fold change=1.2, p-value<0.05,{Abbreviations:AD-Atopic dermatitis, Sparse 
Partial Least Square Discriminant Analysis (sPLS-DA)} 
 
  










Figure 0.13: sPLS-DA score plot analysis for significant metabolites in DOCK8-deficient (n=10) and 
AD (n=9) patients with(+) and without(-) peanut allergy (A,C) with their corresponding volcano plots 
respectively.(B,D) Fold change=1.2, p-value<0.05,{Abbreviations:AD-Atopic dermatitis, Sparse 











Figure 0.14: sPLS-DA score plot analysis for significant metabolites in DOCK8-deficient (n=10) and 
AD (n=9) patients with(+) and without(-) sesame allergy (A,C) with their corresponding volcano plots 
respectively.(B,D) Fold change=1.2, p-value<0.05,{Abbreviations: AD-Atopic dermatitis, Sparse 
Partial Least Square Discriminant Analysis (sPLS-DA)} 
 
  








Figure 0.15 : sPLS-DA score plot analysis for significant metabolites in DOCK8-deficient (n=10) 
and AD (n=9) patients with(+) and without(-) soy allergy (A,C) with their corresponding volcano 
plots respectively.(B,D) Fold change=1.2, p-value<0.05,{Abbreviations: AD-Atopic dermatitis, 
Sparse Partial Least Square Discriminant Analysis (sPLS-DA)} 
 
  










Figure 0.16 Different food allergen groups induce 
differential metabolmics profiles in DOCK8-deficient 
(n=10)  (A-E). Various dipeptides were down-
regulated in association with the allergen sensitisation 
in both  groups.Fold change=1.2, p-value<0.05, 
Abbreviations: Neg = allergen sensitization absent; 
Pos = allergen sensitization present. 
(The loadings plot shows the variables selected by the 
sPLS-DA model for a given component. The variables 
are ranked by the absolute values of their loadings.) 
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Figure 0.17: : Different food allergen groups 
induce differential metabolmics profiles in 
atopic dermatitis (n=9) (F-J). Various 
dipeptides were down-regulated in association 
with the allergen sensitisation in both the 
groups.Fold change=1.2, p-value<0.05, , 
Abbreviations: Neg = allergen sensitization 
absent; Pos = allergen sensitization present 
(The loadings plot shows the variables selected 
by the sPLS-DA model for a given component. 
The variables are ranked by the absolute values 
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Similarly, the AD cohort, showed cluster separation and is demonstrated in sPLS-DA. 
(Figure 0.11C) Volcano plot analysis showed 17 metabolites were significant, (7 down-
regulated and 10 up-regulated). (Figure 0.11D) Similar analysis revealed a distinctive 
metabolic profile for each allergen group including milk (Figure 0.12: C-D) (9 down- 
regulated and 17 upregulated), peanut (Figure 0.13: C-D) (6 down-regulated and 12 up- 
regulated), sesame (4 down-regulated and 7 up-regulated) (Figure 0.14 : C-D) and soybean 
(9 down-regulated and 17 up-regulated). (Figure 0.15: C-D). Significantly expressed 
metabolites, in the five food groups, egg, milk, peanut, sesame and soy are represented in the 
loading plot. (Figure 0.17: F-I). 
For the five food groups, among the most significant differential expressed and disease-
specific metabolites, 50 were identified in the DOCK8- deficient (Table A1.16) and 34 in the 
AD cohort (Table A1.17). For example, in DOCK8- deficient cohort 2R, 5S-2, 5-
diaminohexanoate is not disease-specific for any of the food groups whereas, in the AD 
cohort 3, 4-dihydroxybenzeneacetic acid and glutamyl-methionine are disease-specific in all 
the food groups.  
Pathway analysis in DOCK8-deficient patients (Figure A2 7) showed dysregulation of 
several amino acid metabolism especially arginine, proline, glycine, serine and tryptophan, 
whereas in the AD cohort, the caffeine metabolism pathway was predominantly perturbed. 
Furthermore, pathway analyses stratified by the five food groups (egg, milk, peanut, sesame, 
and soy) were also performed in each cohort. (Table A1.18) As shown, different food-
allergens induced different, non-overlapping- amino acid pathway dysregulation in both 
cohorts. However, the caffeine metabolism pathway induction correlated with egg and peanut 
allergy in patients with AD, taurine and hypotaurine metabolism pathway correlated with 




milk allergy in DOCK8 deficiency and sesame allergy in atopic dermatitis. Tryptophan 
metabolism pathway induction was observed in association with egg and sesame allergy in 
the DOCK8 deficient patients only. 
Discussion 
Associations between food allergies, food sensitization and atopic eczema seem to be 
selective and population-based. The molecular mechanism behind the dramatic elevation in 
IgE levels in DOCK8-deficient patients is not clearly understood. Boos et al.(2014) examined 
the sensitization patterns in 6 DOCK8-deficient and 14 AD patients with 12 allergens (6 aero-
allergens and 6 food-allergens) and demonstrated that the ratio of aero-allergen specific IgE 
to total IgE was the highest in AD, whereas DOCK8-deficient patients showed the highest 
specific serum IgE sensitization towards food-allergens.(12) Furthermore, among the food- 
allergens, higher sensitization was seen in DOCK8-deficient patients towards milk, whereas 
in AD patients towards cat allergen (12), which is in agreement with our findings. Moreover, 
in our study, we targeted 112 allergens compared to 12 allergens in theirs.  
As shown in the study by Boos et.al (2014), our DOCK8-deficient patients also showed the 
highest sensitization towards cow milk allergens, particularly nBosd4, nBosd5, and nBos d8, 
as compared to AD patients. Studies have shown that casein (nBos d8) and beta-lactoglobulin 
(nBos d5) serum IgE antibodies are known markers of milk allergy.(13, 14) Patients with IgE 
antibodies against nBos d8 are reported to be less likely to outgrow this allergy, although 
most milk allergic children outgrow their allergy and develop tolerance towards milk, the 
mechanism of this tolerance is not well understood. The natural tolerance acquisition could 
be due to the decrease in the difference between IgE and IgG binding intensity to cow milk 
epitopes.(15) Furthermore, higher IgE levels to the egg allergene Gal d1 are known risk 




factor for egg allergy, whereas undetectable levels may indicate that these individuals can 
tolerate cooked eggs.(16) nGal d 1 is the dominant egg allergen which we also demonstrated 
in our DOCK8-deficient and AD cohorts. IgE antibodies that react against sequential epitopes 
give rise to persistent allergies whereas IgE antibodies that react with conformational 
epitopes give rise to temporary allergies. (17) Gal d2 is the most abundant but heat-labile 
allergen in egg. Children with specific IgE to nGal d 2 can tolerate heat-denatured forms of 
the egg which is reported as the third most common food to cause anaphylaxis.(18) 
Interestingly in a recent clinical trial, The Learning Early About Peanut Allergy (LEAP) 
demonstrated that the early introduction of peanut decreases the occurrence of peanut 
allergies in children at high risk.(19) Our DOCK8-deficient and AD patients also exhibited 
sensitization towards soy and sesame allergens. Similarities between peanut and soy 
allergens, have been shown through IgE epitope mapping which may explain the IgE cross-
reactivity between peanut and soybean.(20) Sensitization towards soybean allergens like Gly 
m5 and Gly m6 can also lead to allergic reaction. Severe allergic reactions in Japanese 
children have been reported towards soy allergens. (21) Allergic sensitisation towards sesame 
allergens are higher in the Middle East regions, and especially in Saudi Arabia sesame is 
reported as the third most common food to cause anaphylaxis.(22) Allergies towards peanuts, 
soybean, egg, and sesame, commonly seen in our cohort could be also due to the ethnic 
differences in food exposures and consumptions. 
Among the aero-allergens, DOCK8-deficient patients showed high sensitization towards latex 
(Hev b1, 3) seems to be clinically irrelevant because no association between allergens and 
severity of the reactions have been identified so far.(23, 24) Studies from KFSH&RC in 
Saudi Arabia have also shown that latex allergy was observed in 3.4% of study subjects. (22) 
Grass pollen is the most common cause of seasonal respiratory allergy affecting the general 




population worldwide.(25, 26) In a Spanish study, 99.4% patients allergic to grass pollen 
were polysensitized to unrelated pollens with rPhl p1, rPhl p5, rPhl p7 and rPhl p12. In our 
study, an average of 50% of sensitization was seen for rPhl p1, rPhl p4 and rPhl p5in both 
cohorts. Palao et.al (2016) showed in their study that there was no relationship between the 
molecular sensitization profile of these allergens and clinical features of respiratory allergy in 
their population. (27) DOCK8-deficient patients also showed higher sensitization towards 
olive allergen, nOle e9 compared to AD patients. Olive tree is a main source of allergy in the 
Mediterranean basin like Saudi Arabia and the prevalence of this allergen is dependent on the 
geographic area of sensitization. (28)Studies have shown that the in high in areas where the 
pollen counts reach up to 5000 per m3 (certain regions of Andalucía and Italy) Ole e9 is 
highly prevalent allergen with sensitization rates of 50-60% among the allergenic population. 
(29) The above finding reflect that AD patients show more sensitization to inhaled allergens 
as compared to the DOCK patient 
However, DOCK8-deficient patients showed higher sensitization towards olive, nOle e9, as 
compared to AD patients. Olive tree is a main source of allergy in the Mediterranean basin 
including Saudi Arabia and the prevalence of this allergen is dependent on the geographic 
area of sensitization. (28) Studies have shown that sensitization is high in areas where the 
pollen counts reach up to 5000 per m3(certain regions of Andalucía and Italy) Ole e9 is highly 
prevalent allergen with sensitization rates of 50-60% among the allergic population.(29) In 
our study, 40% DOCK8-deficient patients were sensitized to Ole e9 as compared to only 20% 
in the AD cohort. 
Most of our AD patients suffered from asthma and showed high sensitization towards cat 
allergen, Fel d1 particularly, compared to no sensitization among the DOCK8-deficient 




patients. Gronlund et.al (2008) have shown that higher levels of IgE antibodies against Fel d1  
were associated with asthma in cat allergic individuals. (30) which we observed in our AD 
cohort. IgE reactivity against aeroallergens was in general lower in our DOCK8-deficient 
patients, the difference in disease severity between both cohorts alone does not explain the 
different sensitization patterns,indicates towards a more specific role of food allergy in the 
pathogenesis of DOCK8 deficiency. 
Furthermore, among the cytokines analysed in the DOCK8 cohort, dysregulated expression 
of CCL11 and CSF3 were commonly seen in egg, milk, and soybean sensitisation. CCL11 
has been demonstrated to play an important role in inflammatory responses and the 
pathophysiology of food allergies in asthma and AD. (31) In the intestinal epithelial cells, 
CCL11 is also known to restrict the severity of allergic responses to food antigens.(32) The 
significance of this cytokine in the DOCK8 deficient cohort seems to be associated with the 
clinical profiles of these patients, inclusing asthma, infections and food allergies. While CSF3  
is a glycoprotein linked to proliferation and maturation of neutrophils, the role in cancer 
development has been shown.(33) Scd40L and IL-4 were significant upregulated cytokines 
seen for egg sensitization in our study. Scd40L is known to act as an immunosuppressant in 
HIV infections, (34) whereas studies have shown that IL-4 favors food allergy by blocking 
the triggering of allergen specific Treg cells.(35) Significant expression of TGF-A and FGF2 
was also observed in peanut sensitization. These growth factors are involved in many 
biological processes including, embryonic development, cell growth, morphogenesis, tissue 
repair, tumor growth and invasion. 
Among the AD patients also FGF2 was also significantly expressed in peanut allergen, 
whereas IL3 was significant in sesame allergen, IL3 is known to play a critical role in 




modulating innate immune effector functions in humans.(36) Taken together, significant 
expression of these cytokines and growth factors supports the role of pathogenic immune 
responses including food allergies, infections, favoring tumor growth and progression which 
is in agreement with disease phenotypes seen in the DOCK8 deficient and AD cohorts. 
Metabolomics profiling in DOCK8-deficient patients revealed, aminoacid metabolism 
pathways to be commonly dsyregulated among the different food groups. Glycine and 
phenylalanine are known to play an essential role in cell signaling by impacting specific 
amino acid degradation pathways.(37).Hypotaurine behaves as an antioxidant and protective 
agent under physiological conditions, whereas under hypoxic signaling, hypotaurine behaves 
as an onco-metabolite promoting tumor progression.(38) Mammals are known to 
oxidizehypotaurine to taurine using trace amounts of hydrogen peroxide (H2O2) produced by 
cellular metabolism, which is likely to be more frequent in the brain than the liver. 
Alterations in tryptophan metabolism was seen among DOCK8 cohort, which confirms our 
previous study. (8) and it may be disease specific and not allergy specific. Hence the 
alterations in tryptophan metabolism seen in our cohorts reflect upon the pathophysiology of 
the disease, in relation to infections during the course of the disease. 
In AD patients, the most significantly altered pathways among the five food groups was 
tyrosine metabolism, caffeine metabolism, and glutamine & glutamate metabolism. Tyrosine 
is a precursor to catecholamine compounds like dopamine, norepinephrine, and epinephrine. 
(39) released by the body in response to stress and was specific in AD patients only, hence it 
seems allergy specific and not disease specific. Glutamine plays an important role in the 
maintenance of gut mucosal integrity and function. Changes in intestinal permeability 
through cytokine release in response to food-allergens could manifest into food allergy.(40) 




The Caffeine metabolism pathway was shown to be perturbed in egg and peanut food groups. 
Caffeine (1, 3, 7-trimethylxanthine) is a competitive antagonist of neurotransmitter adenosine 
or adenosine receptors, (42) that play an important role in many functions including  
regulation of neutrophils and their degranulation, ultimately having an effect on immunity. 
(43, 44) Merve et.al (2018) showed that caffeine inhibits STAT1 signaling and suppresses 
gene expression of pro inflammatory genes and cytokines that play an important role in 
autoimmune diseases.(45) Generally among both the cohorts perturbations in amino acid 
metabolism was observed and these changes have been reported in some cancers as well as 
neurodegenerative disorders such as Alzheimer disease and Parkinson diseases (46-48) 
In summary, the differences in the comprehensive sensitization patterns in DOCK8-deficient 
and AD patients, were studied leveraging metabolomics and cytokine profiling, which 
revealed novel insights into the complexity of the immune and allergic responses that 
characterize DOCK8 deficiency (a rare inborn error of immunity) and atopic dermatitis (a 
more common human disease).Such studies will likely reveal additional molecular 
heterogeneity underpinning the varying disease severity and clinical responses to various 










5.5  References 
 
1. Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodeficiency 
diseases associated with increased susceptibility to viral infections and malignancies. The 
Journal of allergy and clinical immunology. 2011;127(6):1329-41 e2; quiz 42-3. 
2. Biggs CM, Keles S, Chatila TA. DOCK8 deficiency: Insights into pathophysiology, 
clinical features and management. Clinical immunology (Orlando, Fla). 2017;181:75-82. 
3. Wollenberg A, Rawer HC, Schauber J. Innate immunity in atopic dermatitis. Clinical 
reviews in allergy & immunology. 2011;41(3):272-81. 
4. Boyce JA, Assa'ad A, Burks AW, Jones SM, Sampson HA, Wood RA, et al. 
Guidelines for the diagnosis and management of food allergy in the United States: summary 
of the NIAID-sponsored expert panel report. Nutrition research (New York, NY). 
2011;31(1):61-75. 
5. Kong J, Chalcraft K, Mandur TS, Jimenez-Saiz R, Walker TD, Goncharova S, et al. 
Comprehensive metabolomics identifies the alarmin uric acid as a critical signal for the 
induction of peanut allergy. Allergy. 2015;70(5):495-505. 
6. Minnie Jacob DBK, Safa Alhissi, Rand Arnout, Bander Alsaud, Hamoud Al-Mousa , 
Andreas L Lopata, Anas M Alazami, Majed Dasouki, Anas M. Abdel Rahman. Quantitative 
profiling of cytokines and chemokines in DOCK8 deficient and Atopic dermatitis patients. 
Allergy 2018. 
7. Jacob M, Gu X, Luo X, Al-Mousa H, Arnaout R, Al-Saud B, et al. Metabolomics 
Distinguishes DOCK8 Deficiency from Atopic Dermatitis: Towards a Biomarker Discovery. 
Metabolites. 2019;9(11). 
8. Deinhofer K, Sevcik H, Balic N, Harwanegg C, Hiller R, Rumpold H, et al. 
Microarrayed allergens for IgE profiling. Methods (San Diego, Calif). 2004;32(3):249-54. 
9. Huan T, Wu Y, Tang C, Lin G, Li L. DnsID in MyCompoundID for rapid 
identification of dansylated amine- and phenol-containing metabolites in LC-MS-based 
metabolomics. Anal Chem. 2015;87(19):9838-45. 
10. Li L, Li R, Zhou J, Zuniga A, Stanislaus AE, Wu Y, et al. MyCompoundID: using an 
evidence-based metabolome library for metabolite identification. Anal Chem. 
2013;85(6):3401-8. 
11. Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual 
analogue scale: evaluation of the instrument for the assessment of pruritus. Acta dermato-
venereologica. 2012;92(5):497-501. 
12. Boos AC, Hagl B, Schlesinger A, Halm BE, Ballenberger N, Pinarci M, et al. Atopic 
dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization 
pattern. Allergy. 2014. 
13. Caubet J-C, Nowak-Węgrzyn A, Moshier E, Godbold J, Wang J, Sampson HA. 
Utility of casein-specific IgE levels in predicting reactivity to baked milk. The Journal of 
allergy and clinical immunology. 2013;131(1):222-4.e44. 




14. Hernandez-Trujillo VP, Nguyen WT, Belleau JT, Jeng M, Conley ME, Lew DB. 
Cow's milk allergy in a patient with hyper-IgE syndrome. Annals of Allergy, Asthma & 
Immunology. 2004;92(4):469-74. 
15. Caubet JC, Lin J, Ahrens B, Gimenez G, Bardina L, Niggemann B, et al. Natural 
tolerance development in cow's milk allergic children: IgE and IgG4 epitope binding. 
Allergy. 2017;72(11):1677-85. 
16. Caubet JC, Kondo Y, Urisu A, Nowak-Wegrzyn A. Molecular diagnosis of egg 
allergy. Current opinion in allergy and clinical immunology. 2011;11(3):210-5. 
17. Jarvinen KM, Beyer K, Vila L, Bardina L, Mishoe M, Sampson HA. Specificity of 
IgE antibodies to sequential epitopes of hen's egg ovomucoid as a marker for persistence of 
egg allergy. Allergy. 2007;62(7):758-65. 
18. Al-Muhsen S, Clarke AE, Kagan RS. Peanut allergy: an overview. CMAJ : Canadian 
Medical Association journal = journal de l'Association medicale canadienne. 
2003;168(10):1279-85. 
19. Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, et al. 
Randomized trial of peanut consumption in infants at risk for peanut allergy. The New 
England journal of medicine. 2015;372(9):803-13. 
20. Chruszcz M, Maleki SJ, Majorek KA, Demas M, Bublin M, Solberg R, et al. 
Structural and immunologic characterization of Ara h 1, a major peanut allergen. The Journal 
of biological chemistry. 2011;286(45):39318-27. 
21. Ito K, Sjolander S, Sato S, Moverare R, Tanaka A, Soderstrom L, et al. IgE to Gly m 
5 and Gly m 6 is associated with severe allergic reactions to soybean in Japanese children. 
The Journal of allergy and clinical immunology. 2011;128(3):673-5. 
22. Sheikh F, Amin R, Rehan Khaliq AM, Al Otaibi T, Al Hashim S, Al Gazlan S. First 
study of pattern of anaphylaxis in a large tertiary care hospital in Saudi Arabia. Asia Pacific 
allergy. 2015;5(4):216-21. 
23. Ott H, Schroder C, Raulf-Heimsoth M, Mahler V, Ocklenburg C, Merk HF, et al. 
Microarrays of recombinant Hevea brasiliensis proteins: a novel tool for the component-
resolved diagnosis of natural rubber latex allergy. Journal of investigational allergology & 
clinical immunology. 2010;20(2):129-38. 
24. Ebo DG, Hagendorens MM, De Knop KJ, Verweij MM, Bridts CH, De Clerck LS, et 
al. Component-resolved diagnosis from latex allergy by microarray. Clinical and 
experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 
2010;40(2):348-58. 
25. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in 
Europe. The European respiratory journal. 2004;24(5):758-64. 
26. Dahl R, Andersen PS, Chivato T, Valovirta E, de Monchy J. National prevalence of 
respiratory allergic disorders. Respiratory medicine. 2004;98(5):398-403. 
27. Palao-Ocharan P, Dominguez-Ortega J, Barranco P, Diaz-Almiron M, Quirce S. Does 
the Profile of Sensitization to Grass Pollen Allergens Have Clinical Relevance? Journal of 
investigational allergology & clinical immunology. 2016;26(3):188-9. 




28. Bousquet J, Cour P, Guerin B, Michel FB. Allergy in the Mediterranean area. I. 
Pollen counts and pollinosis of Montpellier. Clinical allergy. 1984;14(3):249-58. 
29. Barber D, Polo F, Lombardero M, Villalba M, Rodriguez R. The importance of minor 
allergens in allergen standardization. Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur 
Sera und Impfstoffe) zu Frankfurt aM. 2006(95):128-34; discussion 34, 55. 
30. Gronlund H, Adedoyin J, Reininger R, Varga EM, Zach M, Fredriksson M, et al. 
Higher immunoglobulin E antibody levels to recombinant Fel d 1 in cat-allergic children with 
asthma compared with rhinoconjunctivitis. Clinical and experimental allergy : journal of the 
British Society for Allergy and Clinical Immunology. 2008;38(8):1275-81. 
31. Ahmadi Z, Hassanshahi G, Khorramdelazad H, Zainodini N, Koochakzadeh L. An 
Overlook to the Characteristics and Roles Played by Eotaxin Network in the Pathophysiology 
of Food Allergies: Allergic Asthma and Atopic Dermatitis. Inflammation. 2016;39(3):1253-
67. 
32. Kim E, Lembert M, Fallata GM, Rowe JC, Martin TL, Satoskar AR, et al. Intestinal 
Epithelial Cells Regulate Gut Eotaxin Responses and Severity of Allergy. Frontiers in 
immunology. 2018;9:1692. 
33. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-
macrophage colony-stimulating factor (2). The New England journal of medicine. 
1992;327(2):99-106. 
34. Jenabian MA, Patel M, Kema I, Vyboh K, Kanagaratham C, Radzioch D, et al. 
Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T 
cell expansion in HIV infection. Clinical and experimental immunology. 2014;178(1):102-11. 
35. Noval Rivas M, Burton OT, Oettgen HC, Chatila T. IL-4 production by group 2 
innate lymphoid cells promotes food allergy by blocking regulatory T-cell function. The 
Journal of allergy and clinical immunology. 2016;138(3):801-11.e9. 
36. Borriello F, Galdiero MR, Varricchi G, Loffredo S, Spadaro G, Marone G. Innate 
Immune Modulation by GM-CSF and IL-3 in Health and Disease. International journal of 
molecular sciences. 2019;20(4). 
37. Reshkin SJ, Ahearn GA. Intestinal glycyl-L-phenylalanine and L-phenylalanine 
transport in a euryhaline teleost. The American journal of physiology. 1991;260(3 Pt 
2):R563-9. 
38. Gao P, Yang C, Nesvick CL, Feldman MJ, Sizdahkhani S, Liu H, et al. Hypotaurine 
evokes a malignant phenotype in glioma through aberrant hypoxic signaling. Oncotarget. 
2016;7(12):15200-14. 
39. Minnie Jacob XG, Xian Luo, Hamoud Al-Mousa, Rand Arnaout, Bandar Al Saud, 
Andreas L. Lopata, Liang Li, PhD, Majed Dasouki, Rahman aAMA. Metabolomics 
distinguishes DOCK8 deficiency from atopic dermatitis: A Biomarker discovery 
Frontiers in immunology. 2019. 
40. Lieberman HR, Georgelis JH, Maher TJ, Yeghiayan SK. Tyrosine prevents effects of 
hyperthermia on behavior and increases norepinephrine. Physiology & behavior. 
2005;84(1):33-8. 




41. DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation and 
gastrointestinal disease. Journal of clinical gastroenterology. 2002;34(4):385-96. 
42. Namuslu M, Kocaoglu H, Celik HT, Avci A, Devrim E, Genc Y, et al. Effects of 
aqueous soybean, mistletoe and red clover extracts on activities of adenosine deaminase and 
xanthine oxidase enzyme. Bratislavske lekarske listy. 2014;115(6):367-71. 
43. Sullivan GW, Luong LS, Carper HT, Barnes RC, Mandell GL. Methylxanthines with 
adenosine alter TNF alpha-primed PMN activation. Immunopharmacology. 1995;31(1):19-
29. 
44. Chan ES, Fernandez P, Cronstein BN. Adenosine in inflammatory joint diseases. 
Purinergic signalling. 2007;3(1-2):145-52. 
45. Iris M, Tsou PS, Sawalha AH. Caffeine inhibits STAT1 signaling and downregulates 
inflammatory pathways involved in autoimmunity. Clinical immunology (Orlando, Fla). 
2018;192:68-77. 
46. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis 
mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-
specific profiles. Metabolomics. 2010;6(1):78-95. 
47. Fonteh AN, Harrington RJ, Tsai A, Liao P, Harrington MG. Free amino acid and 
dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino acids. 
2007;32(2):213-24. 
48. Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, et al. Fecal 
metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 
2014;35(9):2089-96. 
  




5.6  Chapter 5 summary  
 
 Comprehensive ISAC based sensitization patterns were studied in DOCK8 deficient 
and atopic dermatitis patients 
 The sensitization patterns were compared to metabolomics and cytokine profiling, 
revealing insights into the complexity of the immune and allergic responses that characterize 
DOCK8 deficiency and atopic dermatitis 
 Such studies are likely to reveal additional molecular heterogeneity underpinning the 
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Over the past decade, several studies have led to the hypothesis that DOCK8 deficiency 
might be a disease of impaired inflammatory response rather than a disease of pathologic IgE 
production. Elevated IgE levels, eczema, asthma, food, and environmental allergies are 
common or overlapping to both DOCK8 deficient and AD patients. If not treated with bone 
marrow transplantation, this condition may cause high morbidity and mortality. The DOCK8 
protein deficient lymphocytes have difficulties migrating through the collagen gel matrices, 
which translates into high incidence of severe cutaneous viral infection commonly seen in 
these patients. Futhrermore, the molecular mechanism(s) underlying the significantly 
increased risk of cancer development in these patients is not clearly understood. So far, no 
definitive single or set of biomarkers have been identified, capable of distinguishing inherited 
DOCK8 deficient and AD patients. 
The work outlined in this PhD thesis aimed at the development of a comprehensive 
metabolomics method involving a panel of 225 metabolites. Signature cytokine biomarkers 
were identified as outlined in Chapter 2 and metabolomics biomarkers are discussed in 
Chapter 4. Furthermore, in chapter 5 IgE sensitization pattersn to food and aero-allergens 
were studied and correlated with the cytokine and metabolomics profiles that were 
investigated in Chapters 2 and 4. 
The panel of metabolites included in the metabolome represents a distinct metabolic 
fingerprint or signature, indicative of its current state. Finding metabolomic signature profiles 
can be useful in clinical care, biomarker discovery for several common and rare human 
diseases, and in understanding disease mechanisms and response to therapy. Metabolomics 
has influenced pharmacological research to a great extent and has made personalized health 
care increasingly possible. Metabolomics data are vast and complex; however, the use of 
multivariate analytical techniques for data processing and availability of high-quality analysis 
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software has made the data less complex. Thus, metabolomics is an essential component in 
biomarker discovery and its translation to clinical care strategies. 
Comprehensive cytokine profiling revealed seven cytokines that were differentially expressed 
among the three comparative groups (DOCK8, AD and Ctrls). Interestingly, CXCL10 and 
TNF‐A were the only signature cytokines, which were above the volcano plot's cutoff values 
and were significantly upregulated in DOCK8‐deficient patients. CXCL10 is a chemokine, 
known to be highly expressed in various autoimmune diseases, pneumonia triggered by viral 
and bacterial infection as well as in asthma. Up regulation of this cytokine in the DOCK8‐
deficient cohort seems to be associated with the frequently occurring clinical phenotypes 
(asthma, infections, allergies, and pneumonia) seen in these patients. The higher circulating 
levels of CXCL10 in blood is due to either a higher competitive binding with a viral protein 
inflammation, (as it attracts the activated T lymphocytes, which are the only inflammatory 
cells expressing the chemokine receptor CXCR3), or DOCK8 inhibition of HS-GAG 
synthesis. In contrast, TNF‐A is a multifunctional pro-inflammatory cytokine, known to 
mediate AD, psoriasis, tumor initiation and autoimmune diseases, and participates in cell 
survival/death and cancer. Up-regulation of TNF‐A seems to contribute toward the pruritus 
and immune dysregulation observed in DOCK8 patients. In this study, EGF expression was 
significantly down-regulated in AD patients, but not in most DOCK8‐deficient patients, when 
compared with controls, hence, low levels of EGF impair proliferation and anti‐inflammatory 
immune response in the skin as has been demonstrated in several studies. IL‐31 is a recently 
discovered cytokine produced by Th2 cells, and elevated levels of IL‐31 are correlated with 
increased serum IgE levels and disease severity and are possibly responsible for the induction 
of pruritus in the AD patients. 
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An important approach for biomarker discovery is through understanding the metabolome, 
the ultimate functional product of the genome, which can be studied through identification 
and quantification of small molecules. The global metabolome influences the individual’s 
phenotype in response to clinical and environmental interventions. The unique metabolic 
profiling can be useful in clinical care, biomarker discovery for several common and rare 
human diseases, as well as in understanding disease mechanisms and response to therapy. 
There is a strong clinical need to develop and validate quantitative methods capable of 
measuring the largest number of metabolites subject to wide and rapid dynamic changes 
present in a biological system. This is particularly challenging since several important factors 
such as metabolite dilution, stability, low abundance, sample matrix, concentration and 
availability of internal standards may significantly impact the ability to quantify these 
analytes. Development of an LC-MS/MS-based comprehensive targeted metabolomics panel, 
in Chapter 3, encompasses a broad range of clinical and biochemical genetic disorders and is 
applicable to different biological matrices such as whole blood, serum, dried blood spots 
(DBS) and tissues. The highlights of this methodology are the requirement of small sample 
volume, cost effectiveness and its utility in early and better management of these diseases. In 
this study, the effect of sample matrix on expression profiles was also investigated on a large 
set of clinically oriented metabolites, which may help to guide the choice of the optimal 
sample types and matrix in which it is collected.  
A central objective of the experimental work conducted in this thesis, was identification of 
metabolomics biomarkers, using Chemical isotope labeling liquid chromatography-mass 
spectrometry (CIL LC-MS), capable of distinguishing DOCK8-deficient from AD patients. 
These biomarkers coupled with the identification of pathways potentially play an important 
role in the pathogenesis of DOCK8-deficient and AD patients and contribute towards 
improved disease monitoring and ultimately novel clinical interventions. It is critical to 
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recognize DOCK8 deficiency and differentiate its various clinical and molecular forms 
before severe life-threatening complications arise. Aydin, et.al (2015) in a study on 136 
DOCK8-deficient patients, reported malignancies in 17%, life-threating infections in 58% 
and non-infections cerebral events in 10% of their patients. Krause et.al (2009) studied the 
neuroprotective activity of the tryptophan metabolite, 3-HAA, which may be helpful in future 
therapeutic approaches for neuroinflammatory disorders. Kyneurine pathway metabolomics 
profiling is dysregulated in the pathogenesis of many diseases characterized by inflammation 
and neurodegeneration, like Alzheimer’s disease and Parkinson’s disease. Metabolic finger 
printing studies by Rombust et.al (2017) has shown that 3-hydroxykynurenine and 3-
hydroxyanthranilic acid can induce the formation of reactive oxygen species (ROS) under 
certain micro-environmental conditions, thereby playing a crucial role in the mechanisms 
underlying the relationship between consumption of red meat and associated diseases. 
Aspartic acid is a major excitatory neurotransmitter and has been found to be increased in 
some epileptic and stroke patients. Since gut microbiota play important roles in host 
metabolism, especially in diabetes, Kai et.al (2019) found significantly altered metabolites, 
like aspartic acid, cholestan-3-ol (5β, 3α), and campesterol in association with lipogenesis 
and inflammation in pre diabetic mice. Furthermore, intraperitoneal injection of aspartic acid 
in mice has been found to have more beneficial effects on Experimental autoimmune 
encephalomyelitis, (EAE) widely used model for multiple sclerosis, reflecting upon the role 
of aspartate in therapy.  In chapter 4, significant differential overexpression of 3-HAA and 
aspartic acid coupled with under expression of hypotaurine, guanosine, leucyl-phenylalanine, 
glycyl-phenylalanine, together seem to contribute to some of the immune and malignancy 
related phenotypes observed in this disease. 
Furthermore, since both DOCK8 deficient and AD patients have food allergies in common, 
the cross reactivity sensitization pattern revealed difference in the sensitization patterns that 
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help understanding the allergic triggers, which may give some insight into disease 
manifestations and pathogenesis. Unique and shared cytokine and metabolomics alterations 
detected in this study reflect upon the distinct mechanisms functioning in these disorders. 
Although more and larger studies are needed, the existing study gives a broader picture of the 
sensitization patterns, providing information on specific and cross-reactive sensitizations that 
facilitate diagnosis, risk assessment and disease management. 
Differentiating DOCK8‐deficient patients from those with atopic diseases at an early stage is 
significant in a child's development, as treatment modalities differ considerably.   
Naturally, arising somatic reversions of germ line mutations have been observed in several 
primary immunodeficiency disorders, including the Wiskott-Aldrich syndrome, severe 
combined immunodeficiencies, and X-linked lymphoproliferative diseases. Jing et.al (2014) 
showed that 50% of their DOCK8-deficient patients had somatic reversions and they were 
from a non-consanguineous background. This could be due to the DOCK8’s location within a 
recombination hotspot that is characterized by many sub telomeric repetitive sequences. Such 
locations are known to contribute to large intragenic germ line deletions found in other 
human diseases, and contribute to the recombination-mediated somatic repair. In DOCK8 
deficiency, only certain combinations of germline mutations support secondary somatic 
repair. Those patients had an ameliorated disease course with longer survival, but still had 
fatal complications or required hematopoietic cell transplantation.  
In our cohort, none of DOCK8-deficient patients had somatic reversion and all came from a 
consanguineous background. Since all our patients had homozygous large deletions or 
compound heterozygous overlapping large deletion mutations, they were incapable of 
generating revertants, and are predicted to have a more severe form of the disease. In this 
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patient subgroup especially, HSCT is recommended to minimize the development of 
infection-related disease pathology. 
Since DOCK8 deficient patient’s shares clinical and laboratory features with AD patients, 
clinicians face a challenge of misdiagnosis in patients with DOCK8 deficiency. Elevated IgE 
levels, eczema, asthma, food, and environmental allergies are common to HIES and AD, 
although severe bacterial and viral infections, and pneumonia are exclusively seen in 
DOCK8-deficient patients. The cytokine and metabolomics profiling can add clinical value in 
distinguishing DOCK8-deficient patients from AD in timely fashion to start the treatment and 
management, while waiting for genetic confirmation. These biomarkers can be used in 
screening programs and follow up of post-transplanted patients. Pathway analysis insight can 
be useful to understand the pathophysiology of the disease and also used as a platform for 
future studies in the diagnosis of other types of HIES. 
 The outcome of this particular study reflects upon identification of differentiating biomarkers 
which may reveal insight, linking these disorders with their clinical phenotypes, thus 
facilitating improved understanding of disease pathogenesis, progression and better 
management. 
Future direction: 
The experimental data outlined in this thesis extensively characterizes major biomarkers 
differentiating DOCK8-deficent and AD patients, including the development of a 
comprehensive metabolomics method for biomarker discovery. The findings of this thesis 
provide a platform for the development of improved diagnostic approaches in biomarker 
discovery. Future advances in this field of research may be pursued in various aspects as 
follows: 
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a) Evaluation of the method using a larger patient cohort - The developed metabolomics 
panel requires small sample volume and is cost effective. However, an extensive panel with 
more metabolites needs to be investigated and validated in a larger patient cohort, so as to be 
used in clinical laboratories for the early detection and distinction of DOCK8-deficent and 
AD patients. 
b) Evaluate additional biomarkers using other OMICs - Combining high throughput 
experimental “OMIC based” techniques such as genomics, proteomics, and metabolomics 
with computational techniques such as bioinformatics and computer simulations enable a 
better understanding of biomarker discovery. Differences within the proteome and 
dysregulation of protein expression aid in the identification of the perturbed pathways that 
might play a role in the immunological and pathological development of the disease thereby 
enabling therapeutic intervention. Future OMICs studies on these patient samples may help in 
the development of quantitative diagnostic markers to monitor disease progression or 
responses to therapy using proteomic and transciptomic approaches. 
c)  Biomarker evaluation in a cohort before and after stem cell transplantation - Apart 
from severe viral infection in DOCK8 deficient patients, high risk of malignancy is also 
reported in these patients and the only definitive and curative treatment option is 
hematopoietic stem cell transplantation. Current studies show that clinical findings, including 
eczema and food allergies, are resolved in majority of these patients after transplantation, 
although in many cases food allergies seem to persist, post transplantation (Aydin et.al, 
2019).The patients recruited in this study were not transplanted. Future studies in 
investigating the metabolome and proteome, before and after transplantation are essential, 
and subsequent analysis of the changes will provide a detailed insight into the role of these 
immune related proteins and provide a deeper insight into the pathogenesis of the HEIS. 
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d) Evaluate specific food and aero-allergens from Saudi Arabia - The ISAC 
ImmunoCAP panel used in our Allergy Microarray has 112 antigenic epitopes and quantifies 
the IgE antibody concentrations in patient serum. However, this panel lacks common 
allergens seen in the Middle Eastern region including Saudi Arabia, including the edible fruit 
from dates (palm family) and other pollen allergens. There is a need to study the IgE 
sensitization pattern in the local population.  
The experimental work and data analysis presented in this thesis generated substantial 
knowledge for the development of OMICs diagnostic platforms and is the foundation for the 























































































































4.09 D-Fructose (2-13C) Neg 166 122 20 11 0000232 16219881 C03722 
21-Deoxycortisol 5.8 Alanine-d4 Neg 345 87 25 18 04030 222803 C05497 
2-hydroxyglutaric 
acid 0.75 Alanine-d4 Pos 193 175 30 13 HMDB06213 4394846 C02917 
2-Isopropyl malic 
acid 4.13 Citric acid-d4 Neg 175 115 32 16 HMDB00402 5280523 C02504 
2-Ketobutyric acid 4.28 D-Fructose (2-13C) Neg 101 57 52 8 HMDB00005 58 C00109 
2-Phosphoglyceric 












(2-13C) Neg 145 83 28 14 HMDB00752 12284 NA 
3-Methylhistidine 0.86 D-Fructose (2-13C) Pos 170 109 38 20 HMDB00479 64969 C01152 
Methylmalonic acid 4.29 Methyl malonate-d3 Neg 117 73 30 12 HMDB00202 487 C02170 
3-Phosphoglyceric 




3.49 D-Fructose(2-13C) Neg 157 99 24 8 HMDB0000635 5312 NA 
4-Hydroxy-L-
glutamic acid 2.72 
D-Fructose(2-
13C) Pos 163 100 20 15 HMDB02273 5460078 C03079 
4-Hydroxyphenyl 
pyruvic acid 3.89 
D-Fructose(2-
13C) Pos 179 107 20 10 HMDB00707 979 C01179 
4-Hydroxyproline 2.01 Ornithine-d6 Pos 132 69 2 16 HMDB00725 5810 C01157 
5,6-Dihydro-5-
methyl uracil 1.62 
Adenosine 
C13 Neg 127 42 17 15 HMDB00079 93556 C00906 
5,6-Dihydrouridine 1.57 Adenosine C13 Neg 277 194 24 10 HMDB00497 94312 C00429 
5-Aminolevulinic 




3.92 D-Fructose(2-13C) Pos 192 146 25 15 HMDB00763 1826 C05635 








Acetyl-CoA 5.61 D-Fructose(2-13C) Neg 808 408 20 40 HMDB01206 444493 C00024 
Adenine 1.47 Adenosine C13 Neg 134 107 24 24 HMDB00034 190 C00147 
Adenosine 2.34 Adenosine C13 Neg 266 
133.




C13 Neg 426 
133.




C13 Neg 346 
96.8




C13 Neg 506 
158.
83 48 46 HMDB00538 5957 C00002 
Adenylsuccinic acid 4.96 Adenosine C13 Neg 462 134 62 46 HMDB00536 440122 C03794 
Adonitol 1.1 D-Fructose(2-13C) Neg 151 89 24 10 HMDB00508 6912 C00474 
Alanine 0.94 Alanine-d4 Neg 90 72 20 6 HMDB0000161 5950 C01401 
Aldosterone 4.86 Adenosine C13 Neg 359 199 15 17 HMDB00037 24758425 C01780 
Aminoadipic acid 2.19 Leucine-d3 Neg 160 116 28 12 HMDB00510 469 C00956 




13C) Neg 289 131 25 27 HMDB00052 16950 C03406 
Betaine 1.28 Citrulline-d2 Pos 118 59 36 16 HMDB00043 247 C00719 
Biopterin 1.38 L-Citrulline-d7 Neg 236 192 30 15 HMDB00468 445040 C06313 
Biotin 4.46 Glucose-d7 Pos 245 227 50 25 HMDB00030 171548 C00120 
Cholic acid 6.71 Citric acid-d4 Neg 407 343 78 42 HMDB00619 221493 C00695 
Citrulline 1.02 Citrulline-d2 Pos 176 70 30 26 HMDB00904 9750 C00327 
Coenzyme A 5.5 Alanine-d4 Neg 766 79 160 65 HMDB01423 6816 C00010 
Corticosterone 7.69 Glucose-d7 Pos 347 121 48 24 HMDB01547 5753 C02140 
Cortisone 6.82 D-Fructose(2-13C) Pos 361 163 55 25 HMDB02802 222786 C00762 
Creatinine 1 Ornithine-d6 Pos 114 44 20 13 HMDB00562 588 C00791 




9 46 22 HMDB00058 6076 C00575 
Cyclic GMP 3.32 Adenosine C13 Neg 
361.
9 78.9 28 26 HMDB01314 24316 C00942 
Cysteine-sulfate 2.72 D-Fructose(2-13C) Neg 200 81 20 16 HMDB00731 115015 C05824 
Cytidine 1.1 Adenosine C13 Neg 242 
108.













C13 Neg 482 
158.
83 46 30 HMDB00082 6176 C00063 




Carnitine-d3 Neg 402 
158.
84 44 26 HMDB01546 6132 C00112 
D-Arabitol 1.02 D-Fructose(2-13C) Neg 151 89 30 10 HMDB00568 827 C01904 
D-Aspartic acid 2.34 Ornithine-d6 Neg 132 88 27 13 HMDB06483 83887 C00402 
Deoxyadenosine 4.8 Adenosine C13 Neg 250 
133.








0 16 HMDB00905 12599 C00360 








Deoxyguanosine 1.54 Adenosine C13 Neg 266 
149.
9 40 16 HMDB00085 187790 C00330 
Deoxyinosine 1.5 Adenosine C13 Neg 251 
134.




C13 Neg 213 
96.8
3 26 16 HMDB01031 45934311 C00673 




d3 Neg 199 97 21 8 HMDB01321 122357 C00279 
Dexamethasone 5.76 D-Fructose(2-13C) Neg 391 361 20 18 HMDB15364 5743 C15643 
Dextrose 1.12 D-Fructose(2-13C) Neg 179 89 25 10 HMDB00122 5793 C00031 
D-Fructose 0.93 D-Fructose(2-13C) Neg 179 89 16 8 HMDB00660 439709 C02336 
D-Galactono-1,4-
lactone 1.07 Glucose-d7  177 129 26 15 HMDB0002541 6857365 C01115 
D-Glucose 0.95 Glucose-d7 Neg 179 89 25 10 HMDB00122 5793 C00031 
D-Glucuronic acid 2.45 Glucose-d7 Neg 193 113 20 17 HMDB00127 444791 C00191 
D-Glutamic acid 0.9 Glutamate-d5 Pos 148 84 24 12 HMDB03339 23327 C00217 




Carnitine-d3 Neg 169 79 25 17 HMDB01473 668 C0011 
Dimethylallylpyrop
hosphate (DMAPP) 4.96 
C2-Carnitine-
d3 Neg 245 74 34 16 HMDB01120 647 C00235 
DL-Homocystine 1.14 Inosine-15N4 Pos 269 136 30 10 HMDB00575 10010 C01817 
D-Maltose 1.02 Glucose-d7 Neg 341 101 30 20 HMDB00163 10991489 C00208 
D-Mannose 0.95 Glucose-d7 Neg 179 59 25 17 HMDB00169 18950 C00159 
D-Mannose-1-
phosphate 2.73 Glucose-d7 Neg 259 79 25 20 HMDB06330 644175 C00636 




13C) Neg 229 97 25 15 HMDB01548 439167 C00117 
D-Threitol 2.51 D-Fructose(2-13C) Pos 123 105 30 8 HMDB04136 169019 C16884 
D-Tryptophan 3.97 Ornithine-d6 Pos 205 146 30 18 HMDB13609 9060 C00525 
Dulcitol 1.15 Inosine-15N4 Neg 181 101 50 15 HMDB00107 11850 C01697 
D-Xylitol 1.04 Alanine-d4 Pos 153 117 22 8 HMDB02917 6912 C00379 
D-Xylose 0.99 D-Fructose(2-13C) Neg 149 89 30 15 HMDB00098 135191 C00181 
Estradiol 7.98 C8-Carnitine-d3 Pos 273 186 25 24 HMDB00151 5757 C00951 
Estriol 4.64 Alanine-d4 Neg 287 145 25 40 HMDB00153 5756 C05141 
Estrone 8.36 Alanine-d4 Pos 271 133 40 20 HMDB00145 5870 C00468 








13C) Neg 259 197 30 15 HMDB00124 69507 C00085 








0.98 Alanine-d4 Pos 104 69 26 14 HMDB00112 119 C00334 
Gluconolactone 1.42 Glucose-d7 Neg 177 129 20 8 HMDB00150 7027 C00198 
Glucosamine-6-
phosphate 1.04 Glucose-d7 Pos 260 126 20 12 HMDB01254 439217 C00352 
Glucose-6-




Glutaric acid 3.02 Alanine-d4 Neg 131 69 30 14 HMDB00661 743 C00489 
Glutathione 1.9 L-Citrulline-d7 Pos 308 179 18 12 HMDB00125 124886 C00051 
Glyceric acid 1.33 Alanine-d4 Pos 251 145 25 18 HMDB00139 439194 C00258 
Glycerol 1.05 Glucose-d7 Neg 93 57 20 8 HMDB00131 753 C00116 
Glycine 0.95 Alanine-d4 Pos 76 30 19 12 HMDB00123 750 C00037 
Glycolic acid 2.13 D-Fructose(2-13C) Pos 77 51 57 14 HMDB00115 757 C00160 
Glycoursodeoxycho
lic acid 6.87 
D-Fructose(2-
13C) Neg 448 74 72 36 HMDB00708 12310288 NA 
Guanine 0.86 Valine-d8 Pos 152 135 20 20 HMDB00132 764 C00242 
Guanosine 1.5 Guanosine-15N5 Neg 282 
149.












15N5 Neg 522 
158.
83 46 28 HMDB01273 6830 C00044 
Homocitrulline 1.05 Ornithine-d6 Pos 190 127 12 16 HMDB00679 65072 C02427 
Homo-arginine 3.37 D-Fructose(2-13C) Pos 189 144 25 15 HMDB00670 9085 C01924 
Homovanillic acid 4.34 Alanine-d1 Pos 183 94 18 26 HMDB00118 1738 C05582 
Hydroxykynurenine 1.22 Methionine-d3 Neg 223 206 28 7 HMDB00732 89 C02794 
Hypoxanthine 1.15 D-Fructose(2-13C) Neg 135 92 44 18 HMDB00157 790 C00262 
Indoleacetic acid 5.86 Methyl malonate-d3 Pos 176 103 34 30 HMDB00197 802 C00954 
Inosine 1.41 Inosine-15N4 Neg 267 134.93 44 26 HMDB00195 6021 C00294 
Inosine diphosphate 4.39 Inosine-15N4 Neg 427 134.92 50 22 HMDB03335 644173 C00104 




13C) Neg 245 79 50 25 HMDB01347 1195 C00129 
Isoxanthopterin 1.38 D-Fructose(2-13C) Neg 178 136 14 30 HMDB00704 10729 C03975 
Itaconic acid 4.07 D-Fructose(2-13C) Neg 129 85 22 12 HMDB02092 811 C00490 
L-Acetylcarnitine 1.26 Carnitine-d9 Pos 204 85 20 21 HMDB00201 7045767 C02571 
L-Alloisoleucine 2 Leucine-d3 Pos 132 69 20 18 HMDB00557 99288 C21096 
L-Arginine 0.88 Arginine-d7 Pos 175 70 32 20 HMDB00517 6322 C00062 
L-Asparagine 2.01 Arginine-d7 Pos 133 87 26 8 HMDB00168 6267 C00152 
L-Carnitine 1.14 Carnitine-d9 Pos 162 85 15 11 HMDB00062 2724480 C15025 
L-Cystathionine 0.91 Ornithine-d6 Neg 221 134 30 12 HMDB00099 439258 C02291 
L-Cystine 3.37 Ornithine-d6 Pos 241 109 32 20 HMDB00192 67678 C00491 
L-Dihydroorotic 
acid 2.75 Ornithine-d6 Neg 157 114 34 18 HMDB02923 439216 C00337 
L-Glutamine 0.84 Glutamate-d5 Pos 147 84 22 16 HMDB00641 5961 C00064 
L-Histidine 0.86 Leucine-d3 Pos 83 83 26 22 HMDB00177 6274 C00135 
L-Homoserine 1.1 Leucine-d3 Neg 118 100 30 8 HMDB00719 12647 C00263 
L-Isoleucine 2.01 Leucine-d3 Pos 132 86 28 14 HMDB00172 6306 C00407 
Lithium 
acetoacetate 1.97 Alanine-d4 Pos 109 65 30 13 HMDB0000060 96 C00164 
L-Kynurenine 1.89 D-Fructose(2-13C) Neg 207 144 25 17 HMDB00684 161166 C00328 
L-Lactic acid 2.73 Alanine-d4 Pos 89 43 30 12 HMDB00190 107689 C00186 




L-Lysine 0.88 Ornithine-d6 Pos 147 84 26 26 HMDB00182 5962 C00047 
L-Methionine 1.62 Methionine-d3 Pos 150 56 22 16 HMDB00696 6137 C00073 
L-Monapterin 1.07 D-Fructose(2-13C) Neg 252 
191.
95 34 16 HMDB0000877 440842 NA 
L-Phenylalanine 2.85 Phenylalanine-d5 Pos 166 103 24 28 HMDB00159 6140 C00079 
L-Proline 0.9 Alanine-d4 Pos 116 71 22 20 HMDB00162 145742 C00148 
L-Ribulose 1.03 Alanine-d4 Neg 149 89 20 7 HMDB03371 439204 C00310 
L-Serine 0.95 Ornithine-d6 Neg 104 74 27 11 HMDB00187 5951 C00065 
L-Sorbose 0.98 Alanine-d4 Neg 179 89 72 8 HMDB01266 441484 C08356 
L-threonine 0.98 Tyrosine-d4 Pos 120 74 24 16 HMDB00167 6288 C00188 
L-Tyrosine 2.05 Tyrosine-d4 Pos 182 91 24 26 HMDB00158 6057 C00082 
L-Valine 1.36 Valine-d8 Pos 118 72 24 18 HMDB00883 6287 C00183 
Malic acid 4 Methyl malonate-d3 Neg 133 71 24 14 HMDB00744 525 C00711 
Malonic acid 3.89 Methyl malonate-d3 Neg 103 59 20 10 HMDB00691 867 C00383 
Mannitol 0.93 Glucose-d7 Neg 181 89 30 12 HMDB00765 6251 C00392 




C13 Pos 227 97 26 16 HMDB01343 439400 NA 
Myoinositol 2.36 Glucose-d7 Pos 181 109 18 10 HMDB00211 892 C00137 
N-Acetylspermine 0.95 Glucose-d7 Pos 245 99 25 22 HMDB01186 916 C02567 
N-Acetyl-D-








1.03 Glucose-d7 Pos 221 126 24 17 HMDB01129 11096158 C00645 
N-Acetylneuraminic 
acid (NANA, Sialic 
acid) 
2.63 D-Fructose(2-13C) Neg 308 87 22 8 HMDB00230 445063 C19910 








C13 Neg 742 
619.
9 28 18 HMDB00217 5886 C00006 
Neopterin 1.07 D-Fructose(2-13C) Neg 252 192 30 15 HMDB00845 4455 C05926 
Niacinamide 2.39 Ornithine-d6 Pos 124 81 6 20 HMDB01406 936 C00153 
Nicotinamide 
ribotide 6.3 Ornithine-d6 Pos 335 123 30 22 HMDB00229 14180 C00455 
Nicotinic acid 6.29 Ornithine-d6 Neg 122 78 25 15 HMDB01488 938 C00253 
Nicotinic acid 
mononucleotide 6.26 Ornithine-d6 Pos 336 125 42 22 HMDB01132 53477721 C01185 
O-phosphoethanol 
amine 1.97 Alanine-d4 Pos 142 81 26 20 HMDB00224 1015 C00346 
Ornithine 0.9 Ornithine-d6 Pos 134 71 18 14 HMDB00214 6262 C00077 
Orotic acid 3.02 Ornithine-d6 Neg 155 111 2 14 HMDB00226 967 C00295 
Orotidine-5'-
monophosphate 4.41 Ornithine-d6 Neg 367 79 14 14 HMDB00218 160617 C01103 
O-Succinyl-L-
homoserine 0.96 Alanine-d4 Neg 218 117 30 11 NA 439406 C01118 
Oxalacetic acid 1.2 D-Fructose(2-13C) Neg 133 23 
17
0 20 HMDB00223 970 C00036 
Oxalic acid 6.13 Citric acid-d4 Neg 89 61 18 4 HMDB02329 971 C00209 
Oxidized 




Oxoglutaric acid 0.81 Citric acid-d4 Pos 147 84 25 15 HMDB00208 51 C00026 
Pantothenic acid 3.07 Glucose-d7 Pos 239 128 30 20 HMDB00210 988 C00864 
Phenylpyruvic acid 4.7 Glucose-d7 Neg 163 91 20 15 HMDB00205 997 C00166 
Phosphoserine 5.9 Ornithine-d6 Neg 186 88 44 26 HMDB00272 68841 C01005 
Pipecolic acid 1.77 D-Fructose(2-13C) Pos 130 84 10 10 HMDB00070 849 C00408 
Porphobilinogen 2.3 D-Fructose(2-13C) Neg 226 26 
17
0 52 HMDB00245 1021 C00931 
Progesterone 9.63 Phenylalanine-d5 Pos 315 109 44 30 HMDB01830 5994 C00410 
Pterin 1.38 D-Fructose(2-13C) Neg 162 119 30 15 HMDB00802 73000 C00715 








13C) Neg 246 97 27 10 HMDB01491 1051 C00018 
Raffinose 1.07 Methionine-d3 Pos 505 163 25 20 HMDB03213 10542 C00492 
Ribitol 0.96 Glucose-d7 Neg 151 89 24 10 HMDB00508 NA C00474 
Saccharopine 1.07 Alanine-d4 Pos 277 84 111 20 HMDB00279 160556 C00762 




13C) Neg 289 97 50 12 HMDB0001068 165007 C05382 
Sepiapterin 2.35 D-Fructose(2-13C) Neg 236 
163.
99 44 18 HMDB00238 65253 C00835 
Sodium 4-methyl-2-




1 Glucose-d7 Pos 
472.




13C) Pos 127 84 30 12 HMDB0000336 87 C01188 
Sorbitol 1.02 D-Fructose(2-13C) Neg 181 101 32 10 HMDB00247 5780 C00794 
Spermine 0.73 Alanine-d4 Pos 203 129 20 18 HMDB01256 1103 C00750 
Sphingosine 9.58 Alanine-d4 Pos 299 252 12 15 HMDB00252 5353955 C00319 
S-Sulfocysteine 2.78 D-Fructose(2-13C) Neg 200 81 25 16 HMDB00731 115015 C05824 
Succinic acid 4.05 D-Fructose(2-13C) Neg 117 73 30 15 HMDB00254 1110 C00042 
Taurine 0.95 Ornithine-d6 Neg 124 80 30 18 HMDB00251 1123 C00245 
Taurodeoxycholic 
acid 9.48 Glucose-d7 Pos 522 147 46 28 HMDB00896 2733768 C05463 
Thiamine 3.16 Methionine-d3 Pos 266 77 40 18 HMDB00235 1130 C00378 
Thymidine 2.1 D-Fructose(2-13C) Neg 241 42 30 20 HMDB00273 5789 C00214 
Thymine 1.46 Adenosine C13 Neg 125 42 26 14 HMDB00262 1135 C00178 
Tryptophanol 1.3 Adenosine C13 Neg 189 129 30 15 HMDB03447 10685 C00955 




C13 Neg 131 88 18 16 HMDB00026 111 C02642 




4.23 Adenosine C13 Neg 606 282 30 28 HMDB00290 445675 C00043 
Uridine-5′-
diphospho galactose 2.18 
Adenosine 
C13 Pos 611 449 
10




C13 Neg 403 
158.




C13 Neg 323 
96.8





(Abbrevations: Internal Standard, Neg-Negative, Pos-Positive)  
  
Uridine-diphospo- 
glucuronic acid 5.34 
Adenosine 
C13 Neg 579 403 
17
0 25 HMDB00935 17473 C00167 
Xanthine 1.23 Adenosine C13 Neg 151 
79.8




2.83 Adenosine C13 Neg 662 
539 




2.6 NA Pos 271 154 150 15 NA NA NA 
*Adenosine C13 2.31 NA Neg 267 134 14 14 NA NA NA 
*Alanine-d1 0.98 NA Pos 91 45 28 10 NA NA NA 
*Alanine-d4 0.95 NA Pos 94 78 18 6 NA NA NA 
*Arginine-d7 0.91 NA Pos 182 77 32 20 NA NA NA 
*Aspartate-d3 1.03 NA Pos 137 77 58 18 NA NA NA 
*C10-Carnitine-d3 8.39 NA Pos 319 85 18 22 NA NA NA 
*C12-Carnitine-d3 9.71 NA Pos 247 85 18 20 NA NA NA 
*C14-Carnitine-d3 10.89 NA Pos 375 85 18 24 NA NA NA 
*C16-Carnitine-d3 10.9 NA Pos 403 85 18 22 NA NA NA 
*C18-Carnitine-d3 10.18 NA Pos 431 85 52 24 NA NA NA 
*C2-Carnitine-d3 1.26 NA Pos 207 85 28 18 NA NA NA 
*C3-Carnitine-d3 2.46 NA Pos 221 85 30 18 NA NA NA 
*C4-Carnitine-d3 3.1 NA Pos 235 85 28 20 NA NA NA 
*C5-Carnitine-d9 3.86 NA Pos 255 85 28 18 NA NA NA 
*C6-Carnitine-d3 4.93 NA Pos 263 85 34 20 NA NA NA 
*C8-Carnitine-d3 6.8 NA Pos 291 85 16 20 NA NA NA 
*Carnitine-d9 2.78 NA Pos 171 106 24 24 NA NA NA 
*Citric acid-d4 4.51 NA Neg 195 132 24 12 NA NA NA 
*Citrulline-d2 1.03 NA Pos 178 72 22 20 NA NA NA 
*D-Fructose(2-13C) 0.99 NA Neg 180 90 25 10 NA NA NA 
*Glucose-d7 1.04 NA Neg 186 124 50 15 NA NA NA 
*Glutamate-d5 0.99 NA Pos 153 88 22 14 NA NA NA 
*Guanosine-15N5 1.48 NA Neg 155 137 50 15 NA NA NA 
*Inosine-15N4 1.35 NA Neg 271 139 30 25 NA NA NA 
*L-Citrulline-d7 1.04 NA Neg 181 138 30 15 NA NA NA 
*Leucine-d3 1.92 NA Pos 135 89 22 24 NA NA NA 
*Methionine-d3 0.99 NA Pos 153 88 22 16 NA NA NA 
*Methyl malonate-
d3 1.07 NA Pos 120 76 30 8 NA NA NA 
*Ornithine-d6 0.83 NA Pos 139 76 18 16 NA NA NA 
*Phenylalanine-d5 2.82 NA Pos 171 103 22 26 NA NA NA 
*Tyrosine-d4 5.33 NA Pos 186 57 76 24 NA NA NA 




Table A1.3: Metabolites Linearity and lower limit of quantification 
Compound ID 
Linearity LLOQ 
nM Intercept Slope R2 
2,3-Pyridinedicarboxylic acid 127.69 1.43 0.993 5 
21-Deoxycortisol 22.62 32.587 0.995 750 
2-Hydroxyglutaric acid -68.22 12.65 0.996 750 
2-Isopropylmalic acid -19.92 4.259 0.996 5 
2-Ketobutyric acid 49.67 0.859 0.996 1 
2-Phosphoglyceric acid 29.36 0.147 0.995 25 
3,4-Dihydroxyphenylacetic acid -45.61 18.622 0.991 25 
3-Hydroxyanthranilic acid 35.88 6.877 0.994 750 
3-Methylglutaric acid 48.22 0.926 0.991 5 
3-Methylhistidine 420.12 193.03 0.995 1 
3-Phosphoglyceric acid 0 29.06 0.995 750 
4,6-Dioxoheptanoic acid 14.319 12.16 0.992 5 
4-Hydroxy-L-glutamic acid 0 28.74 0.995 1 
4-Hydroxyphenylpyruvic acid 0 0.822 0.991 750 
4-Hydroxyproline 52.34 28.65 0.995 25 
5,6-Dihydro-5-methyluracil 0 9.547 0.994 750 
5,6-Dihydrouridine 68.75 42.082 0.991 500 
5-Aminolevulinic acid 0 0.742 0.992 250 
5-Hydroxyindoleacetic acid 0 0.404 0.993 25 
5-Hydroxylysine 134.22 440.39 0.997 1 
6-Phosphogluconic acid -120.33 4.666 0.995 5 
Acetylcarnitine -162.33 33.15 0.995 750 
Acetyl-CoA 0 0.544 0.992 750 
Acetylspermine 12.35 1.36 0.995 1 
Adenine -8.053 0.619 0.996 10 
Adenosine -0.6814 0.102 0.995 5 
Adenosine diphosphate 262.44 0.57 0.996 1 
Adenosine monophosphate 0.488 0.201 0.992 10 
Adenosine triphosphate -1.846 3.74 0.987 25 
Adenylsuccinic acid -2.572 0.197 0.995 5 
Adonitol 0 0.625 0.992 1 
Alanine 52.65 27.48 0.997 1 
Aldosterone 13.66 0.855 0.992 1 
Aminoadipic acid 53.976 4.428 0.991 1 
Arabinose 16.04 1.285 0.992 1 
Argininosuccinic acid 293.27 0.182 0.996 1 
Betaine 62.33 38.77 0.994 1 
Biopterin 19.329 1.107 0.996 1 
Biotin 72.55 26.56 0.998 500 
Cholic acid 82.22 0.284 0.998 750 




Coenzyme A -92.33 6.48 0.991 750 
Corticosterone 62.22 7.39 0.991 1 
Cortisone 40.55 34.74 0.996 5 
Creatinine 28.33 60.1 0.992 25 
Cyclic AMP 23.45 0.11 0.995 10 
Cyclic GMP 28.62 0.29 0.998 100 
Cysteine-S-sulfate -30.55 3.168 0.995 1 
Cytidine -11.07 0.253 0.996 50 
Cytidine monophosphate -19.75 1.14 0.995 25 
Cytidine monophosphate-N-acetylneuraminic acid 62.22 1.14 0.995 750 
Cytidine triphosphate -67.05 7.17 0.993 1 
Cytosine 26.65 4.37 0.995 1 
Cytosine diphosphate 18.12 3.76 0.991 1 
D-Arabitol 16.04 1.0002 0.99 1 
D-Aspartic acid 293.27 7.934 0.995 1 
Deoxyadenosine 102.36 0.196 0.996 1 
Deoxyadenosine monophosphate 125.35 0.246 0.988 750 
Deoxycytidine 162.35 0.246 0.996 1 
Deoxyguanosine 55.26 0.684 0.996 750 
Deoxyinosine 75.22 0.148 0.994 5 
Deoxyribose-5-phosphate 162.14 0.244 0.995 10 
Deoxyuridine 62.48 1.688 0.995 500 
D-Erythrose-4-phosphate -14.54 0.652 0.996 25 
Dexamethasone 0 26.54 0.992 1 
Dextrose 0 1.668 0.992 1 
D-Fructose 0 0.181 0.991 10 
D-Glucose 52.77 0.578 0.996 750 
D-Glucuronic acid -4.053 0.197 0.992 1 
D-Glutamic acid 104.22 235.47 0.991 1 
Dihydrouracil 0 2.465 0.995 750 
Dihydroxyacetone phosphate -2.29 1.028 0.996 5 
Dimethylallylpyrophosphate (DMAPP) 88.25 0.216 0.995 5 
DL-Homocystine 25.55 94.23 0.993 1 
Dopamine 35.87 1.449 0.99 5 
D-Threitol 65.01 16.23 0.992 1 
D-Tryptophan 68.47 204.06 0.996 750 
Dulcitol 24.68 0.682 0.995 1 
D-Xylitol 68.22 4.98 0.993 1 
Estradiol 104.22 1.41 0.991 1 
Estriol 509.18 1.48 0.991 1 
Estrone 62.85 5.306 0.992 1 
Ethanolamine 106.28 17.09 0.995 1 
Fructose-1,6-bisphosphate 10.32 0.525 0.986 1 




Fumaric acid 76.67 0.112 0.992 25 
Galactose-1-phosphate 112.69 2.412 0.993 25 
Gamma-Amino Butyric acid (GABA) 394.77 7.02 0.995 1 
Gluconolactone 10.554 0.264 0.991 25 
Glucosamine-6-phosphate 0 25.86 0.991 25 
Glucose-6-phosphate 45.05 2.409 0.994 1 
Glutaric acid 0 0.114 0.994 25 
Glutathione 68.11 0.855 0.994 750 
Glyceric acid 108.22 6.847 0.995 25 
Glycerol 107.69 82.56 0.996 25 
Glycine 104.57 7.7 0.996 1 
Glycolic acid 807.06 28.17 0.994 750 
Glycoursodeoxycholic acid 0 38.62 0.992 5 
Guanine 196.52 12.74 0.986 5 
Guanosine 1.524 0.47 0.994 750 
Guanosine diphosphate 11.61 0.318 0.995 1 
Guanosine monophosphate 11.69 1.24 0.993 1 
Guanosine triphosphate 22.62 0.307 0.993 1 
Homo-arginine 63.66 2.62 0.991 5 
Homocitrulline 0 45.62 0.99 1 
Homovanillic acid 92.77 48.22 0.991 1 
Hydroxykynurenine 65.55 0.442 0.991 25 
Hypoxanthine -5.242 0.399 0.995 1 
Indoleacetic acid 12.58 52.664 0.991 5 
Inosine -14.27 0.726 0.997 5 
Inosine diphosphate 11.07 0.59 0.997 1 
Inosine triphosphate 0 0.133 0.991 500 
Isopentenyl pyrophosphate -100.24 28.06 0.995 1 
Isoxanthopterin 68.49 0.832 0.995 1 
Itaconic (3-methylsuccinic) acid 114.22 23.62 0.992 1 
L-Alloisoleucine 128.66 75.06 0.991 750 
L-Arginine 163.44 276.08 0.995 1 
L-Asparagine 133.9 253.36 0.996 1 
L-Carnitine 50.72 10.65 0.993 1 
L-Cystathionine 23.444 0.84 0.995 1 
L-Cystine 72.94 0.303 0.997 1 
L-Dihydroorotic acid 0 1.968 0.993 500 
L-Galactono-1,4-lactone 0 5.544 0.996 1 
L-Glutamine 274.06 12.409 0.989 1 
L-Histidine 152.73 102.69 0.995 1 
L-Homoserine 47.68 11.822 0.998 1 
L-Isoleucine 162.22 1798 0.995 1 
Lithium acetoacetate 89.26 0.745 0.995 25 




L-Lactic acid 138.22 0.826 0.992 750 
L-Leucine 132.66 200.56 0.995 1 
L-Lysine 404.3 138.003 0.994 1 
L-Methionine 130.22 353.88 0.997 1 
L-Phenylalanine 102.33 155.1 0.995 1 
L-Proline 0 33.65 0.995 750 
L-Ribulose 74.44 1.852 0.997 750 
L-Serine 27.98 2.01 0.996 1 
L-Sorbose 52.55 0.122 0.994 1 
L-Threonine 125.9 44.43 0.993 1 
L-Tyrosine 152.3 335.44 0.992 1 
L-Valine 182.6 471.002 0.995 1 
Malic acid 0 0.249 0.993 750 
Malonic acid 296.366 2.208 0.992 1 
Maltose 182.55 0.266 0.997 1 
Mannitol 162.44 1.586 0.992 750 
Mannose 0 3.65 0.992 250 
Mannose-1-phosphate -5.391 0.622 0.996 1 
Melibiose 92.66 2.46 0.997 25 
Methylmalonic acid 102.44 6.844 0.998 1 
Mevalonic acid 3-phosphate  0 56.242 0.996 1 
Mevalonic acid-5P 0 3.648 0.992 1 
Monapterin -8.017 1.06 0.996 5 
Myoinositol -18.25 0.284 0.996 1 
N-Acetyl-D-glucosamine -193.77 0.1109 0.996 5 
N-Acetyl-D-glucosamine-6-phosphate -120.66 0.956 0.994 750 
N-Acetylmannosamine 0 52.66 0.999 500 
N-Acetylneuraminic acid (NANA, Sialic acid) 282.36 2.33 0.993 25 
N-Acetylputrescine 62.33 152.6 0.998 1 
NADH -13.061 0.104 0.995 10 
NADP 1.733 0.891 0.997 25 
Neopterin -0.739 1.012 0.995 1 
Niacinamide 152.56 12.655 0.995 750 
Nicotinamide adenine dinucleotide(NAD) 0 0.065 0.996 500 
Nicotinamide ribotide 418.45 32.087 0.991 25 
Nicotinic acid 22.37 1.182 0.992 750 
Nicotinic acid mononucleotide 22.299 28.066 0.996 25 
O-Phosphoethanolamine -151.22 4.15 0.993 750 
Ornithine 536.74 25.97 0.993 1 
Orotic acid 248.35 1.295 0.994 1 
Orotidine-5'-monophosphate 0 1.855 0.992 750 
O-Succinyl-L-homoserine 188.2 4.855 0.995 25 
Oxalacetic acid 162.44 0.283 0.996 750 




Oxidized glutathione 90.5 0.543 0.994 750 
Oxoglutaric acid 56.77 0.648 0.996 750 
Pantothenic acid 62.77 64.05 0.996 500 
Phenylpyruvic acid 103.22 5.844 0.986 750 
Phosphoenolpyruvic acid -21.919 0.14 0.993 25 
Phosphoserine 82.77 12.082 0.997 25 
Pipecolic acid -26.94 0.088 0.993 1 
Porphobilinogen 68.48 0.454 0.995 750 
Progesterone 46.55 23.12 0.995 5 
Pterin -29.96 1.434 0.997 1 
Putrescine 123.61 9.221 0.99 25 
Pyridoxal  Hydrochloride -1.318 26.12 0.994 5 
Pyridoxal-5'-phosphate 0 0.576 0.992 5 
Raffinose 82.44 1.285 0.998 25 
Ribitol 75.55 8.64 0.992 250 
Ribose-5-phosphate 132.44 0.511 0.995 5 
Saccharopine -18.26 222.08 0.995 750 
Sarcosine 62.87 8.655 0.996 750 
Sedoheptulose-7-phosphate 82.55 1.74 0.995 5 
Sepiapterin 112.5 0.872 0.993 25 
Sodium 4-methyl-2-oxovalerate 0 0 0.999 750 
Sodium glycodeoxycholate 18.62 33.64 0.996 25 
Sodium β-hydroxyisobutyrate 0 66.5 0.998 750 
Sorbitol 12.82 0.848 0.991 5 
Spermine 45.514 4.11 0.992 25 
Sphingosine 62.88 8.062 0.995 750 
S-Sulfocysteine -22.96 2.42 0.996 1 
Succinic acid 0 25.62 0.992 750 
Taurine 67.82 3.79 0.996 1 
Taurodeoxycholic acid -18.22 62.08 0.995 750 
Tauroursodeoxycholic acid 56.78 0.845 0.996 1 
Thiamine -1.734 0.181 0.994 1 
Thymidine 13.507 0.326 0.992 1 
Thymine -18.68 0.413 0.995 25 
Tryptophanol -59.22 32.082 0.991 750 
Uracil -1.824 1.59 0.995 25 
Ureidopropionic acid 142.55 0.395 0.993 25 
Uridine 1.381 0.48 0.995 5 
Uridine diphosphate-N-acetylglucosamine 0 5.82 0.996 750 
Uridine diphospho-glucuronic acid -13.551 0.457 0.992 1 
Uridine-5′-diphosphogalactose 92.69 0.955 0.996 750 
Uridine-5'-diphosphate -1.882 1.41 0.995 1 
Uridine-5'-monophosphate -4.728 1.386 0.996 5 






Table A1.4: Metabolites intraday and interday precision and accuracy 
Name 











750 250 25 750 250 25 750 250 25 750 250 25 
17 α-Hydroxypregnenolone 12.5 11.2 8.2 115 96.5 118.8 14.6 14.3 9.2 
105.
4 95.7 102.2 
17 α-
Hydroxyprogesterone 2.8 9.5 11.2 87.5 
115.




0.8 13.4 17.8 101 86.6 113.2 1.3 11.0 16.5 
103.
9 89.0 106.5 
































2-Isopropylmalic acid 0.6 15.5 6.4 101 87.5 93.6 0.9 18.9 8.8 97.0 91.1 108.8 
2-Ketobutyric acid 5.8 15.9 20.9 94.2 110.9 
120.
2 3.3 14.5 17.5 
106.
7 118.5 113.5 

















2-Phosphoglyceric acid 2.6 0.5 7.2 98.2 115.5 
105.
2 3.9 0.9 9.1 
105.

























3-Methylglutaric acid 11.6 9.8 20.3 103 119.2 86.4 8.3 15.4 17.7 
120.
7 94.8 97.7 
3-Methylhistidine 18 20.2 13.4 112 102.2 86.6 19.1 19.3 18.2 
108.
9 106.7 91.8 

















4,6-Dioxoheptanoic acid 0.8 12.6 3.4 99.2 107.4 96.6 1.4 14.9 5.4 95.6 118.1 95.4 
4-Hydroxy-L-glutamic 
acid 13.8 13.7 2.8 86.2 
116.





















4-Hydroxyproline 4.9 14.7 1.6 95.1 114.7 99.4 4.2 18.5 1.2 
104.



















5,6-Dihydrouridine 17.2 11.2 5.8 93.6 109.6 94.6 20.2 16.5 7.8 
112.
3 111.3 100.6 
5-Aminolevulinic acid 12.6 2.6 BLLOQ 116 105 
BLL
OQ 11.3 3.2 
BLLO























5-Hydroxylysine 12.8 20.1 15.1 87.2 102.1 88.9 14.4 17.5 19.3 88.6 92.5 93.7 
6-Phosphogluconic acid 4.8 15.2 16.6 119 98.2 119.6 6.2 17.3 18.9 
107.
5 118.4 103.2 















Adenine 6.5 10.2 4.2 85.6 102 98.2 5.5 12.5 6.2 94.5 117.5 103.8 
Adenosine 14.1 12.1 4.1 103 103.7 119 19.3 15.2 5.5 90.7 120.2 100.5 
Adenosine diphosphate 16.5 17.4 1.7 104 117.4 
105.
7 14.2 18.5 3.2 94.2 101.5 109.2 
Adenosine 
monophosphate 11 4.6 15.4 120 95.4 
115.
4 10.3 6.9 19.4 
110.
3 106.9 119.4 




Adenylsuccinic acid 12.5 13 20.1 108 113 104.1 11.4 19.6 23.6 
118.
6 110.4 103.6 
Adonitol 2.8 8.5 5.6 98.2 102.8 93.1 3.2 9.8 6.6 
108.
2 105.3 99.1 
Alanine 5.7 12.4 10.5 106 112.4 
120.
5 7.3 11.6 9.9 
116.
7 120.6 120.1 
Aldosterone 16.5 6.2 7.2 94.5 85.2 118.5 17.6 8.8 6.5 
102.
4 91.2 113.5 
Aminoadipic acid 3.1 3.2 12.8 96.9 96.8 112.8 4.1 5.0 16.8 93.9 90.0 117.2 
Arabinose 9.2 6.8 5.7 98.5 112.5 88.5 11.0 7.9 7.5 
102.
0 107.9 120.5 
Argininosuccinic acid 12.5 13 9.1 118 113 94.1 17.6 11.5 17.7 112.4 108.5 105.3 
Betaine 6.5 16.7 12 107 116.7 88 8.1 16.4 10.1 
116.
9 107.6 99.9 
Biopterin 6.4 18.3 17.5 106 111.7 
112.
5 8.8 19.3 18.2 
101.
8 102.7 99.8 
Biotin 16.8 4.8 BLLOQ 95.2 88.5 
BLL






















Citrulline 13.2 16.6 11.1 103 103.4 98.9 18.2 15.3 12.9 
108.
2 95.3 88.9 

















Corticosterone 17.1 14.7 15.2 103 88.3 114.8 20.8 18.2 18.3 
117.
2 98.8 104.7 
Cortisone 10.2 11.8 12.9 89.2 91.8 94.9 11.4 14.9 18.8 93.6 102.1 96.2 
Creatinine 12.3 15.4 15.3 87.7 94.6 85.3 15.8 16.6 18.6 94.2 103.4 102.6 
Cyclic AMP 17.9 15.7 12 88.5 102.5 
101.
2 19.5 18.2 14.6 87.5 95.8 117.4 
Cyclic GMP 5.2 9.6 13 94.8 89.4 113 8.8 11.6 18.3 108.8 111.6 108.3 
Cysteine-S-sulfate 2.1 10.5 11.9 97.9 89.5 88.1 3.3 15.4 13.6 92.7 105.4 103.6 
Cytidine 10.2 15 11 89.8 95 111 12.5 14.4 13.0 109.5 115.6 120.0 
Cytidine 

























Cytidine triphosphate 2.2 4.1 11 97.8 95.9 109 3.3 6.8 13.3 101.7 117.2 120.3 
Cytosine 19.3 12.4 13.3 119 85.4 93.3 20.0 11.2 15.1 120.0 98.8 104.9 
Cytosine diphosphate 7.6 6.8 6.5 108 93.2 103.5 9.6 10.8 8.0 
112.
4 87.2 92.0 
D-Arabitol 15.8 10.2 16.8 94.2 119.8 
106.
8 18.2 11.9 19.3 
113.
2 88.1 109.3 
D-Aspartic acid 8.2 11.1 10 91.8 108.9 90 11.5 17.9 14.7 
108.
5 112.1 114.7 
D-Cytosine 













Deoxyadenosine 13 13.4 16 92.7 113.5 96.8 18.0 14.6 15.3 
112.





















Deoxycytidine 8.6 20.1 6.5 91.4 120.1 
106.
5 9.9 18.5 9.2 
100.
1 116.5 119.2 















Deoxyinosine 14.1 12.1 4.1 85.9 85.9 120.1 17.8 11.2 10.5 92.2 88.8 112.5 
Deoxyribose-5-
phosphate 13.9 18.1 13.5 106 
111.
9 86.5 18.8 20.1 17.3 88.8 97.1 87.3 
Deoxyribose-5-
phosphate 13.9 18.1 13.5 116 
111.
9 96.5 12.3 20.1 15.6 
119.
3 115.2 100.3 





















phosphate 4 6 
Dexamethasone 6.8 4.2 6.2 88.8 99.2 95.5 8.8 5.6 7.2 98.3 105.3 115.6 
Dextrose 5.8 16.2 11.2 88.5 119.2 85.2 7.7 18.2 15.3 87.6 120.3 87.3 
D-Fructose 8.7 16.2 4.8 109 112 98.2 9.4 17.9 6.5 100.6 102.1 93.5 

















D-Glucuronic acid 15.3 9 7.7 115 86 101.7 19.5 11.3 8.3 
116.
8 99.2 105.7 
D-Glutamic acid 12.5 12.1 3.6 97.5 92.1 103.6 10.3 18.1 4.2 88.6 102.3 114.6 






















2 14.8 5.6 20.3 96.5 113.2 120.4 
Dimethylallylpyrophosp




4 9.2 10.5 20.8 
104.
3 118.5 120.4 
DL-Homocystine 9.6 14.6 4.8 90.4 104.6 
104.
8 11.2 15.2 5.6 99.5 98.2 114.8 
D-Maltose 16.8 11 20 113 99.2 98.5 19.2 14.3 20.4 118.3 103.0 114.5 
D-Mannose 8.2 16.2 BLLOQ 85.4 96.2 
BLL








phosphate 12 6.4 6.8 108 93.6 
106.
8 15.2 7.8 9.2 89.8 113.5 116.9 
Dopamine 8.7 10 16.2 91.3 100 96.2 7.2 12.3 18.4 95.3 107.3 111.4 
D-Ribose-5-phosphate 6.9 18.1 13.5 96.1 111.9 86.5 9.2 20.1 15.6 
112.
3 98.6 99.6 
D-Threitol 0.3 4.2 18.5 99.7 104.2 
115.
5 0.4 5.2 20.3 
104.
5 114.5 119.5 

















Dulcitol 14.2 5.3 5.2 106 118.2 
101.
2 17.3 6.8 7.2 
116.
2 120.3 116.2 
D-Xylitol 15.5 13.6 13.1 116 89.6 93.1 18.2 19.2 14.3 117.2 98.5 99.3 

















Estradiol 13.1 12.6 14.6 96.9 103.4 
104.
6 14.8 16.2 18.6 
108.
6 112.3 120.3 
Estriol 5.8 4.2 6.2 88.5 89.2 102.5 7.2 5.8 9.2 91.5 98.5 112.5 
Estrone 0.1 0.9 10.6 100 99.1 90.6 0.6 1.2 12.3 105.3 105.2 88.3 
Ethanolamine 17.5 18.1 11.4 103 102.9 86.4 20.2 19.3 16.4 
116.
5 94.2 106.4 
Fructose-1,6-
bisphosphate 14.3 18.9 1.4 95.7 
101.
1 98.6 20.3 12.3 1.9 
105.
5 98.1 103.6 
Fructose-6-phosphate 6.5 8.1 12.4 93.5 108.1 87.6 9.9 10.3 15.5 
105.
3 112.1 109.5 











Galactose-1-phosphate 2.2 8.8 12.7 97.8 108.8 
107.
3 3.5 9.2 14.8 
107.
2 118.5 120.3 
Gamma-aminobutyric 
acid (GABA) 10.1 17.4 14.6 110 92.6 
112.
6 18.3 20.3 12.3 88.3 102.4 119.3 
Gluconolactone 13.4 11.7 15.7 117 118.3 
105.
7 16.4 12.4 19.2 
118.
3 120.5 115.7 
Glucosamine-6-
phosphate 5.8 18.2 20.2 102 
112.
2 91.2 7.2 20.2 18.2 
114.
2 106.9 119.8 
Glucose-6-phosphate 2.1 10.9 19.3 97.9 110.9 
109.
3 2.3 12.9 17.5 
115.
7 87.1 117.5 
Glutaric acid 1.9 12.5 13.5 102 117.5 
103.
5 1.2 14.8 16.2 
111.
8 120.3 113.5 















Glyceric acid 7.9 14.5 15.9 92.1 85.5 86.1 10.8 10.3 16.5 106.2 110.3 96.5 
Glycerol 12.6 6.7 5.4 97.4 116.7 96.4 9.2 10.2 8.4 
107.




Glycine 12.2 18.6 17.9 112 118.6 
120.
1 18.5 14.4 16.4 91.5 112.6 118.4 


















acid 18.2 16.3 19.4 109 95.7 98.1 20.8 19.4 20.7 
118.
0 109.0 102.7 
Guanine 17 12.5 4 103 87.5 96 12.9 18.3 6.0 107.1 97.7 96.0 

















Guanosine diphosphate 6.2 17.9 19.6 103 93.5 96.8 9.0 19.9 15.5 104.0 91.9 108.5 
Guanosine 
monophosphate 0.2 5.2 8.9 98 103 119 0.6 7.4 12.1 
106.
0 114.2 113.1 
Guanosine triphosphate 17.3 16.5 19.8 93.2 118 120.4 18.7 17.7 17.3 97.3 102.3 117.3 
Homocitrulline 6.2 8.2 11.2 97.6 98.4 117.2 8.5 9.1 13.0 
101.
5 101.9 100.0 
Homo-L-arginine 5.1 8.9 13 94.9 91.1 113 2.7 6.9 14.8 87.3 93.1 105.8 
Homovanillic acid 13.5 13 9.2 90.5 85.8 107.5 17.0 18.6 7.8 
107.
0 91.4 115.2 
Hydroxykynurenine 11.6 17.2 6.8 102 111.1 98.2 14.2 20.3 8.8 
113.
2 109.2 100.2 
Hypoxanthine 17.4 2.8 7.4 107 102.8 92.6 20.3 3.2 9.9 
119.
2 98.2 102.4 
Indoleacetic acid 5.9 19.2 18.1 102 103.8 92.5 9.1 12.1 16.2 
120.
1 92.1 106.2 
Inosine 11.9 8.8 6.4 102 108.2 
116.
4 15.4 11.2 8.5 
105.
4 118.8 103.5 
Inosine diphosphate 0.2 11.4 13.5 100 111.4 98.5 0.3 15.2 19.2 
112.
3 102.3 105.3 
















pyrophosphate 17.9 9 8.3 92.1 109 
118.
3 20.3 11.3 9.4 
103.
2 111.4 120.4 
Isoxanthopterin 2.5 15.7 13 97.5 115.7 103 4.3 20.9 12.7 
110.
3 120.9 119.2 
Itaconic (3-
methylsuccinic) acid 14.2 18 17.2 111 103 
112.
9 19.2 20.3 19.3 
102.
3 111.4 120.2 


































L-Arginine 2.7 15.9 12.7 97.3 115.9 
102.
7 3.2 18.2 15.6 
107.
5 108.2 98.5 
L-Asparagine 8.2 1.4 14.1 91.8 101.4 
105.
9 9.9 2.3 19.3 
101.
3 111.2 115.4 
L-Carnitine 16.1 14.1 6.4 88.9 115.1 86.4 19.1 12.6 9.7 89.9 102.6 102.7 
L-Cystathionine 10.5 17.1 13.4 121 90.1 100.4 12.4 19.2 15.2 
120.
3 98.3 105.2 
L-Cystine 14.9 15.4 12.4 115 105.4 
112.
4 18.2 16.3 11.2 
119.
2 109.3 120.3 

















L-Galactono-1,4-lactone 12 16.5 5.3 88.2 106.2 112 15.2 19.2 7.2 96.2 119.3 115.3 
L-Glutamine 9.7 10.2 17.6 90.3 89.8 102.4 11.2 12.5 19.2 
102.
3 90.2 92.3 
L-Histidine 3.3 15.4 17.3 103 85.4 117.3 5.2 18.2 19.2 
113.
2 98.2 120.3 
L-Homoserine 15 19.2 2.2 98.5 109.3 101 19.2 20.2 3.6 
104.
2 112.2 104.2 
L-Isoleucine 7.4 5.3 10.5 92.6 105.3 89.5 8.4 9.6 16.5 
111.
6 107.4 93.5 
Lithium acetoacetate 14.2 3.5 5.8 104 92.5 92.5 17.9 5.6 8.9 86.1 107.4 100.1 
L-Kynurenine 11.9 7.7 15.3 88.1 107.7 
111.
3 16.9 6.7 19.6 93.1 113.3 119.6 

















L-Leucine 8.6 11.7 1.5 91.4 111.7 98.5 11.1 17.7 1.9 
108.




L-Lysine 2.2 17.3 18.2 97.8 100.7 
118.
2 3.5 19.6 20.2 
110.
5 88.4 120.2 
L-Methionine 7.3 10.2 17.7 100 90.2 117.7 8.3 15.2 17.7 
111.
7 88.8 87.7 



















































L-Serine 6.1 2.6 19.8 106 102.6 
109.
8 9.4 3.6 17.1 
108.
6 107.4 120.1 
L-Sorbose 7.5 6.2 9.8 93.8 102.4 
118.
2 9.5 8.4 11.3 
103.
4 113.4 100.4 
L-Threonine 14.6 11.5 12.3 95.4 101.5 
120.
3 20.3 16.5 9.6 88.4 111.3 119.4 
L-Tyrosine 5 18.8 10.3 95 109.8 90.3 7.5 15.3 8.3 
105.
3 113.4 89.3 
L-Valine 17.4 10.6 9.4 113 110.6 
110.
6 15.5 11.2 8.3 
102.
3 103.4 118.5 















Malonic acid 16.5 15.3 7.9 93.5 94.7 107.9 14.3 11.3 5.6 
103.
2 115.6 111.3 

















Melibiose 16.8 12.4 14.2 118 112.8 
118.
5 19.2 11.2 19.3 
104.
3 114.3 98.3 
Methylmalonic acid 6.2 5.8 4.2 108 116.8 98.2 8.5 6.7 3.4 
119.
5 103.3 86.6 
Mevalonic acid 3-
phosphate  8.2 1.2 9.2 113 88.5 
115.
5 11.2 1.4 5.0 
118.
8 98.6 115.0 
Mevalonic acid-5-
phosphate 11.2 6.8 5.2 98.7 102 97.2 13.6 7.5 4.6 
103.
6 108.5 85.4 
Monapterin 13.2 16.7 10.3 86.8 103.3 
119.
7 11.8 14.0 12.4 91.8 94.0 110.4 
Myoinositol 11.2 8.2 6.5 91.5 112.8 
101.
5 17.5 16.0 7.2 
112.
5 104.0 97.2 
N-Acetyl-D-
glucosamine 13.2 16.5 2.9 96.8 
103.





















N-Acetylmannosamine 8.2 5.2 BLLOQ 99.5 91.5 
BLL
OQ 12.4 7.9 
BLLO




acid (NANA, Sialic 
acid) 
8.6 8.8 18.5 91.4 111.2 
118.
5 6.2 7.6 17.6 89.8 100.4 107.6 
N-Acetylputrescine 8.5 13.8 5.2 100 111.2 92.5 9.3 11.3 6.4 99.2 119.2 108.3 
N-Acetylspermine 6.6 16.1 19.2 93.4 103.9 
103.
8 5.7 10.6 20.5 88.3 99.4 113.5 
NADH 11.3 12.8 20.2 98.7 107.2 
111.
2 12.7 16.4 17.2 
107.
3 113.6 117.2 
NADP 0.5 7.3 14.9 99.5 117.3 
114.
9 0.9 9.8 17.7 
107.
8 120.2 112.3 
Neopterin 4.7 14.8 15.5 95.3 115.2 
105.
5 3.6 17.5 16.9 86.4 112.5 90.1 















Nicotinamide ribotide 15.8 11.4 12.6 94.2 88.6 88.4 17.9 15.6 13.7 104.1 107.6 98.7 


















mononucleotide 8.7 13.1 16.5 89.2 
115.
6 92.5 9.9 15.4 20.0 97.7 116.3 104.0 

















Ornithine 2.1 9.9 17.9 97.9 109.9 
117.
9 3.1 11.2 13.2 
107.
9 118.8 106.8 























homoserine 16.6 9.2 4.2 103 98.8 
119.
2 13.4 11.2 5.3 99.4 102.3 109.3 





















OQ 11.4 20.3 
BLLO
Q 98.5 118.4 
BLL
OQ 

















Pantothenic acid 16.2 18.2 BLLOQ 86.5 95.4 
BLL
OQ 10.2 14.7 
BLLO
Q 89.3 105.7 
BLL
OQ 






















5 16.9 13.2 9.2 93.1 111.2 109.2 
Phosphoserine 2.8 5.2 BLLOQ 88.8 109 
BLL







Pipecolic acid 18.8 19.1 15.5 91.2 119.1 95.5 14.3 12.8 14.3 
105.
7 97.2 104.3 

















Progesterone 6.3 20.2 12.9 106 107.8 87.1 5.3 16.7 11.1 94.7 86.3 97.9 
Pterin 14.8 19.8 11.6 85.2 91.2 101.6 12.2 20.0 12.6 97.8 98.0 102.6 
Putrescine 12.5 2.6 13.1 107 102.6 
116.
9 17.9 3.0 15.7 
112.
1 96.0 104.3 
Pyridoxal  
Hydrochloride 12.8 14.6 9.2 108 115 
117.
2 10.4 11.5 7.6 99.2 112.4 107.5 
Pyridoxal-5'-phosphate 15 16.1 11.6 85 113.9 98.4 11.2 17.9 15.8 
105.
8 102.1 105.8 
Raffinose 18.2 7.9 5.6 95.2 91.2 116.5 13.4 9.2 6.2 95.6 89.4 105.7 











Saccharopine 18.8 12.3 14.3 91.2 101.7 
115.
7 19.3 18.5 18.2 
100.
7 91.5 119.8 


















phosphate 4.3 14.6 8.2 95.7 95.4 98.2 5.9 15.8 10.6 92.1 104.2 109.4 
Sepiapterin 8.2 9.2 18.2 106 118.2 102 10.0 12.3 15.0 
118.




















glycodeoxycholate 13.2 9.5 15.8 92.8 92.4 
115.
2 19.2 11.4 18.6 
112.





















Sorbitol 16.5 20.3 18.9 106 118.4 
104.
2 12.3 13.2 20.9 
112.
3 111.3 97.3 
Spermine 19.1 13.8 18.7 109 86.2 111.3 17.3 11.0 20.5 
112.
7 109.0 109.5 

















S-Sulfocysteine 20.9 13.2 11.5 121 106.8 91.5 12.2 11.1 14.2 
119.
2 86.9 114.2 

















Taurine 13.3 6.5 17.6 86.7 1000.5 92.4 12.0 8.3 20.8 98.0 108.3 103.2 


















Acid 5.2 10.3 16.2 112 85 89.5 7.0 11.5 20.2 91.0 98.5 99.8 
Thiamine 0.8 14.1 18.7 101 85.9 99.7 1.2 13.3 14.5 93.8 96.7 104.5 
Thymidine 18.9 11.2 14 109 98.8 86 16.3 14.1 16.8 103.7 85.9 113.2 
Thymine 9.5 17.4 15.3 90.5 102.6 
105.
3 5.1 18.3 11.7 
104.
























Uracil 3.4 15.7 14.1 96.6 104.3 
114.
1 5.2 19.5 11.9 
110.
2 100.5 103.9 
Ureidopropionic acid 7.3 15.2 13.9 98.7 104.8 
118.
3 10.2 19.3 10.2 
108.
2 98.3 88.4 






















12 13.9 11.2 112 106.1 
131.



















Uridine-5'-diphosphate 5.5 7.2 11 106 92.8 111 7.7 6.7 10.3 90.3 103.3 102.3 
Uridine-5'-




4 14.3 19.0 16.9 95.7 105.0 116.9 
Xanthine 7.8 18.6 19.5 92.8 102.6 
109.
5 10.8 14.5 13.6 
102.




















BLLOQ: Below limit of quantification. 




Table A1.5: Stability of QC samples (25, 250, 750 nM at room temperature (RT) at bench top , 7 
days in the refrigerator (4º C) and 30 days storage in the freezer (-20 º C) 
Name Freezer (-20), 30 days (%) 
Fridge (4ºC), 7days 
(%) 
Bench top (RT), 6 hrs 
(%) 
QC level (nM) 750 250 25 750 250 25 750 250 25 
17 α-Hydroxypregnenolone 112.8 84.5 114.8 113.3 99.0 108.7 54.9 21.1 122.3 
17 α-Hydroxyprogesterone 112.8 74.5 64.8 113.3 89.0 108.7 54.9 21.1 100.2 
2,3-Pyridinedicarboxylic 
acid 
111.0 112.8 71.2 128.7 128.1 89.0 20.6 135.9 62.2 
21-Deoxycortisol 92.5 BLLOQ BLLOQ 71.9 BLLOQ BLLOQ 70.2 BLLOQ BLLOQ 
2-hydroxyglutaric acid 104.5 BLLOQ BLLOQ 105.2 BLLOQ BLLOQ 107.9 BLLOQ BLLOQ 
2-Isopropylmalic acid 124.2 84.7 109.8 90.8 103.6 94.3 83.7 88.1 93.7 
2-Ketobutyric acid 70.0 62.1 78.9 113.8 67.0 94.5 129.9 65.0 76.2 
2-Phosphoglyceric acid 99.4 100.4 99.1 104.7 101.8 97.9 103.5 98.9 99.2 
3,4-Dihydroxyphenylacetic 
acid 
103.5 86.8 65.8 116.2 73.7 115.6 168.2 92.7 20.4 
3-Hydroxyxanthranilic acid 98.3 BLLOQ BLLOQ 89.8 BLLOQ BLLOQ 93.2 BLLOQ BLLOQ 
3-Methylglutaric acid 128.2 90.4 82.3 128.5 113.1 99.4 88.3 76.6 82.4 
3-Methylhistidine 106.1 99.9 113.5 114.4 116.7 121.3 120.1 126.3 122.2 
3-Phosphoglyceric acid 95.5 BLLOQ BLLOQ 101.9 BLLOQ BLLOQ 67.7 BLLOQ BLLOQ 
4,6-Dioxoheptanoic acid 94.3 128.2 96.0 91.1 106.4 68.2 85.1 124.8 98.2 
4-Hydroxy-L-glutamic acid 77.3 119.9 79.6 84.3 124.8 66.8 87.3 151.2 115.9 
4-Hydroxyphenylpyruvic 
acid 
98.7 BLLOQ BLLOQ 101.8 BLLOQ BLLOQ 81.3 BLLOQ BLLOQ 
4-Hydroxyproline 107.4 90.9 95.6 110.4 93.0 84.5 113.0 86.6 78.4 
5,6-Dihydro-5-methyluracil 74.0 BLLOQ BLLOQ 84.0 BLLOQ BLLOQ 93.5 BLLOQ BLLOQ 
5,6-Dihydrouridine 122.6 85.6 66.5 121.2 68.9 98.4 106.2 102.0 67.6 
5-Aminolevulinic acid 68.9 78.6 BLLOQ 78.4 68.4 BLLOQ 28.4 68.9 BLLOQ 
5-Hydroxyindoleacetic acid 60.1 BLLOQ BLLOQ 107.5 BLLOQ BLLOQ 88.2 BLLOQ BLLOQ 
5-Hydroxylysine 65.8 93.0 102.2 116.7 132.1 92.1 88.2 133.1 109.0 
6-Phosphogluconic acid 88.6 102.0 112.3 112.7 101.0 98.3 71.9 52.3 33.4 
Acetyl-CoA 90.3 BLLOQ BLLOQ 108.5 BLLOQ BLLOQ 52.3 BLLOQ BLLOQ 
Adenine 78.2 85.6 102.0 93.8 88.8 105.0 80.7 94.9 44.5 
Adenosin 79.5 198.6 65.0 118.7 121.3 60.5 54.1 181.3 32.8 
Adenosine diphosphate 114.4 128.8 83.6 118.1 105.4 80.0 41.3 24.3 18.6 
Adenosine 
monophosphate 
120.5 108.8 88.0 110.1 78.7 88.0 149.8 84.7 18.2 
Adenosine 
triphosphate 
114.3 120.0 128.0 117.2 117.6 113.0 99.3 82.1 128.0 
Adenylosuccinic acid 93.3 85.0 78.0 75.0 106.0 66.5 117.7 0.0 22.5 
Adonitol 123.4 108.1 79.4 79.3 77.2 64.0 55.5 83.4 163.9 
Alanine 105.3 95.8 181.7 125.0 127.4 117.4 132.1 100.8 131.8 




Aminoadipic acid 111.8 105.7 95.5 93.4 85.2 48.2 93.3 77.9 22.3 
Arabinose 117.8 127.1 82.8 106.1 113.3 114.4 80.9 0.2 88.0 
Argininosuccinic acid 84.2 78.8 122.8 61.8 124.5 114.5 75.6 138.9 108.2 
Betaine 81.0 118.8 69.5 181.4 118.4 72.6 134.9 162.3 40.6 
Biopterin 110.9 76.5 125.7 72.9 72.8 127.1 122.8 66.5 104.9 
Biotin 119.7 62.8 BLLOQ 96.5 56.2 BLLOQ 231.8 42.3 BLLOQ 
Cholic acid 74.7 BLLOQ BLLOQ 120.8 BLLOQ BLLOQ 113.8 BLLOQ BLLOQ 
Citrulline 112.3 72.7 134.5 103.6 73.6 25.7 122.2 68.5 16.6 
Coenzyme A 97.4 BLLOQ BLLOQ 109.3 BLLOQ BLLOQ 100.6 BLLOQ BLLOQ 
Corticosterone 101.2 122.8 103.3 90.8 81.0 107.6 70.5 90.0 126.3 
Cortisone 127.2 64.4 74.0 113.6 78.2 91.9 108.1 91.2 50.0 
Creatinine 119.9 72.4 112.3 120.5 90.7 107.0 28.0 91.2 250.8 
Cyclic AMP 101.0 103.6 128.6 82.0 97.9 142.0 84.8 90.5 96.1 
Cyclic GMP 111.2 120.0 63.2 99.0 102.0 118.0 197.6 23.8 19.4 
Cysteine-S-sulfate 113.1 87.1 101.0 115.4 99.4 68.3 102.3 73.2 73.3 
Cytidine 79.0 118.6 124.0 97.3 86.4 80.6 78.0 92.0 68.8 
Cytidine monophosphate 115.8 112.1 125.0 89.0 118.0 82.0 118.0 114.0 95.5 
Cytidine monophosphate N-
acetylneuraminic acid 
102.0 BLLOQ BLLOQ 102.7 BLLOQ BLLOQ 108.3 BLLOQ BLLOQ 
Cytidine triphosphate 91.1 104.1 95.0 129.4 130.3 88.9 14.0 26.0 132.1 
Cytosine 100.2 110.7 97.1 106.4 112.1 116.1 315.5 18920.9 168.7 
Cytosine diphosphate 97.8 97.6 89.7 108.2 86.6 105.0 101.3 100.0 62.6 
D-Arabitol 97.3 125.0 120.0 109.7 112.3 68.5 71.0 52.3 48.3 
D-Aspartic acid 102.0 104.9 114.6 102.7 117.1 91.8 108.3 132.7 143.0 
D-Cytosine monophosphate 107.4 BLLOQ BLLOQ 115.1 BLLOQ BLLOQ 126.5 BLLOQ BLLOQ 
Deoxyadenosine 102.6 86.5 81.5 173.8 79.1 119.3 89.9 41.2 146.5 
Deoxyadenosine 
monophosphate 
97.6 BLLOQ BLLOQ 108.0 BLLOQ BLLOQ 108.0 BLLOQ BLLOQ 
Deoxycytidine 105.8 85.7 111.9 71.7 85.4 114.4 98.9 64.6 96.9 
Deoxyguanosine 113.1 BLLOQ BLLOQ 116.7 BLLOQ BLLOQ 197.5 BLLOQ BLLOQ 
Deoxyinosine 70.6 110.6 128.0 102.9 84.5 85.3 104.8 25.6 15.2 
Deoxyribose-5’-phosphate 98.4 118.2 105.0 61.8 88.8 68.0 89.5 105.7 33.4 
Deoxyribose-5’-phosphate 35.0 86.3 84.5 120.6 89.3 62.6 128.6 64.3 28.4 
Deoxyuridine 128.4 BLLOQ BLLOQ 106.8 BLLOQ BLLOQ 113.6 BLLOQ BLLOQ 
D-Erythrose-4-phosphate 118.6 70.7 65.3 288.4 194.7 98.0 114.2 121.0 98.0 
Dexamethasone 129.5 106.8 65.0 68.7 88.6 78.5 78.3 58.4 68.5 
Dextrose 124.3 106.2 118.0 101.4 80.4 86.9 167.9 120.5 169.9 
D-Fructose 120.9 94.3 106.2 79.7 120.7 67.9 125.5 76.4 71.9 
D-Glucose 98.1 BLLOQ BLLOQ 72.1 BLLOQ BLLOQ 101.6 BLLOQ BLLOQ 
D-Glucuronic acid 93.1 68.6 109.0 72.6 118.3 77.8 99.9 90.0 102.0 
D-Glutamic acid 71.6 111.1 150.7 47.1 93.8 133.7 45.0 84.6 151.8 
Dihydrouracil 117.9 BLLOQ BLLOQ 90.0 BLLOQ BLLOQ 93.6 BLLOQ BLLOQ 
Dihydroxyacetone phosphate 92.7 73.4 68.0 83.5 66.1 65.0 25.4 79.8 48.3 
Dimethylallylpyrophosphate 118.7 65.2 98.2 94.1 61.0 88.6 83.4 97.1 29.3 
DL-Homocystine 80.6 94.6 142.7 118.2 119.1 115.1 45.2 114.8 127.2 
D-Maltose 92.1 95.2 105.3 105.6 120.7 125.8 124.8 96.5 79.5 
D-Mannose 122.1 BLLOQ BLLOQ 79.4 BLLOQ BLLOQ 151.9 BLLOQ BLLOQ 




Dopamine 109.8 68.5 78.2 121.4 84.3 102.0 158.7 93.5 75.3 
D-Ribose-5’-phosphate 98.4 68.2 125.2 61.8 88.8 98.0 89.5 105.7 67.5 
D-Threitol 111.6 77.1 91.0 119.6 90.2 120.0 113.2 102.4 71.8 
D-Tryptophan 101.4 BLLOQ BLLOQ 97.8 BLLOQ BLLOQ 90.0 BLLOQ BLLOQ 
Dulcitol 123.9 93.7 110.6 116.2 98.2 105.8 115.2 19.4 61.7 
D-Xylitol 79.7 106.4 120.5 81.1 101.3 80.6 58.3 152.5 70.2 
D-Xylose 122.3 BLLOQ BLLOQ 112.3 BLLOQ BLLOQ 98.3 BLLOQ BLLOQ 
Estradiol 128.2 120.1 117.2 117.6 113.0 114.2 99.3 82.2 189.8 
Estriol 91.5 80.3 96.3 88.7 70.3 98.2 115.4 67.2 73.2 
Estrone 206.7 275.6 37.5 91.9 62.1 61.4 172.1 38.2 122.6 
Ethanolamine 128.2 74.1 82.0 105.2 116.2 65.0 189.4 151.7 87.0 
Fructose-1,6-bisphosphate 114.7 92.5 68.0 121.4 81.1 116.3 143.3 99.3 62.3 
Fructose-6-phosphate 115.6 103.9 39.7 108.0 87.8 96.2 101.5 85.5 19.8 
Fumaric acid 97.4 125.5 BLLOQ 96.8 82.5 BLLOQ 85.7 57.9 BLLOQ 
Galactose-1-phosphate 111.7 78.5 122.4 124.2 102.4 114.4 119.8 116.9 127.9 
Gamma-aminobutyric acid 
(GABA) 
115.6 230.2 112.5 127.2 113.3 95.5 125.4 92.0 84.0 
Gluconolactone 92.7 102.7 116.9 95.0 113.9 27.8 77.4 90.0 110.2 
Glucosamine-6-phosphate 126.7 74.8 103.1 108.4 91.8 68.2 85.9 69.4 73.2 
Glucose-6-phosphate 111.7 78.5 122.4 124.2 102.4 114.4 119.8 116.9 107.9 
Glutaric acid 91.8 86.7 85.6 83.7 105.6 90.4 47.4 48.4 90.4 
Glutathione 114.1 BLLOQ BLLOQ 111.7 BLLOQ BLLOQ 0.8 BLLOQ BLLOQ 
Glyceric acid 95.5 120.0 66.0 101.9 94.8 66.5 67.7 65.3 38.2 
Glycerol 96.3 112.4 91.1 108.4 106 131 112.6 197.2 112 
Glycine 98.0 86.4 95.8 110.1 64.6 92.8 110.7 121.8 127.8 
Glycolic acid 100.7 BLLOQ BLLOQ 107.6 BLLOQ BLLOQ 115.6 BLLOQ BLLOQ 
Glycoursodeoxycholic acid 98.6 122.0 90.9 124.7 79.1 128.8 109.6 60.5 45.6 
Guanine 109.3 106.9 97.4 123.6 108.1 96.8 199.4 205.9 88.6 
Guanosine 82.2 BLLOQ BLLOQ 95.7 BLLOQ BLLOQ 112.3 BLLOQ BLLOQ 
Guanosine diphosphate 168.3 34.6 58.5 86.4 96.9 90.0 62.4 105.9 42.3 
Guanosine monophosphate 12.4 68.2 72.6 68.4 142.3 90.0 112.3 78.5 60.6 
Guanosine triphosphate 103.3 97.5 100.4 102.9 107.8 114.7 122.9 103.1 119.9 
Homocitrulline 96.9 104.7 113.7 113.6 122.9 117.5 177.4 105.2 150.6 
Homo-L-arginine 102.5 93.8 85.6 104.3 111.2 98.6 100.4 100.5 55.4 
Homovanillic acid 87.1 108.1 90.0 106.6 105.2 100.0 149.8 116.5 90.0 
Hydroxykynurenine 121.0 81.8 97.8 98.0 105.0 109.0 90.0 104.0 103.5 
Hypoxanthine 97.8 111.2 70.7 66.0 112.2 97.9 107.5 81.1 120.3 
Indoleacetic acid 99.1 120.0 101.9 116.2 116.6 113.4 76.9 106.9 89.4 
Inosine 123.9 117.0 91.3 100.0 112.6 125.6 92.1 77.8 105.9 
Inosine diphosphate 123.6 112.1 89.2 111.8 85.5 120.0 94.6 76.8 52.5 
Inosine triphosphate 82.4 BLLOQ BLLOQ 129.0 BLLOQ BLLOQ 94.0 BLLOQ BLLOQ 
Isopentenyl pyrophosphate 104.9 88.3 108.0 143.0 108.0 65.2 125.1 82.3 92.8 
Isoxanthopterin 72.3 84.1 122.4 129.0 111.2 125.7 99.3 52.0 90.0 
Itaconic acid 98.1 108.9 94.2 105.0 122.1 113.2 82.3 105.1 100.2 
L-Acetylcarnitine 82.3 BLLOQ BLLOQ 122.5 BLLOQ BLLOQ 157.3 BLLOQ BLLOQ 
L-Alloisoleucine 115.8 BLLOQ BLLOQ 127.5 BLLOQ BLLOQ 106.5 BLLOQ BLLOQ 
L-Arginine 102.3 105.9 124.7 111.8 112.0 148.5 121.5 79.7 80.9 




L-Carnitine 125.7 81.8 115.6 113.4 100.2 118.3 148.9 105.2 93.3 
L-Cystathionine 113.8 102.8 100.5 112.4 91.1 109.4 100.7 100.2 26.4 
L-Cystine 108.1 104.8 130.1 173.8 116.0 348.2 102.9 95.9 136.2 
L-Dihydroorotic acid 98.3 BLLOQ BLLOQ 82.4 BLLOQ BLLOQ 75.1 BLLOQ BLLOQ 
L-Galactono-1,4-lactone 95.8 105.3 122.0 116.9 128.0 77.9 106.2 62.3 52.6 
L-Glutamine 97.5 102.2 68.7 98.5 128.0 63.7 92.2 114.9 87.7 
L-Histidine 102.3 107.7 123.9 113.8 125.4 126.3 125.4 141.2 177.2 
L-Homoserine 117.4 29.5 65.3 125.3 73.6 88.0 80.3 128.6 62.3! 
L-Isoleucine 112.8 96.3 113.0 106.3 98.9 80.1 95.7 81.4 81.6 
Lithium acetoacetate 103.2 92.8 263.3 92.4 88.2 107.6 80.5 30.0 122.6 
L-Kynurenine 98.3 84.0 104.2 74.6 62.5 99.8 148.9 482.9 48.2 
L-Lactic acid 127.3 BLLOQ BLLOQ 124.1 BLLOQ BLLOQ 90.7 BLLOQ BLLOQ 
L-Leucine 118.2 98.9 92.3 116.1 86.8 76.8 141.9 101.3 88.4 
L-Lysine 95.4 97.2 110.8 102.3 121.2 109.3 99.9 138.3 138.2 
L-Methionine 118.4 108.1 102.3 174.4 122.1 90.6 169.1 119.4 104.1 
L-Phenylalanine 101.4 BLLOQ BLLOQ 105.3 BLLOQ BLLOQ 96.8 BLLOQ BLLOQ 
L-Proline 123.3 BLLOQ BLLOQ 97.7 BLLOQ BLLOQ 106.8 BLLOQ BLLOQ 
L-Ribulose 103.3 BLLOQ BLLOQ 148.7 BLLOQ BLLOQ 97.6 BLLOQ BLLOQ 
L-Serine 125.0 98.0 68.7 111.6 81.3 94.5 99.6 73.4 73.9 
L-Sorbose 100.3 84.6 119.9 156.4 113.2 60.0 158.7 151.0 121.0 
L-threonine 132.8 131.4 71.2 143.9 111.3 99.0 130.0 104.0 46.8 
L-Tyrosine 109.4 90.6 97.8 115.0 98.2 75.5 130.6 97.3 80.1 
L-Valine 133.8 84.7 100.8 125.7 85.5 80.8 121.6 86.5 93.3 
Malic acid 104.5 BLLOQ BLLOQ 101.3 BLLOQ BLLOQ 103.7 BLLOQ BLLOQ 
Malonic acid 100.1 122.8 121.4 107.5 124.7 122.3 88.2 148.9 114.2 
Mannitol 104.9 BLLOQ BLLOQ 96.4 BLLOQ BLLOQ 96.2 BLLOQ BLLOQ 
Melibiose 150.0 197.7 73.7 81.1 112.4 109.5 108.1 95.9 97.7 
Methylmalonic acid 92.8 82.9 92.3 118.4 72.8 62.8 134.2 191.2 68.7 
Mevalonic acid 3-phosphate 121.6 88.0 127.8 128.5 118.0 104.9 73.1 158.2 95.0 
Mevalonic acid-5-phosphate 107.2 99.3 98.2 118.4 98.2 120.0 107.7 74.2 68.6 
Monapterin 115.6 124.2 106.6 84.1 107.1 120.0 80.1 97.9 80.8 
Myoinositol 92.6 112.0 106.0 92.0 68.6 98.2 65.6 20.3 42.6 
N-Acetyl-D-glucosamine 76.1 82.5 98.2 93.2 99.7 78.5 131.0 15.0 12.3 
N-Acetyl-D-glucosamine-6-
phosphate 
112.4 BLLOQ BLLOQ 70.4 BLLOQ BLLOQ 123.2 BLLOQ BLLOQ 
N-Acetylmannosamine 83.1 67.2 BLLOQ 103.2 61.7 BLLOQ 16.3 13.4 BLLOQ 
N-Acetylneuraminic acid 115.0 77.2 124.2 103.7 78.1 95.7 135.3 76.5 140.9 
N-Acetylputrescine 97.4 99.3 109.0 105.8 91.0 111.7 95.3 102.9 98.4 
N-Acetylspermine 88.9 92.3 74.5 103.7 94.3 106.7 104.8 56.4 5.4 
NADH 97.8 97.6 89.7 108.2 86.6 85.0 101.3 100.0 72.6 
Neopterin 70.4 90.1 127.4 91.5 96.9 128.5 78.0 46.4 76.2 
Niacinamide 107.7 BLLOQ BLLOQ 103.1 BLLOQ BLLOQ 129.1 BLLOQ BLLOQ 
Nicotinamide ribotide 92.7 101.0 102.3 98.7 102.2 101.6 110.1 104.2 78.6 
Nicotinic acid 97.0 BLLOQ BLLOQ 119.3 BLLOQ BLLOQ 118.9 BLLOQ BLLOQ 
Nicotinic acid 
mononucleotide 
96.5 60.2 114.2 125.6 92.0 98.2 105.2 22.8 16.8 
O-Phosphoethanolamine 128.1 BLLOQ BLLOQ 115.6 BLLOQ BLLOQ 167.2 BLLOQ BLLOQ 




Orotic acid 85.3 112.1 122.0 117.6 102.0 79.8 67.2 62.3 58.2 
Orotidine-5'-monophosphate 82.4 109.2 BLLOQ 61.8 104.8 BLLOQ 74.3 120.3 BLLOQ 
O-Succinyl-L-homoserine 88.5 129.0 152.3 88.6 106.2 99.2 44.8 32.8 22.8 
Oxalacetic acid 82.3 BLLOQ BLLOQ 105.6 BLLOQ BLLOQ 120.3 BLLOQ BLLOQ 
Oxalic acid 81.5 91.1 BLLOQ 117.1 143.4 BLLOQ 139.1 120.3 BLLOQ 
Oxidized glutathione 68.2 BLLOQ BLLOQ 101.2 BLLOQ BLLOQ 98.6 BLLOQ BLLOQ 
Oxoglutaric acid 115.0 BLLOQ BLLOQ 98.9 BLLOQ BLLOQ 102.6 BLLOQ BLLOQ 
Pantothenic acid 105.3 114.7 BLLOQ 118.6 121.9 BLLOQ 10.8 108.5 BLLOQ 
Phenylpyruvic acid 88.7 BLLOQ BLLOQ 101.8 BLLOQ BLLOQ 81.3 BLLOQ BLLOQ 
Phosphoenolpyruvic acid 115.0 107.4 95.2 113.4 122.1 78.0 110.9 10.5 102.0 
Phosphoserine 120.0 112.0 BLLOQ 116.9 65.0 BLLOQ 55.3 23.5 BLLOQ 
Pipecolic acid 81.4 97.3 88.2 128.2 94.0 122.0 163.4 115.0 14.2 
Porphobilinogen 126.9 BLLOQ BLLOQ 103.6 BLLOQ BLLOQ 109.2 BLLOQ BLLOQ 
Progesterone 121.6 198.7 67.5 117.9 129.8 77.4 97.1 94.4 15.2 
Pterin 94.5 50.1 162.8 85.4 115.8 128.1 119.0 69.0 90.0 
Putrescine 65.4 86.9 76.9 63.8 86.3 83.6 58.8 49.5 196.3 
Pyridoxal  Hydrochloride 114.7 99.5 101.5 108.4 94.9 101.0 107.4 99.2 148.2 
Pyridoxal-5'-phosphate 113.1 84.8 122.0 115.7 105.9 114.1 105.7 108.0 96.0 
Raffinose 124.6 115.8 98.4 89.8 103.8 92.8 93.2 128.4 134.8 
Ribitol 86.1 85.9 BLLOQ 84.6 82.4 BLLOQ 95.8 105.0 BLLOQ 
Saccharopine 83.8 107.2 85.2 57.2 85.9 100.8 53.5 99.5 23.2 
Sarcosine 96.0 BLLOQ BLLOQ 101.1 BLLOQ BLLOQ 97.0 BLLOQ BLLOQ 
Sedoheptulose-7-phosphate 90.1 129.8 78.3 80.1 67.8 77.8 70.5 102.9 53.2 
Sepiapterin 92.9 81.6 68.0 77.4 126.3 68.2 56.2 94.2 68.2 
Sodium 4-methyl-2-
oxovalerate 
111.0 BLLOQ BLLOQ 126.4 BLLOQ BLLOQ 121.0 BLLOQ BLLOQ 
Sodium glycodeoxycholate 113.8 116.5 117.0 102.5 103.5 91.8 88.2 95.4 91.6 
Sodium β-
hydroxyisobutyrate 
76.8 BLLOQ BLLOQ 93.2 BLLOQ BLLOQ 125.1 BLLOQ BLLOQ 
Sorbitol 117.9 108.3 94.9 103.8 155.7 683.5 119.8 84.3 107.8 
Spermine 93.3 79.0 80.5 88.6 91.0 104.2 91.9 16.7 52.2 
Sphingosine 188.4 BLLOQ BLLOQ 129.2 BLLOQ BLLOQ 280.0 BLLOQ BLLOQ 
S-Sulfocysteine 128.5 119.2 81.4 103.9 124.9 92.5 121.9 113.2 113.1 
Succinic acid 74.4 BLLOQ BLLOQ 85.8 BLLOQ BLLOQ 72.2 BLLOQ BLLOQ 
Taurine 105.8 85.7 131.9 71.7 85.4 174.4 98.9 64.6 96.9 
Taurodeoxycholic acid 115.0 BLLOQ BLLOQ 103.7 BLLOQ BLLOQ 135.3 BLLOQ BLLOQ 
Tauroursodeoxycholic Acid, 28.3 66.4 28.3 112.3 96.5 88.3 113.6 101.9 90.5 
Thiamine 78.6 99.9 65.2 112.0 65.3 88.0 90.0 109.8 42.3 
Thymidine 106.5 122.5 64.2 114.7 120.0 118.0 121.1 123.9 77.0 
Thymine 115.8 130.6 98.0 94.1 68.3 77.8 121.8 101.3 25.3 
Tryptophanol 128.0 BLLOQ BLLOQ 122.8 BLLOQ BLLOQ 46.9 BLLOQ BLLOQ 
Uracil 111.2 105.3 95.3 126.6 125.2 63.5 70.1 91.4 96.6 
Ureidopropionic acid 120.0 122.0 67.0 105.8 106.5 99.8 112.8 111.6 108 
Uridine 110.3 120.1 122.0 89.7 125.8 61.1 84.0 65.0 91.9 
Uridine diphosphate-N-
acetylglucosamine 
85.7 BLLOQ BLLOQ 109.3 BLLOQ BLLOQ 68.6 BLLOQ BLLOQ 
Uridine 
diphosphoglucuronic acid 










124.3 BLLOQ BLLOQ 121.4 BLLOQ BLLOQ 167.9 BLLOQ BLLOQ 
Uridine-5'-diphosphate 83.3 96.6 90.6 89.9 111.4 75.9 28.3 15.3 4.8 
Uridine-5'-monophosphate 92.8 127.0 125.0 92.2 79.4 82.6 73.9 96.0 109.1 
Xanthine 108.3 120.2 108.0 127.6 116.0 65.8 124.3 73.1 68.0 
β-Nicotinamide adenine 
dinucleotide(NAD) 




Table A1.6: Long-term stability of detected metabolites in DBS after 2 and 4 months at 4 ̊C 
 
Metabolite 2 Months (%) 
4 Months 
(%) 
17 α-Hydroxypregnenolone 77 88.5 
17 α-Hydroxyprogesterone 111.38 92.62 
2-Dexoycytidine 97.42 84.11 
2-Hydroxyglutaric acid 75.27 77.5 
2-ketobutyric acid 122.71 103.84 
2-Oxo-glutaric acid 76.52 75.59 
2-Phoshoglyceric acid 130.56 135.89 
3,4-Dihydrophenylacetic acid 88.73 108.81 
3-Indoleacetic acid 77.9 59.91 
3-Methylglutaric acid 88 79.23 
3-Methylhistidine 100.37 67.11 
3-phoshoglyceric acid 66.03 77.55 
3-Ureidopropionic acid 69.28 68.59 
4,6-Dioxoheptanoic acid (Succinylacetone) 63.12 61.75 
4-Hydroxy-L-glutamic acid 103.33 63.81 
4-Hydroxyproline 38.05 103.84 
5-Aminoleuvillinic acid 64.38 81.68 
5-Hydroxyindole-3-acetic acid 75.64 70.14 
5-Hydroxylysine HCL 105.16 51.62 
Adenosine 124.19 101.04 
Adenosine-3’,5’-monophosphate (cAMP) 89.36 99.78 
Alanine 46.14 65.35 
Aminoadipic acid 57.24 52.38 
Arabinose 98 55.36 
Arabitol 101.79 54.22 
Arginine 82.88 66.34 
Asparagine 40.46 60.97 
Aspartic acid 70.87 59.75 
Betaine 58.28 90.44 
Biotin 104.57 95.4 
Citrulline 102.88 130.5 
Corticosterone 116.88 98.49 
Cortisone 83.82 91.83 
Creatinine 45.37 100.5 
Cysteine sulphate 88.82 66.29 
Cystine 90.26 101.13 
Cytidine-5-triphoshate (CTP) 85.2 69.63 
Cytidne-5-diphosphate (CDP) 103.95 73.54 




Dextrose 108.12 57.78 
D-Galactose-1-phosphate 133.75 102.45 
Dihydroxyacetone phosphate 109.49 77.56 
Diydhyrouracil 57.6 62.37 
Dopamine 110.82 92.21 
D-Panthothenic acid 106.4 85.46 
D-Ribose-5-Phosphate 84.94 60.97 
Estradiol 107.05 89.5 
Ethanolamine 114.29 93.58 
Fructose 102.12 92.57 
Fructose-6-phosphate 70.78 139.07 
Gamma aminobutyric acid (GABA) 75.12 105.84 
Glucosamine-6-phosphate 63.91 87.55 
Glucose-6-phosphate 67.39 51.62 
Glucuronic acid 78.89 100.37 
Glutamic acid 90.37 103.84 
Glutamine 92.79 105.2 
Gluthathione 103.83 81.42 
Glyceric acid 105.77 93.68 
Glycine 67.81 99.29 
Glycolic acid 91.43 106.4 
Glycursodeoxycholic acid 67.81 78.87 
Guanine 76.83 81.29 
Guanosine 81.91 87.89 
Histidine 99.29 77.44 
Homoarginine 83.14 90.7 
Homocitrulline 81.49 11.14* 
Homocystine 99.29 106.59 
Homovanillic acid 69.52 102.26 
Hypoxanthine 104.68 113.25 
Inosine 88.01 64.28 
Inosine 5’-diphosphate (IDP) 50.72 57.28 
Isoleucine 65.23 90.37 
Isopropyl malic acid 56.8 115.54 
Itaconic (2-methylenesuccinic) acid  89.16 81.56 
Kynurenine 78.54 95.02 
L-Carnitine 120.91 120.46 
Leucine 124.19 92.79 
Lysine 90.37 75.91 
Malic acid 71.78 93.33 
Malonic acid 71.95 55.13 
Mannose 103.5 72.53 
Mannose-1-phosphate 103.58 106.57 




Methylmalonate (MMA) 87.37 100.58 
Mevalonate-5-phosphate 65.08 90.15 
N-Acetyl-D-mannosamine 109.39 80.87 
N-Acetylglucosamine 99.84 70.44 
N-Acetyl-glucosamine-1-phosphate 65.08 105.16 
N-Acetylneuraminic acid (Sialic acid) 56.14 77.44 
N-Acetylspermine 80.77 81.65 
Niacinamide 97.5 114.16 
Nicotinamide ribotide 106.43 103.4 
Nicotinic acid 57.44 130.5 
Nicotinic acid mononucleotide 110.06 94.03 
O-Acetyl-carnitine 74.6 88.35 
O-Phoshoserine 117.02 112.64 
O-Phosphoserine 111.97 118.31 
Ornithine 89.36 66.29 
Orotic acid 103.32 91.41 
Oxalic acid 98.03 82.3 
Oxaloacetate 68.77 149.31 
Phenylalanine 33.45 102.45 
Phosphoenolpyruvic acid 71.82 87.77 
Phosphoethanolamine 64.16 82.56 
Pipecolic acid 89.22 90.69 
Progesterone 111.26 102.64 
Proline 81.91 100.37 
Raffinose 95.41 79.66 
Ribitol (adonitol) 75.33 76.42 
Ribulose 98.71 62.81 
Saccharopine 110.44 82.47 
Sarcosine 5.96 101.51 
Sepiaterin 65.6 74.53 
Serine 127.66 101.51 
Sodium 4-methyl-3-oxovalerate 88.1 77.73 
Sodium beta-hydroxy-isobutyrate 32.63 85.35 
Sodium glycodeoxycholate 81.67 21.06 
Sodium taurodeoxycholate 115.62 10.64* 
Sorbose 78.54 149.22 
Spermine 53.05 67.11 
S-Sulfocysteine 98.03 84.76 
Succinic acid 96.42 72.26 
Taurine 130.44 67.11 
Threitol 98.55 69.37 
Threonine 88.01 182.88 
Tyrosine 92.79 101.51 




Uridine 65.23 102.83 
Uridine 5-diphospho-N-acetylglycosamine 93.79 66.34 
Valine 105.84 115.23 
Xanthine 75.12 57.81 







































C 16 Carnitine-d3 89.5 
C10 Carnitine-d3 79.26 
C12 Carnitine-d3 68.51 
C14 Carnitine-d3 102.94 
C18 Carnitine-d3 125.43 
C4 Carnitine-d3 122.94 
C5 Carnitine-d9 86.6 
C6 Carnitine-d3 87.12 
C8 Carnitine-d3 71.73 














Table A1.8: List of DBS metabolites with the reference ranges, the reference interval was calculated 






2-Deoxyadenosine 20.60 5.17 
2-Deoxycytidine 5 monophosphate 18.26 3.6 
2-Deoxyinosine 55.52 7.65 
2-Deoxyribose 5 phosphate 135.53 24.07 
2-ketobutyric acid 160.92 7.06 
3,4, Dihydrophenylacetic acid 207.89 67.44 
3-ureidopropionic acid 116.93 9.25 
4,6,Dioxoheptanoic acid 6.10 1.54 
4-Hydroxyglutamic aicd 133.31 24.51 
4-Hydroxy-proline 169.66 35.48 
Adenine 74.21 9.86 
Adenosine 154.96 5.70 
Adenosine 3,5 monophosphate(cAMP) 18.10 3.37 
Adenosine 5 diphosphate(ADP) 86.28 7.92 
Adenosine 5 triphosphate(ATP) 20.925 6.87 
Adenosine monophosphate(AMP) 43.54 7.77 
Adenylosuccinic acid 34.11 6.48 
Alanine 39.88 7.66 
Aminoadipic 14.13 4.07 
Arabitol 58.58 4.77 
Arginine 124.68 6.28 
Asparagine 301.93 6.39 
Aspartic acid 276.07 5.23 
Betaine 201.49 9.37 
Biopterin 19.07 4.48 
cGMP 51.91 13.12 
Citrulline 52.45 10.70 
Corticosterone 13.61 3.81 
Cortisone 48.44 2.25 
Creatinine 92.90 17.61247 
Cysteine sulphate 12.25 0.413485 
Cysthathionine 19.11 5.91 
Cystine 366.14 94.16 
Cytidine 40.78 6.71 
Cytidine 5 triphoshate(CTP) 13.85 2.25 
Cytidine monophosphate(CMP) 93.44 38.40 




Cytosine 134.75 37.04 
D-Galactose 1 phosphate 179.15 9.04 
Dihydroxyacetone Phosphate 327.57 24.86 
dopamine 84.69 11.31 
D-Ribose 5 Phosphate 347.04 23.54 
D-Sedoheptulose 7 phosphate 139.01 21.03 
Erythrose 4 phosphate 371.78 48.76 
Estradiol 113.96 3.73 
Estrone 56.88 2.28 
Ethanolamine 108.25 18.50 
Fructose 1 6 Bisphosphate 456.08 34.77 
Fructose 6 phosphate 377.25 67.23 
Gluconic acid lactone 27.74 3.62 
Glucose 6 Phosphate 204.61 85.07 
Glucuronic acid 193.07 4.92 
Glutamic acid 2279.93 85.81 
Glutamine 976.22 103.95 
Glycerol 974.46 45.39 
Glycine 171.28 7.09 
Glycolic acid 168.43 40.19 
GMP 119.64 2.09 
Guanine 327.79 74.76 
Guanosine 298.11 76.85 
Guanosine di phosphate(GDP) 119.73 37.37 
Guanosine triphosphate(GTP) 28.76 88.80 
Histidine 94.26 5.03 
Homoarginine 269.58 38.81 
Homocystine 43.80 10.65 
Hypoxanthine 429.55 95.55 
Inosine 43.56 8.94 
Inosine 5 diphosphate(IDP) 71.87 21.84 
Isoleucine 187.48 6.57 
Isopentyl pyrophoshate 273.62 9.16 
Isoprophymallic 3.79 0.56 
Isoxanthopterin 28.75 4.00 
Kynurenine 58.63 8.57 
L-Carnitine 274.95 48.53 
Leucine 171.14 5.35 
Lysine 433.13 85.58 
Malonic acid 38.50 9.85 
Mannose 1 phosphate 136.13 14.00 
Methionine 197.26 5.39 
Monapterin 12.95 4.06 






























N-Acetylspermine 18.08 5.23 
NADH 75.11 12.96 
NADP 30.87 2.82 
Neopterin 44.24 7.00 
Nicotinic acid 39.69 7.75 
O-Phoshoserine 185.06 10.57 
Ornithine 11.51 3.09 
Orotic acid 179.35 4.71 
Phenylalanine 2153.58 42.174 
Phosphoenolpyruvic acid 292.76 18.16 
Pipecolinic acid 61.50 81.73 
Progesterone 848.24 160.24 
pterin 23.45 3.40 
putrescine 130.38 27.42 
Saccharopine 23.05 6.08 
Serine 387.16 31.86 
Spermine 88.64 53.10 
Sulfocystiene 15.21 1.715252 
Taurine 144.98 40.35 
Thiamine 240.91 26.88 
Threitol 57.17 9.45 
Threonine 850.63 17.87 
Thymidine 22.81 5.56 
Thymine 5.61 1.20 
Tyrosine 829.63 53.74 
Tyrptophan 419.64 10.18 
Uracil 15.58 3.36 
Uridine 82.75 25.74 
Uridine 5 monophosphate(UMP) 175.97 9.5 
Uridine di phosphate(UDP) 11.51 3.08 
Valine 422.27 10.61 
Xanthine 196.32 42.14 
Xylitol 37.85 7.73 










IgE Levels RBC WBC Eosinophils 
CD4/ 
CD8 VAS SCORAD 









16 M 9140 4.17 3.72 35 0.8 13 67 
P3 NM_203447.3:c.5625T>G:p.Y1875 16 F 1690 4.2 4.63 50.3 1 14 59.8 
P4 NM_203447:c.827+6T>C 16 F 11240 5.9 4.9 11.4 0.73 15 77.4 
P5 NM_203447.3:c.5962_6068del  7 M 10170 5.29 9.93 26.4 0.7 17 79.5 
P6 NM_001193536:c.3949+1G>T 14 M 15550 6.82 4.46 11.7 1.3 15 62.5 
P7 NM_001193536:c.1593+1G>T 4 M 86940 5.3 24.9 31.4 9 17 70.6 
P8 NM_001193536:c.1593+1G>T 9 F 44630 5.26 12.49 34.8 8.1 9 58.2 
P9 NM_001190458:c.1905_1905+1delGG 8 F 26340 3.81 21.42 35.1 3.2 14 58.8 
P10 NM_203447.3:c.5625T>G:p.Y1875 21 M 265 4.7 9.7 12 1.1 12 70.1 
Average±SEM     13.2±5.9 
5/5 
(M/F) 19817.30±4772.6 4.5±0.57 10.53±2.3 27.29±4.02 2.8±0.99 14.1±0.75 
67.26 
±2.37 
ATOPIC      
DERMATITIS 
P11 
DOCK8 mutation negative 
6 M 6540 5.2 10.6 16.5 0.9 16 64.4 
P12 15 M 16500 6.39 3.72 15.6 1.4 14 71.3 
P13 10 M 1612 5.48 8.01 13.9 1.2 16 73.3 
P14 3 M 839 5.3 6.59 6.7 _ 13 56.1 
P15 8 M 1221 4.9 5.09 13 1.5 9 40.8 
P16 13 M 659 5.2 5.15 13 1.2 10 54.9 
P17 15 F 1387 4.71 9.63 12.3 1.4 15 75 
P18 16 M 365 5.15 2.71 7.9 2.3 14 65.1 
P19 12 M 4587 5.66 9.2 5.1 1.5 16 70.6 
Average±SEM     10.8±1.4 
8/1 








Table A1.10: Positively identified (DOCK8 Vs Control) 
HMDB.No Name Acc.mass mz_light Retention time Fold.change p value 
316 Phenyl-Leucine 278.1631 512.2214 15.9 0.395277836 0.0000603 
HMDB00020 p-Hydroxyphenylacetic acid 152.0473 386.1057 16.91 1.665531722 0.0008974 
HMDB00070 D-Pipecolic acid 129.079 363.1373 13.23 1.587058087 2.12E-04 
HMDB00112 Gamma-Aminobutyric acid 103.0633 337.1216 7.79 1.534256238 4.43E-10 
HMDB00133 Guanosine 283.0917 517.15 2.22 4.122263032 8.87E-07 
HMDB00206 N6-Acetyl-L-Lysine 188.1161 422.1744 5.71 1.681202991 6.36E-10 
HMDB00210 Pantothenic acid 219.1107 453.169 8.37 1.832101063 1.06E-11 
HMDB00224 O-Phosphoethanolamine 141.0191 375.0774 2.02 0.582279964 7.63E-05 
HMDB00251 Taurine 125.0147 359.073 2.24 0.628274512 7.67E-08 
HMDB00259 Serotonin 176.095 322.1058 24.65 1.815645678 3.08E-06 
HMDB00271 Sarcosine 89.0477 323.106 9.34 1.573575643 8.23E-09 
HMDB00300 Uracil 112.0273 346.0856 11.34 2.245592611 3.35E-06 
HMDB00440 3-Hydroxyphenylacetic acid 152.0473 386.1057 16.72 1.665531722 8.97E-04 
HMDB00450 5-Hydroxylysine 162.1004 315.1085 13.88 2.087090747 2.92E-11 
HMDB00452 L-Alpha-aminobutyric acid 103.0633 337.1216 9.13 2.122152479 2.64E-08 
HMDB00469 5-Hydroxymethyluracil 142.0378 376.0962 8.87 0.661087618 6.95E-07 
HMDB00500 4-Hydroxybenzoic acid 138.0317 372.09 17.57 0.481133034 0.032552 
HMDB00500 4-Hydroxybenzoic acid 138.0317 372.09 17.57 0.497054292 1.36E-12 
HMDB00669 Ortho-Hydroxyphenylacetic acid 152.0473 386.1057 16.42 1.665531722 8.97E-04 
HMDB00684 L-Kynurenine 208.0848 442.1431 11.44 1.744385361 1.07E-10 
HMDB00706 L-Aspartyl-L-phenylalanine 280.1059 514.1642 10.07 0.315025661 1.07E-05 
HMDB00716 L-Pipecolic acid 129.079 363.1373 13.45 1.587058087 2.12E-04 
HMDB00750_2 
3-Hydroxymandelic acid - 
COOH 
168.0423 356.0951 21.64 1.586042823 1.04E-13 
HMDB00965 Hypotaurine 109.0197 343.0781 2.47 0.437626734 2.36E-05 
HMDB01123 2-Aminobenzoic acid 137.0477 371.106 16.62 3.014850957 5.37E-10 
HMDB01232 4-Nitrophenol 139.0269 373.0853 23.45 1.730548304 1.06E-11 
HMDB01414 1,4-diaminobutane 88.1 278.1083 21.27 2.039329127 1.10E-10 
HMDB01476 3-Hydroxyanthranilic acid 153.0426 387.1009 18.14 1.808714598 8.01E-10 
HMDB01906 2-Aminoisobutyric acid 103.0633 337.1216 8.91 2.122152479 2.64E-08 
HMDB01918 Thyroxine 776.6867 622.4017 27.74 1.639578496 2.11E-13 
HMDB02064 N-Acetylputrescine 130.1106 364.1689 7.25 2.196515071 3.24E-14 
HMDB02390 3-Cresotinic acid 152.0473 386.1057 16.8 1.665531722 8.97E-04 
HMDB03012 Aniline 93.0578 327.1162 17.32 2.035166282 3.6E-11 
HMDB03334 Symmetric dimethylarginine 202.143 436.2013 3.05 1.92465467 1.95E-17 
HMDB03355 5-Aminopentanoic acid 117.079 351.1373 8.68 1.622041349 7.51E-04 
HMDB03911 3-Aminoisobutanoic acid 103.0633 337.1216 8.67 2.122152479 2.64E-08 
HMDB03911_2 
3-Aminoisobutanoic acid - 
H2O 
103.0633 319.111 16.29 1.943610889 4.66E-07 
HMDB13302 Phenylalanylphenylalanine 312.1474 546.2057 16.55 0.529397252 2.43E-07 
HMDB28848 Glycyl-Phenylalanine 222.1004 456.1588 11.65 0.597854182 0.000037 




Table A1.11: Positively identified (AD Vs Control) 
HMDB.No. Name Acc.mass mz_light 
Retention 
time 
Fold.change p value 
316 Phenyl-Leucine 278.1631 512.2214 15.9 0.221545833 8.30E-06 
HMDB00130 Homogentisic acid 168.0423 318.0794 24.84 0.512373096 3.44E-06 
HMDB00133 Guanosine 283.0917 517.15 2.22 6.402693356 1.20E-12 
HMDB00148 L-Glutamic Acid 147.0532 381.1115 5.05 0.534262485 3.31E-07 
HMDB00152 Gentisic acid 154.0266 388.0849 17.11 0.546812559 0.0150655 
HMDB00191 L-Aspartic Acid 133.0375 367.0958 5.16 0.639508421 0.0004979 
HMDB00210 Pantothenic acid 219.1107 453.169 8.37 1.539230701 4.48E-07 
HMDB00214 Ornithine 132.0899 300.1033 16.58 0.579056214 3.81E-10 
HMDB00224 O-Phosphoethanolamine 141.0191 375.0774 2.02 0.570539227 9.49E-05 
HMDB00251 Taurine 125.0147 359.073 2.24 0.620118218 2.20E-07 




152.0473 386.1057 16.72 0.660875641 0.0219098 
HMDB00450 5-Hydroxylysine 162.1004 315.1085 13.88 2.452586635 2.13E-13 
HMDB00452 L-Alpha-aminobutyric acid 103.0633 337.1216 9.13 1.775708991 6.46E-07 
HMDB00500 4-Hydroxybenzoic acid 138.0317 372.09 17.57 0.53377388 0.035612 












131.0582 365.1166 5.17 1.556154941 2.61E-05 
HMDB00750_2 
3-Hydroxymandelic acid - 
COOH 
168.0423 356.0951 21.64 1.571944665 3.85E-13 
HMDB00991 2-aminooctanoic acid 159.1259 393.1842 19.2 2.092570984 2.32E-10 
HMDB01123 2-Aminobenzoic acid 137.0477 371.106 16.62 1.989599933 6.64E-12 




168.0423 318.0794 23.9 1.6678413 1.63E-06 
HMDB01414 1,4-diaminobutane 88.1 278.1083 21.27 1.80273571 4.66E-07 
HMDB01856 Protocatechuic acid 154.02661 311.0716 24.51 0.560950951 0.0521732 
HMDB01906 2-Aminoisobutyric acid 103.0633 337.1216 8.91 1.775708991 6.46E-07 
HMDB01918 Thyroxine 776.6867 622.4017 27.74 1.624099542 2.76E-10 
HMDB02064 N-Acetylputrescine 130.1106 364.1689 7.25 1.798382188 3.06E-14 
HMDB02390 3-Cresotinic acid 152.0473 386.1057 16.8 0.660875641 0.0219098 
HMDB03012 Aniline 93.0578 327.1162 17.32 3.1256744 0.0009532 
HMDB03334 Symmetricdimethylarginine 202.143 436.2013 3.05 1.82325156 1.23E-22 




HMDB03911 3-Aminoisobutanoic acid 103.0633 337.1216 8.67 1.775708991 6.46E-07 
HMDB13243 Leucyl-phenylalanine 278.163 512.2214 16.59 1.759357659 1.72E-06 
HMDB13302 Phenylalanylphenylalanine 312.1474 546.2057 16.55 0.362381413 9.47E-11 






Table A1.12: Positively identified (DOCK8 vs AD) 
 




change p value 
HMDB00133 Guanosine 283.0917 517.15 2.22 1.553198645 0.006756897 
HMDB00191 L-Aspartic Acid 133.0375 367.0958 5.16 0.552161486 0.005203074 
HMDB00965 Hypotaurine 109.0197 343.0781 2.47 1.898280637 0.000832791 
HMDB00991 2-aminooctanoic acid 159.1259 393.1842 19.2 1.550838574 0.005658227 
HMDB01476 3-Hydroxyanthranilic acid 153.0426 387.1009 18.14 0.624233115 0.00095519 
HMDB13243 Leucyl-phenylalanine 278.163 512.2214 16.59 2.415598554 4.67E-06 







Table A1.13: ImmunoCAP® ISAC panel (112 allergens) 
  
Aeroallergens                       
(64 sources)
Food Allergens             
(44 sources)
Horse rEqu C1 rEqu C3 Egg nGal d1 nGal d2 nGal d3 nGal d5
Cat rFel d1 rFel d2 rFel d4 Milk nBos d4 nBos d5 nBos d6 nBos d8 nBos dlactoferrin
Mouse nMus m1 Shrimp& Cod nPen m1 nPen m2 nPen m4 Rgad c1
Alternaria rAlt a1 rAlt a6 Peanut rAra h1 rAra h2 rAra h3 rAra h6 rAra h8
Aspergillus rAsp f1 rAsp f3 rAsp f6 rAra h9
clasdosporium rCla h8 Soybean rGly m4 rGly m5 rGly m6
House dust mite rBlo t5 nDer f1 nDer f2 nDer p1 nDer p2 Wheat rTria a 14 rTria a 19.0101rTria a Aa_TI
nDer p10 Fruits(Apple,peach,Kiwi,celery) rMal d1 rPru p1 rPru p3 nAct d 1 nAct d 2
storage mite rLep d2 nAct d 5 nAct d 8 rApi g1
Cockroach rBla g1 rBla g2 rBla g5 rBla g7 Nuts(walnut,Hazelnut, nJug r1 nJug r2 nJug r3 rCor a1.0401rCor a8
Latex rHev b1 rHev b3 rHev b5 rHev b6.01 rHev b8 Brazilnut,cashew nut) rCor a9 rBer e1 rAna o2
Sugar epitope from Bromelain Nmuxf3
Bermuda grass nCyn d1
Timothy grass rPhl p1 rPhl p2 rPhl p4 rPhl p5 rPhl p6 Others (4 sources)
rPhl p7 rPhl p11 rPhl p12 Honey bee venom rApi m1 rApi m4
Alder rAln g1 Paper wasp venom rPol d5
Birch rBet v1 rBet v2 rBet v4 common wasp venom rVes v5
Hazel pollen rCor a 1.0101 Anisakis rAni s1 rAni s3
Japanese ceder nCry j1
Cypress nCup a1
Olive nOle e1 nOle e7 nOle e9
Plane tree rPla a1 rPla a2 rPla a3
Ragweed nAmb a1
Mugwort nArtv v1 nArtv v3
Goosefoot rChe a1
Annual mercury rMer a1
Wall pellitory rPar j2
Plantain(English) rPla l1
Salwort nSal k1
Dog rCan f1 rCan f2 rCan f3 rCan f5












% Median IQR Species 
%
% Median IQR Species 
%
nGal d1 Ovomucoid 50 2.3 1.0 44 9.7 6.8
nGal d2 Ovalbumin 50 17 13.0 56 1.9 1.1
nGal d3 Conalbumin 40 7.25 2.9 56 2.4 0.8
nGal d5 serum albumin 20 9.35 5.0 33 1.2 1.0
nBos d4 alpha lactalbumin 50 14 8.5 22 1.1 1.1
nBos d5 beta-lactoglobulin 70 4.8 1.5 22 1.2 0.8
nBos d6 serum albumin 0 0 0.0 11 9.2 9.2
nBos d8 caseins 80 6.05 2.4 33 0.5 0.5
nBos d 
lactoferrin lactoferrin 0 0 0.0 11 2.6 2.6
rGad c1 Cod parvalbumin 0 0 0.0 0 11 1.4 1.4 11
nPen m2 Tropomyosin 0 0 0.0 22 24.1 14.1
nPen m4 Tropomyosin 0 0 0.0 22 21.2 10.8
rAna o2 70 5.1 2.7 56 1.5 0.4
rBer e1 storage protien ,2S albumin 0 0.0 44 1.9 0.7
Cor a9 storage protien ,11S globulin 50 21 2.5 67 0.5 0.4
nJug r1 2S Albumin, a storage protein 30 3.4 1.9 56 22.0 8.8
nJug r2 vicilin 40 5.4 2.4 67 1.3 1.1
nSes i1 sesame storage protien ,2S albumin 60 26 12.3 60 67 22.0 16.5 67
rAra h1 storage protien ,vicilin 50 8.4 4.8 56 26.0 0.9
rAra h2 storage protien ,conglutin 40 20 5.8 44 38.0 19.2
rAra h3 storage protien,11S globulin 60 3.3 1.0 22 12.6 7.3
rAra h6 PR-10 protein 30 18 11.1 44 39.0 24.8
rGly m5 storage protien ,beta-conglycinin 50 9.2 2.0 33 2.1 1.7
rGly m6 storage protien ,glycinin 70 11.9 1.8 56 2.8 0.9
rTria a 14 20 16.35 12.5 22 1.2 0.8












































% Median IQR Species
%
% Median IQR Species%
nCyn d1 barmuda grass  Group 1 Grasses 40.0 2.3 2.0 40 56 5.0 1.7 56
rPhl p1 0 0.0 0.0 11 2.1 2.1
rPhl p4 50 5.0 1.6 50 56 1.7 1.3
rPhl p5  Group 5Grasses 10 0.9 0.9 0 0.0 0
rBet v1 Birch PR-10 protein 10 6.0 6.0 10 11 0.4 0.4 11
nCry j1 ceder 30 6.6 4.6 30 33 0.8 0.8 33
nCup a1 Cypress 30 2.7 2.5 30 33 0.5 0.5 33
nOle e9 olive 40 3.0 1.9 40 22 0.7 0.7 44
rPla a1 10 21.0 21.0 0 0.0 0
rPla a2 50 2.1 0.7 44 1.2 1.2
rChe a1 goosefoot Ole-e-1-like family of 
proteins
0 0.0 0.0 0 11 4.1 4.1 11
rPar j2 wall pellitory PR-14) protein family. 30 0.8 0.8 30 0 0.0 0 11
rPla l1 plantain 10 1.3 1.3 10 0 0.0 0 0
nSal k1 Salwort salsola 0 0.0 0.0 0 11 4.1 4.1 11
rCan f1 Dog lipocalin 0 0.0 0.0 0 11 3.8 3.8 11
rFel d1 cat Ulteroglobin 0 0.0 0.0 0 78 43.0 36.8 78
nMus m1 Mouse lipocalin 10 2.0 2.0 10 0 0.0 0 0
rAlt a1 10 0.4 0.4 11 0.6 0.6
rAlt a6 30 1.4 1.1 22 4.5 3.4
rAsp f1 10 0.6 0.6 0 0.0 0
rAsp f6 0 0.0 0.0 44 1.2 0.4
Bla g 5 cockroach 0 0.0 0.0 0 33 14.0 10.7 33
rPol d5 paper wasp 
venom
10 0.9 0.9 10 11 0.3 0.3 11
rHev b1 30 0.6 0.6 0 0.0 0
rHev b3 30 1.1 0.8 0 0.0 0




















Table A1.16 : Disease specific metabolites in DOCK8-deficient patients in different food groups 
 
Disease specific metabolites Egg Milk Peanut Sesame Soy 
Taurine D D NS NS NS 
L-threo-3-Methylaspartate U NS NS NS NS 
L-Aspartate 4-semialdehyde U NS NS NS NS 
5-Amino-2-oxopentanoic acid U NS NS NS NS 
Tyrosyl-Asparagine D NS NS NS NS 
L-2-Amino-3-oxobutanoic acid U NS NS D NS 
 2'-Deamino-2'-hydroxy-6'-dehydroparomamine U NS NS NS NS 
3-Methoxy-4-hydroxyphenylethyleneglycol D NS NS NS NS 
2-Aminobenzoic acid D NS NS D NS 
5-Hydroxyindoleacetic acid D NS NS NS NS 
2R,5S-2,5-Diaminohexanoate U NS NS U NS 
4-Hydroxy-3-methoxy-benzaldehyde D NS NS NS NS 
Aspartyl-Glycine D NS NS NS NS 
4-Ethylphenol D NS NS NS NS 
Glutamyl-Lysine NS D D NS D 
 L-2-Aminoadipate 6-semialdehyde NS U NS NS NS 
2-Amino-5-oxohexanoate NS U NS NS NS 
Seryl-Threonine NS D NS NS NS 
2,4-Diaminobutyric acid NS D D NS NS 
3-Methoxy-4-hydroxyphenylacetaldehyde NS NS D NS NS 
gamma-L-Glutamylputrescine NS NS D NS NS 
Gentisate aldehyde NS D D NS D 
3-Hydroxymandelic acid NS NS D NS NS 
o-Cresol NS NS D NS NS 
Glycyl-Proline NS NS U NS NS 
Alpha-aminobutyric acid NS NS U NS NS 
3S,5S-3,5-Diaminohexanoate NS NS U NS NS 
3,4-Dihydroxy-L-phenylalanine NS NS D NS NS 
2-Pyrocatechuic acid NS NS U NS NS 
Sarcosine D D D D NS 
Vanillylmandelic acid NS NS D NS NS 
Guanidoacetic acid NS NS NS U NS 
Cystine NS NS NS U NS 
R-1-Aminopropan-2-ol NS NS NS D NS 
Homoarginine NS NS NS U NS 
Cystathionine - Isomer NS NS NS D NS 
Homoserine NS NS NS U NS 
L-Selenocystathionine NS NS NS U U 




trans-2,3-Dihydroxycinnamate NS NS NS D NS 
4-Aminobutyraldehyde NS NS NS U NS 
N6-Acetyl-N6-hydroxy-L-lysine NS NS NS U NS 
Histidine NS NS NS U NS 
Isomer of 1-Aminocyclopropane-1-carboxylate NS NS NS U D 
Methylguanidine NS NS NS U NS 
Aminoadipic acid NS NS NS NS D 
4-Hydroxybenzoic acid NS NS NS NS D 
Leucyl-Aspartate NS NS NS NS U 
2-Hydroxy-2,4-pentadienoate NS NS NS NS D 
2R,5S-2,5-Diaminohexanoate U NS NS U U 
 
 






Table A1.17: Disease specific metabolites in AD patients in different food groups 
 
Disease specific  metabolites Egg Milk Peanut Sesame Soy 
3,4-Dihydroxybenzeneacetic acid U U U U U 
5-Acetylamino-6-amino-3-methyluracil D NS D D U 
Aspartyl-Threonine U U U NS U 
L-Aspartate 4-semialdehyde D NS D NS NS 
Leucyl-Aspartate U U U NS U 
L-Glutamate 5-semialdehyde U NS U NS NS 
Leucyl-phenylalanine U U U D U 
Glutamyl-Methionine D D D D D 
Alanyl-Valine U U U NS U 
Uridine  U U U NS U 
Theophylline D NS D NS NS 
Phenylalanyl-Tryptophan U NS U U NS 
5-Hydroxyindoleacetic acid D NS D U NS 
L-2-Aminoadipate 6-semialdehyde U NS U NS NS 
Glycyl-Phenylalanine U U U NS U 
2'-Deamino-2'-hydroxy-6'-dehydroparomamine D D D NS D 
Methionine Sulfoxide NS D NS NS D 
Pipecolic acid NS U NS NS U 
3-Sulfino-L-alanine NS U NS NS U 
o-Cresol NS U NS NS U 
Leucyl-Isoleucine NS U NS NS U 
 4-Ethylphenol NS U NS NS U 
Gentisic acid NS U NS NS U 
N6-Acetyl-N6-hydroxy-L-lysine NS U NS NS U 
Prolyl-Lysine NS D NS NS D 
2,4-Diaminobutyric acid NS U NS NS U 
S-Glutathionyl-L-cysteine NS U NS NS U 
2-Aminooctanoic acid NS NS NS D NS 
Lysyl-Glutamine NS NS NS U NS 
Taurine NS NS NS U NS 
3-Methoxy-4-hydroxyphenylacetaldehyde NS NS NS U NS 
trans-3-Hydroxy-L-proline/cis-3-Hydroxy-L-proline NS NS NS D NS 
4-Hydroxy-3-methoxy-benzaldehyde NS NS NS U NS 
prolyl-proline D U U U U 
 






















Figure A2.1: Binary comparison between DOCK8 deficient patients and controls (A) Volcano plots 
show up regulation of CXCL10 and TNFA in DOCK8 deficient patients compared to healthy 












Figure A2.2: Volcano plots and Binary comparison: (A) AD vs ctrl,(B) DOCK8 vs AD (C) 
Comparison between AD patients and healthy controls (Q2=0.32) where Q2 represents the level of 
differential expression of the panel analytes (D) Epidermal growth factor (EGF) is down-regulated 









Figure A2.3: PLS-DA loading plots based on binary comparisons in AD and DOCK8 deficient 
patients with/without various clinical phenotypes including (A) asthma, (B) bronchiectasis, (C) 





































Figure A2 6: ISAC profiling in DOCK8-deficient (n=10) and atopic dermatitis (n=9) patients is 
significant for aero-allergens but not for food-allergens.(A) Food-allergens (B) Aero-allergens 
measured in ISU-E units.(* Indicates significance. Not specified ones are not significant, p-value< 
0.05,) 












Figure A2 7 :Differential pathway involvement is revealed in (A) DOCK8-deficient  patients 
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